Peptide for treating heart failure
A peptide inhibiting PDE4-TPNI binding enhances cardiac muscle relaxation by increasing local cAMP levels, addressing impaired cardiac relaxation in HFpEF and diastolic dysfunction with specificity and reduced side effects.
Patent Information
- Application Number
- PCT/GB2026/050767
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for heart failure with preserved ejection fraction (HFpEF), such as beta-blockers, are ineffective and associated with side effects, as they do not address impaired cardiac relaxation, a key issue in this form of heart failure.
A peptide that inhibits the binding of PDE4 protein to TPNI, specifically PDE4D9, to increase cAMP levels locally, promoting PKA-mediated phosphorylation of TPNI and enhancing muscle relaxation in cardiomyocytes.
The peptide selectively increases TPNI phosphorylation, improving cardiac relaxation without affecting other PKA substrates, offering a targeted treatment for HFpEF and diastolic dysfunction with reduced side effects.
Smart Images

Figure IMGF000014_0001 
Figure IMGF000015_0001 
Figure IMGF000020_0001
Abstract
Description
[0001] PEPTIDE FOR TREATING HEART FAILURE
[0002] FIELD OF THE INVENTION
[0003] The present invention relates to a peptide capable of inhibiting a phosphodiesterase-4 (PDE4) protein from binding to a troponin I (TPNI) protein, and the use of such peptide as a medicament, for example in the treatment or prevention of diastolic dysfunction and heart failure.
[0004] BACKGROUND TO THE INVENTION
[0005] Diastolic dysfunction, the inability of the heart to relax properly after contraction, is a typical manifestation of the failing heart. In heart failure with reduced ejection fraction (HFrEF) impaired systolic function — or insufficient contraction — is the primary abnormality, leading to a reduced volume of blood ejected with each heartbeat. Diastolic dysfunction often also develops, due to changes in ventricular structure and compliance, contributing to disease progression. In about 50% of heart failure cases, however, the ejection fraction remains normal even in advanced stages and the problem is exclusively a compromised cardiac relaxation. This is called heart failure with preserved ejection fraction (HFpEF) and is typically treated with p-blockers and diuretics, however these treatments are not equally effective in all patients and are associated with side effects. There is currently no effective treatment for HFpEF.
[0006] Cardiac contraction (systole) and relaxation (diastole) are driven by contractile proteins arranged in sarcomeres consisting of interdigitated thick myosin filaments and thin actin filaments. The sliding of thick and thin myofilaments past each other causes the sarcomeres to shorten during contraction and re-lengthen during relaxation.
[0007] This process is regulated by the binding and unbinding of calcium ions (Ca2+) to and from troponin C (TPNC) which, together with troponin T (TPNT) and troponin I (TPNI), forms the regulatory troponin complex associated with actin and tropomyosin as part of the thin filament.
[0008] The p-adrenergic receptor (P-AR) / cAMP / PKA pathway is a core regulator of cardiac function, including the binding and unbinding of calcium ions to and from troponin C. During sympathetic stimulation, increased cAMP levels activate protein kinase A (PKA), which phosphorylates specific proteins to enhance both contraction and relaxation, allowing the heart to adapt to higher workload demands. Specifically, PKA phosphorylates phospholamban (PLB) at thesarcoplasmic reticulum (SR), enhancing the activity of the sarco-endoplasmic reticulum calcium ATPase (SERCA); this promotes calcium reuptake into the SR, ensuring a greater calcium reserve is available for release during the next contraction. PKA also phosphorylates the thick filament protein myosin-binding protein C (MyBPC) which enhances contraction by extending the force-generating state of the sarcomere. Importantly, PKA also phosphorylates TPNI which facilitates relaxation by lowering the affinity of TPNC for calcium, ensuring timely deactivation of myofilaments to match the faster contraction rate. Thus, muscle relaxation is promoted by cAMP-dependent PKA-mediated phosphorylation of TPNI.
[0009] The cAMP / PKA signalling pathway operates through a complex network of subcellular signalling nanodomains. Cyclic AMP elevation in response to p-AR activation is not homogeneous across the cardiomyocyte but cAMP forms nanometre-sized gradients shaped by cAMP-hydrolysing phosphodiesterases (PDEs). Phosphodiesterases are a large superfamily of enzymes that include multiple isoforms. These spatially confined cAMP pools activate a selected subset of PKA enzymes, typically tethered in proximity of specific phosphorylation targets via scaffold proteins. This spatial organisation enables selective phosphorylation of local PKA targets, resulting in specific cellular effects.
[0010] While drugs targeting receptors at the plasma membrane influence the entire cellular network of cAMP nanodomains, thus producing systemic effects, the compartmentalised nature of cAMP signalling offers a significant and largely untapped opportunity for more precise interventions. Such approaches could selectively modulate cAMP levels within individual compartments achieving nanometre subcellular precision and stringent functional selectivity. It may be possible to apply this principle to TPNI for example, whereby increasing cAMP in the local vicinity of TPNI to promote its PKA-mediated phosphorylation could promote muscle relaxation. However, it is not known whether TPNI is associated with a cAMP nanodomain or how such a nanodomain could be precisely modulated even if it does exist.
[0011] In pathological conditions such as heart failure, chronic p-AR overstimulation disrupts cAMP signalling, impairing contractility and relaxation. Drugs such as p-blockers can be used to mitigate these effects to some extent and improve cardiac efficiency by reducing oxygen demand and preventing further myocardial damage. However, p-blockers are ineffective when the primary issue is not impaired contraction but impaired cardiac relaxation.
[0012] One specific form of heart failure involves preserved ejection fraction. Heart failure with preserved ejection fraction (HFpEF) accounts for up to 50% of heart failure cases and is associated with high mortality rates. In HFpEF, cardiac contraction is not affected, the problemis impaired cardiac relaxation (diastolic dysfunction). Current heart failure therapies such as P-blockers are not effective for treating HFpEF.
[0013] The present invention aims to address one or more of the problems or exploit one or more opportunities in the art mentioned above, or one or more alternative problems or opportunities.
[0014] SUMMARY OF THE INVENTION
[0015] According to a first aspect of the present invention, there is provided a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein, wherein the peptide has a maximum length of 24 amino acids.
[0016] In one embodiment, the PDE4 protein is a PDE4D subfamily protein.
[0017] In one embodiment, the PDE4D subfamily protein is PDE4D9, preferably wherein PDE4D9 comprises a sequence according to SEQ ID NO: 1, or a sequence with at least 70% identity thereto.
[0018] In one embodiment, the peptide is capable of binding to the PDE4 protein.
[0019] In one embodiment, inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of the TPNI protein, preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of a troponin complex that comprises the TPNI protein, more preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of a myofilament that comprises the TPNI protein, more preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of a myofibril that comprises the TPNI protein, most preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in a cell that comprises the TPNI protein
[0020] In one embodiment, inhibiting a PDE4 protein from binding to a TPNI protein promotes the PKA-dependent phosphorylation of a troponin complex that comprises the TPNI protein.
[0021] In one embodiment, inhibiting a PDE4 protein from binding to a TPNI protein promotes dissociation of Ca2+from a troponin complex that comprises the TPNI protein, preferablywherein inhibiting a PDE4 protein from binding to a TPNI protein promotes dissociation of Ca2+from a TPNC protein that is complexed with the TPNI protein as part of a troponin complex.
[0022] In one embodiment, inhibiting a PDE4 protein from binding to a TPNI protein promotes relaxation of a sarcomere that comprises the TPNI protein, preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes relaxation of a myofibril that comprises the TPNI protein, most preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes relaxation of a muscle cell (i.e. , myocyte) that comprises the TPNI protein.
[0023] In one embodiment, the muscle cell is a heart muscle cell (i.e., cardiomyocyte), preferably a ventricular cardiomyocyte.
[0024] In one embodiment, the peptide comprises the motif DLRGKFK (SEQ ID NO: 9), the motif KKED(I / T)EK (SEQ ID NO: 10), the motif KKEDIEK (SEQ ID NO: 14), the motif KKEDTEK (SEQ ID NO: 15), the motif PAPAP (SEQ ID NO: 11), the motif ADAMMQAL (SEQ ID NO: 12), or the motif KKSKISASR (SEQ ID NO: 13), wherein up to four amino acids in the motif may be independently substituted.
[0025] In one embodiment, any one or more of the up to four amino acids are substituted for a positively charged amino acid, preferably wherein the positively charged amino acid may be selected from arginine, histidine, and lysine, more preferably wherein the positively charged amino acid is arginine.
[0026] In one embodiment, the peptide comprises a sequence selected from:
[0027] KIFDLRRKFKR (SEQ ID NO: 52, P2-2);
[0028] FDLRGKFKRP (SEQ ID NO: 49, P1);
[0029] KIFDLRGKFK (SEQ ID NO: 50, P2);
[0030] KIFDLRRKFK (SEQ ID NO: 51, P2-1);
[0031] KIFDLRRKFKRR (SEQ ID NO: 53, P2-3);
[0032] KIFDLRGKFKR (SEQ ID NO: 54, P2-4);
[0033] KIFDLRGKFKRR (SEQ ID NO: 55, P2-5);
[0034] PRPAPAPIRR (SEQ ID NO: 58, P6);
[0035] KKEDIEKENR (SEQ ID NO: 63, P3);
[0036] KQVKKEDIEKENRR (SEQ ID NO: 64, P3-1);
[0037] RPAPAPIRRR (SEQ ID NO: 59, P7);
[0038] IFDLRGKFKR (SEQ ID NO: 56, P8);
[0039] EPRPAPAPIR (SEQ ID NO: 60, P9);REPRPAPAPI (SEQ ID NO: 61, P10);
[0040] KKKSKISASR (SEQ ID NO: 69, P11);
[0041] KKSKISASRK (SEQ ID NO: 70, P12);
[0042] KQVKKEDIEK (SEQ ID NO: 65, P4);
[0043] VKKEDIEKEN (SEQ ID NO: 66, P13);
[0044] KKDENRIEEK (SEQ ID NO: 72, P5);
[0045] KIFDLRGKFKRP (SEQ ID NO: 57, P14);
[0046] REPRPAPAPIRRR (SEQ ID NO: 62, P15);
[0047] KQVKKEDIEKENR (SEQ ID NO: 68, P16);
[0048] KKKSKISASRK (SEQ ID NO: 71, P17);
[0049] MADESSDAAGEPQPAPAPVR (SEQ ID NO: 112, Peptide Z1); SDAAGEPQPAPAPVRRRSSA (SEQ ID NO: 113, Peptide Z2); EPQPAPAPVRRRSSANYRAY (SEQ ID NO: 114, Peptide Z3); PAPVRRRSSANYRAYATEPH (SEQ ID NO: 115, Peptide Z4); RRSSANYRAYATEPHAKKKS (SEQ ID NO: 116, Peptide Z5); NYRAYATEPHAKKKSKISAS (SEQ ID NO: 117, Peptide Z6);
[0050] ATEPHAKKKSKISASRKLQL (SEQ ID NO: 118, Peptide Z7);
[0051] AKKKSKISASRKLQLKTLML (SEQ ID NO: 119, Peptide Z8);
[0052] KISASRKLQLKTLMLQIAKQ (SEQ ID NO: 120, Peptide Z9);
[0053] RKLQLKTLMLQIAKQEMERE (SEQ ID NO: 121, Peptide Z10); KTLMLQIAKQEMEREAEERR (SEQ ID NO: 122, Peptide Z11); QIAKQEMEREAEERRGEKGR (SEQ ID NO: 123, Peptide Z12); EMEREAEERRGEKGRVLSTR (SEQ ID NO: 124, Peptide Z13); AEERRGEKGRVLSTRCQPLV (SEQ ID NO: 125, Peptide Z14); GEKGRVLSTRCQPLVLDGLG (SEQ ID NO: 126, Peptide Z15); VLSTRCQPLVLDGLGFEELQ (SEQ ID NO: 127, Peptide Z16); CQPLVLDGLGFEELQDLCRQ (SEQ ID NO: 128, Peptide Z17); LDGLGFEELQDLCRQLHARV (SEQ ID NO: 129, Peptide Z18); FEELQDLCRQLHARVDKVDE (SEQ ID NO: 130, Peptide Z19); DLCRQLHARVDKVDEERYDV (SEQ ID NO: 131, Peptide Z20); LHARVDKVDEERYDVEAKVT (SEQ ID NO: 132, Peptide Z21); DKVDEERYDVEAKVTKNITE (SEQ ID NO: 133, Peptide Z22); ERYDVEAKVTKNITEIADLT (SEQ ID NO: 134, Peptide Z23);
[0054] EAKVTKNITEIADLTQKIYD (SEQ ID NO: 135, Peptide Z24);
[0055] KNITEIADLTQKIYDLRGKF (SEQ ID NO: 136, Peptide Z25);
[0056] IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137, Peptide Z26);
[0057] QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138, Peptide Z27);LRGKFKRPTLRRVRISADAM (SEQ ID NO: 139, Peptide Z28);
[0058] KRPTLRRVRISADAMMQALL (SEQ ID NO: 140, Peptide Z29);
[0059] RRVRISADAMMQALLGTRAK (SEQ ID NO: 141, Peptide Z30);
[0060] SADAMMQALLGTRAKESLDL (SEQ ID NO: 142, Peptide Z31);
[0061] MQALLGTRAKESLDLRAHLK (SEQ ID NO: 143, Peptide Z32);
[0062] GTRAKESLDLRAHLKQVKKE (SEQ ID NO: 144, Peptide Z33);
[0063] ESLDLRAHLKQVKKEDIEKE (SEQ ID NO: 145, Peptide Z34);
[0064] RAH LKQVKKEDI EKEN REVG (SEQ ID NO: 146, Peptide Z35);
[0065] QVKKEDIEKENREVGDWRKN (SEQ ID NO: 147, Peptide Z36);
[0066] DIEKENREVGDWRKNIDALS (SEQ ID NO: 148, Peptide Z37);
[0067] NREVGDWRKNIDALSGMEGR (SEQ ID NO: 149, Peptide Z38);
[0068] DWRKNIDALSGMEGRKKKFE (SEQ ID NO: 150, Peptide Z39); and WRKNIDALSGMEGRKKKFEG (SEQ ID NO: 151 , Peptide Z40); or a sequence having at least 70% identity thereto.
[0069] In one embodiment, the peptide comprises a sequence selected from any of:
[0070] KIFDLRRKFKR (SEQ ID NO: 52, P2-2);
[0071] FDLRGKFKRP (SEQ ID NO: 49, P1);
[0072] KIFDLRGKFK (SEQ ID NO: 50, P2);
[0073] KIFDLRRKFK (SEQ ID NO: 51, P2-1);
[0074] KIFDLRRKFKRR (SEQ ID NO: 53, P2-3);
[0075] KIFDLRGKFKR (SEQ ID NO: 54, P2-4);
[0076] KIFDLRGKFKRR (SEQ ID NO: 55, P2-5);
[0077] KKEDIEKENR (SEQ ID NO: 63, P3);
[0078] KQVKKEDIEKENRR (SEQ ID NO: 64, P3-1);
[0079] KQVKKEDIEK (SEQ ID NO: 65, P4);
[0080] KKDENRIEEK (SEQ ID NO: 72, P5);
[0081] SDAAGEPQPAPAPVRRRSSA (SEQ ID NO: 113, Peptide Z2);
[0082] EPQPAPAPVRRRSSANYRAY (SEQ ID NO: 114, Peptide Z3);
[0083] RRSSANYRAYATEPHAKKKS (SEQ ID NO: 116, Peptide Z5);
[0084] NYRAYATEPHAKKKSKISAS (SEQ ID NO: 117, Peptide Z6);
[0085] ATEPHAKKKSKISASRKLQL (SEQ ID NO: 118, Peptide Z7);
[0086] AKKKSKISASRKLQLKTLML (SEQ ID NO: 119, Peptide Z8);
[0087] KISASRKLQLKTLMLQIAKQ (SEQ ID NO: 120, Peptide Z9);
[0088] QIAKQEMEREAEERRGEKGR (SEQ ID NO: 123, Peptide Z12);
[0089] EMEREAEERRGEKGRVLSTR (SEQ ID NO: 124, Peptide Z13);
[0090] KNITEIADLTQKIYDLRGKF (SEQ ID NO: 136, Peptide Z25);IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137, Peptide Z26);
[0091] QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138, Peptide Z27);
[0092] RRVRISADAMMQALLGTRAK (SEQ ID NO: 141, Peptide Z30);
[0093] MQALLGTRAKESLDLRAHLK (SEQ ID NO: 143, Peptide Z32);
[0094] GTRAKESLDLRAHLKQVKKE (SEQ ID NO: 144, Peptide Z33);
[0095] QVKKEDIEKENREVGDWRKN (SEQ ID NO: 147, Peptide Z36);
[0096] DWRKNIDALSGMEGRKKKFE (SEQ ID NO: 150, Peptide Z39); and WRKNIDALSGMEGRKKKFEG (SEQ ID NO: 151 , Peptide Z40); or a sequence having at least 70% identity thereto.
[0097] In one embodiment, the peptide comprises the motif DLR(G / R)KFK (SEQ ID NO: 44), and the peptide comprises a sequence selected from any of:
[0098] KIFDLRRKFKR (SEQ ID NO: 52, P2-2);
[0099] FDLRGKFKRP (SEQ ID NO: 49, P1);
[0100] KIFDLRGKFK (SEQ ID NO: 50, P2);
[0101] KIFDLRRKFK (SEQ ID NO: 51, P2-1);
[0102] KIFDLRRKFKRR (SEQ ID NO: 53, P2-3);
[0103] KIFDLRGKFKR (SEQ ID NO: 54, P2-4);
[0104] KIFDLRGKFKRR (SEQ ID NO: 55, P2-5);
[0105] IFDLRGKFKR (SEQ ID NO: 56, P8);
[0106] KIFDLRGKFKRP (SEQ ID NO: 57, P14);
[0107] IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137, Peptide Z26); and QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138, Peptide Z27); or a sequence having at least 70% identity thereto.
[0108] In one embodiment, the peptide comprises the sequence KIFDLRRKFKR (SEQ ID NO: 52, P2-2).
[0109] In one embodiment, the peptide consists of the sequence KIFDLRRKFKR (SEQ ID NO: 52, P2-2).
[0110] In a second aspect, there is provided a nucleic acid sequence encoding the peptide of the first aspect.
[0111] In a third aspect, there is provided an expression construct comprising the nucleic acid sequence of the second aspect.In a fourth aspect, there is provided a vector comprising the nucleic acid sequence of the second aspect, or the expression construct of the third aspect.
[0112] In a fifth aspect, there is provided a conjugate comprising the peptide of the first aspect, nucleic acid sequence of the second aspect, expression construct of the third aspect, or the vector of the fourth aspect, wherein the peptide, nucleic acid sequence, expression construct, or vector is covalently linked to a delivery group, preferably wherein the delivery group is a cell penetrating peptide.
[0113] In a sixth aspect, there is provided a delivery particle comprising the peptide of the first aspect, nucleic acid sequence of the second aspect, expression construct of the third aspect, vector of the fourth aspect, or the conjugate of the fifth aspect, preferably wherein the delivery particle is selected from: a liposome, a lipid nanoparticle, and a virus particle.
[0114] In a seventh aspect, there is provided a pharmaceutical composition comprising the peptide of the first aspect, nucleic acid sequence of the second aspect, expression construct of the third aspect, vector of the fourth aspect, conjugate of the fifth aspect, or the delivery particle of the sixth aspect and one or more pharmaceutically acceptable excipients.
[0115] In an eighth aspect, there is provided a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for use as a medicament.
[0116] In a ninth aspect, there is provided use of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for the manufacture of a medicament.In a tenth aspect, there is provided a method of treating a subject having a disease, or preventing a disease in a subject, wherein the method comprises administering to the subject an effective amount of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle.
[0117] In an eleventh aspect, there is provided a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for use in the treatment or prevention of: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 are upregulated, a disease or condition in which the expression of PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 with TPNI, a disease or condition involving an increased association of PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction, heart failure involving diastolic dysfunction associated with cardiac developmental defects, including paediatric and adult manifestations, hypercontracture and / or hypertrophic cardiomyopathy, preferably wherein the heart failure involves diastolic dysfunction, more preferably wherein the heart failure is heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
[0118] In an twelfth aspect, there is provided use of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expressionconstruct comprising said nucleic acid; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector, wherein the peptide, nucleic acid sequence, expression construct, or vector is covalently linked to a delivery group such as a cell penetrating peptide; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate, wherein the delivery particle may be for example a liposome, lipid nanoparticle, or virus particle; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for the manufacture of a medicament for the treatment or prevention of: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 are upregulated, a disease or condition in which the expression of PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 with TPNI, a disease or condition involving an increased association of PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction, heart failure involving diastolic dysfunction associated with cardiac developmental defects, including paediatric and adult manifestations, hypercontracture and / or hypertrophic cardiomyopathy, preferably wherein the heart failure involves diastolic dysfunction, more preferably wherein the heart failure is heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
[0119] In an thirteenth aspect, there is provided a method of treating a subject having a disease, or preventing a disease in a subject, wherein the method comprises administering to the subject an effective amount of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector, wherein the peptide, nucleic acid sequence, expression construct, or vector is covalently linked to a delivery group such as a cell penetrating peptide; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate, wherein the delivery particle may be for example a liposome, lipid nanoparticle, or virus particle; or a pharmaceutical composition comprising said peptide, nucleic acid sequence,expression construct, vector, conjugate, or delivery particle, wherein the disease is: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 are upregulated, a disease or condition in which the expression of PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 with TPNI, a disease or condition involving an increased association of PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction, heart failure involving diastolic dysfunction associated with cardiac developmental defects, including paediatric and adult manifestations, hypercontracture and / or hypertrophic cardiomyopathy, preferably wherein the heart failure involves diastolic dysfunction, more preferably wherein the heart failure is heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
[0120] In an embodiment of the peptide for use according to the eighth of eleventh aspects, use of the peptide according to the ninth of twelfth aspects, or the method of treating a subject or preventing a disease in a subject comprising administering the peptide according to the tenth of thirteenth aspects, the peptide is as defined in the first aspect.
[0121] The inventors discovered that there is a distinct cAMP nanodomain surrounding TPNI as a result of its interaction with a cAMP-hydrolysing phosphodiesterase (PDE), PDE4. Specifically, it is believed that, at least in some species, TPNI interacts with PDE4 subfamily D isoform 9 (PDE4D9). This interaction is believed to be particularly prominent in heart muscle cells, i.e., cardiomyocytes, particularly ventricular cardiomyocytes. The inventors have found that the interaction between PDE4 and TPNI can be selectively inhibited to increase cAMP levels in the proximity of TPNI to increase its PKA-mediated phosphorylation to promote muscle relaxation and treat or prevent conditions such as diastolic dysfunction. They have found that this can be done with small peptide inhibitors. The key benefit of the peptide inhibitors is their ability to improve muscle relaxation specifically in cardiomyocytes through a mechanism that is specific and highly localised even to a subcellular level by selectively enhancing the phosphorylation of TPNI without affecting the phosphorylation of other PKA substrate molecules such as myosin binding protein C (MyBPC), phospholamban or cAMP response element binding protein (CREB) and / or without affecting phosphorylation in the bulk cytosol ofmyocytes. This is beneficial because any effects on the phosphorylation of any molecule other than TPNI could cause unwanted side-effects. The peptides described herein therefore have the potential to provide a first-in-class treatment option for conditions involving impaired heart muscle relaxation such as heart failure with preserved ejection fraction (HFpEF), diastolic dysfunction and hypertrophic cardiomyopathy (including genetic hypertrophic cardiomyopathy).
[0122] DETAILED DESCRIPTION OF THE INVENTION
[0123] Features and embodiments of the above aspects will now be described under the following headed sections. Any feature, embodiment or definition described herein is not limited to any particular aspect, and may be combined with any other feature, embodiment or definition of the same or a different aspect in any workable combination unless expressly stated otherwise. Workable combinations may be determined using techniques described in the Examples.
[0124] One skilled in the art will recognise many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is not limited to the methods and materials described.
[0125] The section headings used herein are for organisational purposes only and are not to be construed as limiting the subject matter described.
[0126] Definitions
[0127] For purposes of the present invention, the following terms are defined below.
[0128] As used herein, unless otherwise clear from context, the term “a” or “an” may be understood to mean “at least one”; the term “a,” “an” or “the” include plural reference unless the context clearly dictates otherwise; the term “or” may be understood to mean “and / or”; the terms “comprising”, “comprise”, "comprised of", “including” (whether used with “but not limited to” or not) and “include” (whether used with “but not limited to” or not) may be understood to encompass itemised components or steps whether presented by themselves or together with one or more additional components or steps; the term “another” may be understood to mean at least an additional / second one or more; where ranges are provided, all numbers and fractions encompassed within the respective range are included as well as the recited endpoints; “in” includes “in” and “on” unless the context clearly dictates otherwise.As used herein, the terms “identity” or “percent identity” refer to the degree of sequence variation between two aligned nucleic acid or amino acid sequences. For sequence comparison, typically, one sequence acts as a reference sequence to which a test sequence is compared. Methods for aligning sequences are well-known in the art. Various programs and alignment algorithms are described in, for example: Smith and Waterman (1981) Adv. Appl. Math. 2:482; Needleman and Wunsch (1970) J. Mol. Biol. 48:443; Pearson and Lipman (1988) Proc. Natl. Acad. Sci. U.S.A. 85:2444; Higgins and Sharp (1988) Gene 73:237-44; Higgins and Sharp (1989) CABIOS 5:151-3; Corpet et al. (1988) Nucleic Acids Res. 16:10881-90; Huang et al. (1992) Comp. Appl. Biosci. 8:155-65; Pearson et al. (1994) Methods Mol. Biol.
[0129] 24:307-31; Tatiana et al. (1999) FEMS Microbiol. Lett. 174:247-50. A detailed consideration of sequence alignment methods and homology calculations can be found in, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-10. Alignment may also be performed by visual inspection.
[0130] The National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST™; Altschul et al. (1990)) is available from several sources, including the National Center for Biotechnology Information (Bethesda, MD), and on the internet, for use in connection with several sequence analysis programs. In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90: 5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
[0131] The terms “identity” or “percent identity” typically refer to global identity or percent identity unless the context dictates otherwise. In other words, percentage sequence identity is typically calculated over the entire length of the reference sequence. For example, global optimal alignment may be found using the Needleman-Wunsch algorithm with the following scoring parameters: Match score: +2, Mismatch score: -3; Gap penalties: gap open 5, gap extension 2. The resulting percentage identity is suitably calculated as the ratio of the number of aligned bases to the total length of the alignment, where the alignment length includes both matches and mismatches, multiplied by 100%.
[0132] As used herein, the term “homologue” refers to nucleic acid (e.g. promoter or gene) or amino acid (e.g. peptide or protein) sequence that shares common ancestry with another gene or protein as identified by sequence identity or similarity, the conservation of functional domains, and / or any other available information provided by for example phylogenetic analysis. An “orthologue” is a homologous nucleic acid or amino acid sequence in different species thatoriginated from a common ancestor and retains the same function as the sequence to which it is orthologous. A “paralogue” is a homologous nucleic acid or amino acid sequence within the same species that arose from gene duplication and may have diverged in function from the sequence to which it is paralogous. Homologous sequences may have a limited number of amino acid substitutions, deletions, insertions or additions with respect to one another. A homologue may refer to a sequence which has an identity of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or at least 99% identity with a reference sequence. Algorithms for determining sequence identity are publicly available and include, e.g. BLAST, available through the National Center for Biotechnology Information (NCBI). One skilled in the art can determine if two sequences are homologous.
[0133] As used herein, the term “amino acid” may refer to a naturally occurring amino acid or any other amino acid including non-natural amino acids and / or non-proteinogenic amino acids. By “naturally occurring” in this context is meant the 20 amino acids encoded by the standard genetic code, sometimes referred to as proteinogenic amino acids.
[0134] Conventional three-letter and one-letter codes for naturally occurring amino acids are used herein, i.e. A (Ala), G (Gly), L (Leu), I (lie), V (Vai), F (Phe), W (Trp), S (Ser), T (Thr), Y (Tyr), N (Asn), Q (Gin), D (Asp), E (Glu), K (Lys), R (Arg), H (His), M (Met), C (Cys) and P (Pro).
[0135] The term “amino acid” is short for a-amino [alpha-amino] carboxylic acid. Each molecule contains a central carbon (C) atom, called the a-carbon, to which both an amino and a carboxyl group are attached. The remaining two bonds of the a-carbon atom are generally satisfied by a hydrogen (H) atom and the side chain, shown as R below:
[0136]
[0137] Unless otherwise specified, amino acid residues in peptides of the invention are of the L-configuration. However, D-configuration amino acids may be incorporated as modifications.
[0138] As used herein, the term “peptide” refers to a polymeric form of amino acids of any length, but typically less than 50 amino acids, which can include coded (proteinogenic) and non-coded (non-proteinogenic) amino acids. As used herein, amino acid residues will be indicated asabove either by their full name or according to the standard three-letter or one-letter amino acid code.
[0139] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, immunology, and other fields of biology. Such techniques are explained fully in the literature. See, for example, Current Protocols in Molecular Biology (Ausubel, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al, 2001 , Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gaited., 1984); U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (Harries and Higgins eds. 1984); Transcription and Translation (Hames and Higgins eds. 1984); Culture of Animal Cells (Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells and Enzymes (IRL Press, 1986); Perbal, A Practical Guide to Molecular Cloning (1984); the series, Methods in Enzymology (Abelson and Simon, eds. -in-chief, Academic Press, Inc., New York), specifically, Vols.154 and 155 (Wu et al. eds.) and Vol. 185, "Gene Expression Technology" (Goeddel, ed.); Gene Transfer Vectors For Mammalian Cells (Miller and Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook of Experimental Immunology, Vols. I-IV (Weir and Blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).
[0140] Peptide
[0141] The present invention relates to a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein. This may be referred to herein as “the peptide” or “the peptide of the invention”. The peptide may be regarded as an inhibitor, suitably therefore the invention may relate to a peptide inhibitor, suitably which is capable of inhibiting a PDE4 protein from binding to a TPNI protein.
[0142] In one embodiment, the peptide has a maximum length of 24 amino acids. Therefore, the invention also relates to a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein, wherein the peptide has a maximum length of 24 amino acids.
[0143]
[0144] The peptide may be of any length and composed of any number of amino acids. The peptide may have a maximum length of 25 amino acids. The peptide may have a maximum length of24 amino acids. The peptide may have a maximum length of 25, 24, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 amino acids. In one embodiment, the peptide has a maximum length of 24 amino acids.
[0145] The peptide may have a maximum length of 20 amino acids. The peptide may have a maximum length of 14 amino acids. The peptide may have a maximum length of 13 amino acids. The peptide may have a maximum length of 12 amino acids. The peptide may have a maximum length of 11 amino acids. The peptide may have a maximum length of 10 amino acids.
[0146] The peptide may have a minimum length of 5 amino acids. The peptide may have a minimum length of 5, 6, 7, 8, 9, 10, 11 , 12, 13, or 14 amino acids.
[0147] The peptide may have a minimum length of 10 amino acids. The peptide may have a minimum length of 11 amino acids. The peptide may have a minimum length of 12 amino acids. The peptide may have a minimum length of 13 amino acids. The peptide may have a minimum length of 14 amino acids.
[0148] The peptide may have a length of 5-25 amino acids. The peptide may have a length of 5-24 amino acids. The peptide may have a length of 5-23 amino acids. The peptide may have a length of 5-22 amino acids. The peptide may have a length of 5-21 amino acids. The peptide may have a length of 5-20 amino acids. The peptide may have a length of 5-19 amino acids. The peptide may have a length of 5-18 amino acids. The peptide may have a length of 5-17 amino acids. The peptide may have a length of 5-16 amino acids. The peptide may have a length of 5-15 amino acids. The peptide may have a length of 5-14 amino acids. The peptide may have a length of 5-13 amino acids. The peptide may have a length of 5-12 amino acids. The peptide may have a length of 5-11 amino acids. The peptide may have a length of 5-10 amino acids.
[0149] The peptide may have a length of 6-25 amino acids. The peptide may have a length of 6-24 amino acids. The peptide may have a length of 6-23 amino acids. The peptide may have a length of 6-22 amino acids. The peptide may have a length of 6-21 amino acids. The peptide may have a length of 6-20 amino acids. The peptide may have a length of 6-19 amino acids. The peptide may have a length of 6-18 amino acids. The peptide may have a length of 6-17 amino acids. The peptide may have a length of 6-16 amino acids. The peptide may have a length of 6-15 amino acids. The peptide may have a length of 6-14 amino acids. The peptide may have a length of 6-13 amino acids. The peptide may have a length of 6-12 amino acids.The peptide may have a length of 6-11 amino acids. The peptide may have a length of 6-10 amino acids.
[0150] The peptide may have a length of 7-25 amino acids. The peptide may have a length of 7-24 amino acids. The peptide may have a length of 7-23 amino acids. The peptide may have a length of 7-22 amino acids. The peptide may have a length of 7-21 amino acids. The peptide may have a length of 7-20 amino acids. The peptide may have a length of 7-19 amino acids. The peptide may have a length of 7-18 amino acids. The peptide may have a length of 7-17 amino acids. The peptide may have a length of 7-16 amino acids. The peptide may have a length of 7-15 amino acids. The peptide may have a length of 7-14 amino acids. The peptide may have a length of 7-13 amino acids. The peptide may have a length of 7-12 amino acids. The peptide may have a length of 7-11 amino acids. The peptide may have a length of 7-10 amino acids.
[0151] The peptide may have a length of 9-25 amino acids. The peptide may have a length of 9-24 amino acids. The peptide may have a length of 9-23 amino acids. The peptide may have a length of 9-22 amino acids. The peptide may have a length of 9-21 amino acids. The peptide may have a length of 9-20 amino acids. The peptide may have a length of 9-19 amino acids. The peptide may have a length of 9-18 amino acids. The peptide may have a length of 9-17 amino acids. The peptide may have a length of 9-16 amino acids. The peptide may have a length of 9-15 amino acids. The peptide may have a length of 9-14 amino acids. The peptide may have a length of 9-13 amino acids. The peptide may have a length of 9-12 amino acids. The peptide may have a length of 9-11 amino acids. The peptide may have a length of 9-10 amino acids.
[0152] The peptide may have a length of 10-25 amino acids. The peptide may have a length of IQ-24 amino acids. The peptide may have a length of 10-23 amino acids. The peptide may have a length of 10-22 amino acids. The peptide may have a length of 10-21 amino acids. The peptide may have a length of 10-20 amino acids. The peptide may have a length of 10-19 amino acids. The peptide may have a length of 10-18 amino acids. The peptide may have a length of 10-17 amino acids. The peptide may have a length of 10-16 amino acids. The peptide may have a length of 10-15 amino acids. The peptide may have a length of 10-14 amino acids. The peptide may have a length of 10-13 amino acids. The peptide may have a length of IQ-12 amino acids. The peptide may have a length of 10-11 amino acids.In one embodiment, the peptide has a length of 10-14 amino acids. In one embodiment, the peptide has a length of 10-13 amino acids. In one embodiment, the peptide has a length of 10-12 amino acids. In one embodiment, the peptide has a length of 10-11 amino acids.
[0153] The peptide may have a length of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids.
[0154] In one embodiment, the peptide has a length of 10 amino acids. In one embodiment, the peptide has a length of 11 amino acids. In one embodiment, the peptide has a length of 12 amino acids. In one embodiment, the peptide has a length of 13 amino acids. In one embodiment, the peptide has a length of 14 amino acids. In one embodiment, the peptide has a length of 20 amino acids. In one embodiment, the peptide has a length of 25 amino acids.
[0155] net
[0156] The peptide may have any net charge.
[0157] The term “net charge” refers to the number of positively charge residues (arginine, R; histidine, H; lysine, K) minus the number of negatively charged residues (aspartic acid, D; glutamic acid, E) in a peptide at physiological conditions including pH. Physiological pH is around 7.0-7.4.
[0158] The peptide may have a net positive charge. In other words, the peptide may be cationic. The peptide may have a net negative charge. In other words, the peptide may be anionic. In some embodiments, the peptide is cationic.
[0159] The peptide may have a net charge of at least -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, or +14 or more. For example, the peptide may have a net charge of -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, or +14.
[0160] The peptide may have a net charge of -3 or more. The peptide may have a net charge of -2 or more. The peptide may have a net charge of -1 or more. The peptide may have a net charge of 0 or more. The peptide may have a net charge of +1 or more. The peptide may have a net charge of +2 or more. The peptide may have a net charge of +3 or more. The peptide may have a net charge of +4 or more. The peptide may have a net charge of +5 or more. The peptide may have a net charge of +6 or more. The peptide may have a net charge of +7 or more.The peptide may have a net charge of +7 or less. The peptide may have a net charge of +6 or less. The peptide may have a net charge of +5 or less. The peptide may have a net charge of +4 or less. The peptide may have a net charge of +3 or less. The peptide may have a net charge of +2 or less. The peptide may have a net charge of +1 or less. The peptide may have a net charge of 0 or less. The peptide may have a net charge of -1 or less. The peptide may have a net charge of -2 or less. The peptide may have a net charge of -3 or less.
[0161] The peptide may have a net charge of -3 to +7 (i.e., -3, -2, -1, 0, +1, +2, +3, +4, +5, +6 or +7). The peptide may have a net charge of -1 to +6. The peptide may have a net charge of -1 to +5. The peptide may have a net charge of -1 to +4. The peptide may have a net charge of -1 to +3. The peptide may have a net charge of -1 to +2. The peptide may have a net charge of -1 to +1. The peptide may have a net charge of -1 to 0.
[0162] The peptide may have a net charge of 0 to +6. The peptide may have a net charge of 0 to +5. The peptide may have a net charge of 0 to +4. The peptide may have a net charge of 0 to +3. The peptide may have a net charge of 0 to +2. The peptide may have a net charge of 0 to +1.
[0163] The peptide may have a net charge of +1 to +6. The peptide may have a net charge of +1 to +5. The peptide may have a net charge of +1 to +4. The peptide may have a net charge of +1 to +3. The peptide may have a net charge of +1 to +2.
[0164] The peptide may have a net charge of +2 to +6. The peptide may have a net charge of +2 to +5. The peptide may have a net charge of +2 to +4. The peptide may have a net charge of +2 to +3.
[0165] The peptide may have a net charge of +3 to +6. The peptide may have a net charge of +3 to +5. The peptide may have a net charge of +3 to +4.
[0166] The peptide may have a net charge of +4 to +6. The peptide may have a net charge of +4 to +5.
[0167] The peptide may have a net charge of +5 to +6.
[0168] In one embodiment, the peptide has a net charge of +3 to +6. In one embodiment, the peptide has a net charge of +1 and +4. In one embodiment, the peptide has a net charge of -1 and +2. In one embodiment, the peptide has a net charge of +5 and +6.In one embodiment, the peptide has a net charge of -3. In one embodiment, the peptide has a net charge of -2. In one embodiment, the peptide has a net charge of-1. In one embodiment, the peptide has a net charge of 0. In one embodiment, the peptide has a net charge of +1. In one embodiment, the peptide has a net charge of +2. In one embodiment, the peptide has a net charge of +3. In one embodiment, the peptide has a net charge of +4. In one embodiment, the peptide has a net charge of +5. In one embodiment, the peptide has a net charge of +6. In one embodiment, the peptide has a net charge of +7.
[0169] Number of
[0170]
[0171] residues in the
[0172]
[0173] The peptide may comprise any number of positively charged amino acids.
[0174] The term “positively charged amino acids” refers to amino acids which have a positive charge at physiological conditions including pH. Physiological pH is around 7.0-7.4. Positively charged residues include arginine (R), histidine (H), and lysine (K).
[0175] The peptide may comprise at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more positively charged residues. For example, the peptide may comprise 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 positively charged residues.
[0176] The peptide may comprise 1 or more positively charged residues. The peptide may comprise 2 or more positively charged residues. The peptide may comprise 3 or more positively charged residues. The peptide may comprise 4 or more positively charged residues. The peptide may comprise 5 or more positively charged residues. The peptide may comprise 6 or more positively charged residues. The peptide may comprise 7 or more positively charged residues. The peptide may comprise 8 or more positively charged residues.
[0177] The peptide may comprise 8 or less positively charged residues. The peptide may comprise 7 or less positively charged residues. The peptide may comprise 6 or less positively charged residues. The peptide may comprise 5 or less positively charged residues. The peptide may comprise 4 or less positively charged residues. The peptide may comprise 3 or less positively charged residues. The peptide may comprise 2 or less positively charged residues. The peptide may comprise 1 or less positively charged residues.
[0178] The peptide may comprise 1 to 8 (i.e., 1, 2, 3, 4, 5, 6, 7 or 8) positively charged residues. The peptide may comprise 1 to 7 positively charged residues. The peptide may comprise 1 to 6 positively charged residues. The peptide may comprise 1 to 5 positively charged residues.The peptide may comprise 1 to 4 positively charged residues. The peptide may comprise 1 to 3 positively charged residues. The peptide may comprise 1 to 2 positively charged residues.
[0179] The peptide may comprise 2 to 8 (i.e., 2, 3, 4, 5, 6, 7 or 8) positively charged residues. The peptide may comprise 2 to 7 positively charged residues. The peptide may comprise 2 to 6 positively charged residues. The peptide may comprise 2 to 5 positively charged residues. The peptide may comprise 2 to 4 positively charged residues. The peptide may comprise 2 to 3 positively charged residues.
[0180] The peptide may comprise 3 to 7 positively charged residues. The peptide may comprise 3 to 6 positively charged residues. The peptide may comprise 3 to 5 positively charged residues. The peptide may comprise 3 to 4 positively charged residues.
[0181] The peptide may comprise 4 to 7 positively charged residues. The peptide may comprise 4 to 6 positively charged residues. The peptide may comprise 4 to 5 positively charged residues.
[0182] The peptide may comprise 5 to 7 positively charged residues. The peptide may comprise 5 to 6 positively charged residues.
[0183] The peptide may comprise 6 to 7 positively charged residues.
[0184] In one embodiment, the peptide has 4 to 7 positively charged residues. In one embodiment, the peptide has 2 to 5 positively charged residues. In one embodiment, the peptide has 3 to 8 or 3 to 6 positively charged residues. In one embodiment, the peptide has 5 to 6 positively charged residues.
[0185] In one embodiment, the peptide has 1 positively charged residue. In one embodiment, the peptide has 2 positively charged residues. In one embodiment, the peptide has 3 positively charged residues. In one embodiment, the peptide has 4 positively charged residues. In one embodiment, the peptide has 5 positively charged residues. In one embodiment, the peptide has 6 positively charged residues. In one embodiment, the peptide has 7 positively charged residues. In one embodiment, the peptide has 8 positively charged residues.
[0186] A higher net charge and / or higher number of positively charged residues may facilitate penetration of the peptide across cell membranes. For example, cell penetrating peptides (CPP) typically have a net positive charge, usually having five or more positively charged residues. Suitably therefore, peptides of the invention with a net positive charge or specificallythose that comprise five or more positive charged residues may be better at penetrating cell membranes.
[0187] modifications
[0188] The peptide may comprise L-amino acids and / or D-amino acids. The peptide may comprise L-amino acids. The peptide may comprise D-amino acids. In one embodiment, the peptide comprises L-amino acids.
[0189] The peptide may consist of L-amino acids and / or D-amino acids. The peptide may consist of L-amino acids. The peptide may consist of D-amino acids. In one embodiment, the peptide consists of L-amino acids.
[0190] The peptide may be a linear or circular peptide. The peptide may be a linear peptide. The peptide may be a circular peptide. In one embodiment, the peptide is a linear peptide.
[0191] The peptide may comprise any number of modified amino acids and / or non-natural amino acid analogues. Up to half the number of amino acids in the peptide may be modified amino acids and / or non-natural amino acid analogues. Suitably, the peptide may comprise up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified amino acids and / or non-natural amino acid analogues.
[0192] Up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive amino acids from the C-terminus may independently be modified amino acids and / or non-natural amino acid analogues, wherein the modification or analogue at each position is independent of the modification or analogue at any other position. Up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive amino acids from the N-terminus may independently be modified amino acids and / or non-natural amino acid analogues, wherein the modification or analogue at each position is independent of the modification or analogue at any other position.
[0193] The peptide may comprise a N-terminal modification and / or an C-terminal modification. The peptide may comprise an N-terminal modification. The peptide may comprise a C-terminal modification.
[0194] For example, the peptide may be N-acetylated, N-methylated, N-trifluoroacetylated, N-trifluoromethylsulfonylated, or N-methylsulfonylated. Suitably, the peptide is N-acetylated. Suitably, the N-terminus of the peptide may be unmodified.For example, the peptide have a C-terminal modification selected from: carboxy-, thioacid-, aminooxy-, hydrazino-, thioester-, azide, strained alkyne, strained alkene, aldehyde-, thiol or haloacetyl-group. Suitably, the C-terminus of the peptide may be unmodified.
[0195] Modifications and non-natural amino acid analogues may include any amino acid modification (such as any post-translational modification or any other type of modification such as any artificial modification) or analogue known in the art. Modifications and analogues may include:
[0196] an N-methylated amino acid;
[0197] a peptoid analogue;
[0198] a non-proteinogenic amino acid, e.g. hydroxyproline (Hyp: L-hydroxyproline or (2S,4F?)-4-Hydroxyproline), Octahydroindole-2-carboxylic acid (Oic), sarcosine (Sar), norleucine (Nle), a-aminoisobutyric acid (Aib) or thiazolidine-4-carboxylic acid (Thz); a sugar modified amino acid analogue;
[0199] a biotin modified amino acid analogue;
[0200] a beta amino acid;
[0201] a D-configuration amino acid;
[0202] a non-proteinogenic amino acid; and / or
[0203] an a-alkylated amino acid.
[0204] A “peptoid analogue” of an amino acid is an analogue in which the side chain is connected to the nitrogen of the peptide backbone, instead of the a-carbon as in proteinogenic peptides.
[0205] A “biotin modified” amino acid analogue is an amino acid residue which incorporates a biotin moiety as part of the side chain. For example, the biotin moiety may be at a terminal position.
[0206] The term “alkyl” as used herein refers to a saturated linear or branched-chain monovalent hydrocarbon radical, wherein the alkyl radical may be optionally substituted. The number of carbon atoms in the alkyl group may be specified using the above notation, for example, when there are from 1 to 8 carbon atoms the term “Ci-8-alkyl” may be used. Examples of alkyl groups include methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl ( / -Pr, / -propyl, -CH(CH3)2), and 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3).
[0207] Modified amino acids may comprise post-translational modifications such as phosphorylation, methylation, acetylation, amidation, formation of pyrrolidone carboxylic acid, isomerization, hydroxylation, sulfation, flavin-binding, cysteine oxidation and nitrosylation. Modified amino acids may comprise the addition onto an amino acid or amino acid analogue of any moiety that may be incorporated into a peptide via one or more peptide bonds or any other bond suchas an isopeptide bond. Modified amino acids may comprise pegylation, biotinylation, acetylation, dansylation, fluorescein modification, 4-DNP modification, palmitoylation, Mca modification, amidation, fatty-acid conjugation, lipidation, repeat polypeptide extension, the fragment crystallisable region of immunoglobulin G (IgG-Fc), camptothecin (OPT), human serum albumin (HAS), elastin-like polypeptide (ELP), transferrin, albumin modification, or comprise any other known modification.
[0208] Non-natural amino acid analogues may include 2-aminoadipic acid, 3-aminoadipic acid, betaalanine, beta-aminoproprionic acid, 2-aminobutyric acid, 4-aminobutyric acid, piperidinic acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diaminobutyric acid, desmosine, 2,2’-diaminopimelic acid, 2,3-diaminoproprionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allo-hydroxylysine, 3-Hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylglycine, sarcosine, N-methylisoleucine, 6-N-methyllysine, N-methylvaline, norvaline, norleucine, ornithine, for example.
[0209] Modifications may enhance the bioavailability, biostability or functionality of the peptide, such as its capacity to bind a PDE4 protein such as PDE4D9, or its ability to prevent a PDE4 protein such as PDE4D9 from binding to a TPNI protein. The functionality of the peptide may be tested using the techniques described in the Examples such as the TPNI-CUTie assay.
[0210] The peptide may be modified to increase stability (e.g., resistance to enzymatic degradation, increased half-life), improve bioavailability (e.g., better absorption across membranes, including oral, nasal, transdermal, or pulmonary delivery, increase binding affinity to the PDE4 protein, improve solubility in aqueous or physiological environments, enhance cellular permeability (e.g., ability to cross the cell membrane), reduce immunogenicity (e.g., to avoid immune system recognition or response), prolong circulation time (e.g., via PEGylation or lipidation), improve metabolic stability (e.g., resistance to proteases, aminopeptidases, carboxypeptidases), optimise pharmacokinetics and pharmacodynamics profiles, increase resistance to aggregation or improve folding / stability under storage conditions, allow for intracellular targeting or organelle-specific localisation, enable conjugation to imaging agents (e.g., for diagnostics or theranostics), add chemical handles for site-specific conjugation or labelling (e.g., azide, alkyne groups), facilitate passage through the blood-brain barrier (BBB), enable dual or multi-functionality (e.g., bifunctional peptides, fusion constructs), mimic or inhibit protein-protein interactions, create prodrugs (e.g., peptides activated upon cleavage or metabolism), reduce toxicity or unwanted side effects, enhance lipophilicity or hydrophilicity depending on delivery requirements, introduce cyclic structures or conformational constraintsto reduce flexibility and increase binding efficiency to the PDE4 protein, prevent renal clearance (e.g., by increasing molecular weight or adding albumin-binding motifs), and / or to improve manufacturability or formulation stability.
[0211] In some embodiments, the peptide may also be an unmodified peptide. In such embodiments, the peptide may consist of proteinogenic amino acids, without post-translational modifications.
[0212] Motifs
[0213] The peptide may comprise the motif:
[0214] DLRGKFK (SEQ ID NO: 9),
[0215] KKED(I / T)EK (SEQ ID NO: 10),
[0216] PAPAP (SEQ ID NO: 11),
[0217] ADAMMQAL (SEQ ID NO: 12), or
[0218] KKSKISASR (SEQ ID NO: 13),
[0219] wherein up to half the number of amino acids in the motif may be independently substituted for another amino acid, or wherein up to four, three, two or one amino acid in the motif may be independently substituted for another amino acid. In one embodiment, wherein up to four amino acids in the motif may be independently substituted for another amino acid. In one embodiment, up to three amino acids in the motif may be substituted for another amino acid. In one embodiment, up to two amino acids in the motif may be substituted for another amino acid. In one embodiment, up to one amino acid in the motif may be substituted for another amino acid.
[0220] The annotation “(X / Z)” refers to a position where the amino acid may be X or Z. Accordingly, a peptide comprising the motif KKED(I / T)EK (SEQ ID NO: 10) may be a peptide comprising the motif KKEDIEK (SEQ ID NO: 14) or KKEDTEK (SEQ ID NO: 15).
[0221] The peptide may comprise the motif:
[0222] DLRGKFK (SEQ ID NO: 9)
[0223] KKED(I / T)EK (SEQ ID NO: 10),
[0224] PAPAP (SEQ ID NO: 11),
[0225] ADAMMQAL (SEQ ID NO: 12), or
[0226] KKSKISASR (SEQ ID NO: 13),
[0227] or a motif which has at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto. Preferably, a motif which has at least 70% identity thereto. In one embodiment, the motif has at least 85% identity thereto.
[0228] The peptide may comprise the motif:
[0229] DLRGKFK (SEQ ID NO: 9),
[0230] KKEDIEK (SEQ ID NO: 14),
[0231] KKEDTEK (SEQ ID NO: 15),
[0232] PAPAP (SEQ ID NO: 11),
[0233] ADAMMQAL (SEQ ID NO: 12), or
[0234] or KKSKISASR (SEQ ID NO: 13).
[0235] In the motif KKED(I / T)EK (SEQ ID NO: 10), suitably none of the lysine (K) residues are substituted. Suitably therefore, the peptide may comprise the motif KKED(I / T)EK (SEQ ID NO: 10), KKEDIEK (SEQ ID NO: 14), or KKEDTEK (SEQ ID NO: 15), wherein up to four, three, two or one non-lysine amino acid in the motif may be independently substituted for another amino acid. In one embodiment, up to four non-lysine amino acids in the motif may be independently substituted for another amino acid. In one embodiment, up to three non-lysine amino acids in the motif may be independently substituted for another amino acid. In one embodiment, up to two non-lysine amino acids in the motif may be independently substituted for another amino acid. In one embodiment, one non-lysine amino acid in the motif may be independently substituted for another amino acid.
[0236] The peptide may comprise a motif which is a continuous sequence of any number of amino acids, for example at least 3, 4, 5, 6 or 7 amino acids, comprised in one of the following sequences:
[0237] DLRGKFK (SEQ ID NO: 9)
[0238] KKED(I / T)EK (SEQ ID NO: 10),
[0239] PAPAP (SEQ ID NO: 11),
[0240] ADAMMQAL (SEQ ID NO: 12), or
[0241] KKSKISASR (SEQ ID NO: 13).
[0242] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, or 6 amino acids present in DLRGKFK (SEQ ID NO: 9).
[0243] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, or 6 amino acids present in KKED(I / T)EK (SEQ ID NO: 10).The peptide may comprise a motif which is a continuous sequence of at least 3, 4 amino acids present in PAPAP (SEQ ID NO: 11).
[0244] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, 6 or 7 amino acid sequence present in ADAMMQAL (SEQ ID NO: 12).
[0245] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, 6 or 7 amino acid sequence present in KKSKISASR (SEQ ID NO: 13).
[0246] For example, the peptide may comprise the motif:
[0247] DLRGKF (SEQ ID NO: 16),
[0248] DLRG (SEQ ID NO: 17),
[0249] KKED (SEQ ID NO: 18),
[0250] PAPA (SEQ ID NO: 19),
[0251] MQAL (SEQ ID NO: 20),
[0252] ADAM (SEQ ID NO: 21),
[0253] KKS (SEQ ID NO: 22),
[0254] KKSKISAS (SEQ ID NO: 23),
[0255] KISASR (SEQ ID NO: 24), and / or
[0256] KKSK (SEQ ID NO: 25).
[0257] For example, the peptide may comprise the motif:
[0258] GKFK (SEQ ID NO: 26),
[0259] D(I / T)EK (SEQ ID NO: 27),
[0260] APAP (SEQ ID NO: 28),
[0261] MMQAL (SEQ ID NO: 29), or
[0262] SASR (SEQ ID NO: 30).
[0263] The peptide may comprise one of the following motifs:
[0264] - (F / Y)DLRGKFK (SEQ ID NO: 31)
[0265] - KKED(I / T)EK (SEQ ID NO: 10)
[0266] - (QZR)PAPAP(VZI) (SEQ ID NO: 32)
[0267] - SADAMMQALL (SEQ ID NO: 33), or
[0268] - KKSKISASR (SEQ ID NO: 13),
[0269] wherein up to half the number of amino acids in the motif may be independently substituted for another amino acid, or wherein up to four, three, two or one amino acid in the motif may be independently substituted for another amino acid. In one embodiment, up to four aminoacids in the motif may be independently substituted for another amino acid. In one embodiment, up to three amino acids in the motif may be independently substituted for another amino acid. In one embodiment, up to two amino acids in the motif may be independently substituted for another amino acid. In one embodiment, up to one amino acid in the motif may be substituted for another amino acid.
[0270] The annotation “(X / Z)” refers to a position where the amino acid may be X or Z. Accordingly, a peptide comprising the motif (F / Y)DLRGKFK (SEQ ID NO: 31) may be a peptide comprising the motif FDLRGKFK (SEQ ID NO: 34) or YDLRGKFK (SEQ ID NO: 35). A peptide comprising the motif (Q / R)PAPAP(V / I) (SEQ ID NO: 32) may be a peptide comprising the motif RPAPAPI (SEQ ID NO: 36) or QPAPAPV (SEQ ID NO: 37).
[0271] The peptide may comprise one of the following motifs:
[0272] - (F / Y)DLRGKFK (SEQ ID NO: 31)
[0273] - KKED(I / T)EK (SEQ ID NO: 10)
[0274] - (Q / R)PAPAP(V / I) (SEQ ID NO: 32)
[0275] - SADAMMQALL (SEQ ID NO: 33), or
[0276] - KKSKISASR (SEQ ID NO: 13),
[0277] or a motif which has at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto. Preferably, a motif which has at least 70% identity thereto. In one embodiment, the motif has at least 85% identity thereto.
[0278] The peptide may comprise one of the following motifs:
[0279] - FDLRGKFK (SEQ ID NO: 34),
[0280] - YDLRGKFK (SEQ ID NO: 35),
[0281] - KKEDIEK (SEQ ID NO: 14),
[0282] - KKEDTEK (SEQ ID NO: 15),
[0283] - RPAPAPI (SEQ ID NO: 36),
[0284] - RPAPAPV (SEQ ID NO: 38),
[0285] - QPAPAPV (SEQ ID NO: 37),
[0286] - QPAPAPI (SEQ ID NO: 39),
[0287] - SADAMMQALL (SEQ ID NO: 33), or
[0288] - KKSKISASR (SEQ ID NO: 13).The peptide may comprise a motif which is a continuous sequence of any number of amino acids, for example at least 3, 4, 5, 6 or 7 amino acids, comprised in one of the following sequences:
[0289] - (F / Y)DLRGKFK (SEQ ID NO: 31)
[0290] - KKED(I / T)EK (SEQ ID NO: 10)
[0291] - (Q / R)PAPAP(V / I) (SEQ ID NO: 32)
[0292] - SADAMMQALL (SEQ ID NO: 33), or
[0293] - KKSKISASR (SEQ ID NO: 13).
[0294] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, or 6 amino acids present in (F / Y)DLRGKFK (SEQ ID NO: 31).
[0295] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, or 6 amino acids present in KKED(I / T)EK (SEQ ID NO: 10).
[0296] The peptide may comprise a motif which is a continuous sequence of at least 3, 4 amino acids present in (Q / R)PAPAP(V / I) (SEQ ID NO: 32).
[0297] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, 6 or 7 amino acid sequence present in SADAMMQALL (SEQ ID NO: 33)
[0298] The peptide may comprise a motif which is a continuous sequence of at least 3, 4, 5, 6 or 7 amino acid sequence present in KKSKISASR (SEQ ID NO: 13).
[0299] For example, the peptide may comprise the motif:
[0300] (F / Y)DLRGKF (SEQ ID NO: 40),
[0301] FDLRGKF (SEQ ID NO: 41),
[0302] YDLRGKF (SEQ ID NO: 42), and / or
[0303] MQALL (SEQ ID NO: 43).
[0304] Any amino acid that is substituted may be substituted for any other amino acid. Any amino acids that is substituted may be substituted for an amino acid with similar or dissimilar biochemical properties such as charge, molecular size or hydrophobicity. Any amino acids that is substituted may be substituted for a positively charged amino acid or a negatively charged amino acid. Any amino acids that is substituted may be substituted for a positively charged amino acid, suitably arginine (R), histidine (H), or lysine (K). In one embodiment, any amino acid that is substituted may be substituted with arginine (R).For example, glycine (G) may be substituted for arginine (R) in the motif DLRGKFK (SEQ ID NO: 9). Suitably therefore, the peptide may comprise the motif DLR(G / R)KFK (SEQ ID NO: 44). Suitably therefore, the peptide may comprise the motif DLRGKFK (SEQ ID NO: 9) or DLRRKFK (SEQ ID NO: 45).
[0305] For example, glycine (G) may be substituted for arginine (R) in the motif (F / Y)DLRGKFK (SEQ ID NO: 31). Suitably therefore, the peptide may comprise the motif (F / Y)DLR(G / R)KFK (SEQ ID NO: 46). Suitably therefore, the peptide may comprise the motif (F / Y)DLRRKFK (SEQ ID NO: 105). Suitably therefore, the peptide may comprise the motif FDLRGKFK (SEQ ID NO: 34), YDLRGKFK (SEQ ID NO: 35), FDLRRKFK (SEQ ID NO: 47), or YDLRRKFK (SEQ ID NO: 48).
[0306] The motifs mentioned hereinabove may correspond to sequence fragments present in human (Homo sapiens) or rodent (e.g., rat, Rattus norvegicus', or mouse, Mus musculus) TPNI protein. Accordingly, the motif may correspond to a sequence fragment present in TPNI protein from another (non-human, non-rat, non-mouse) species. Suitably therefore, the peptide may comprise a motif that is a fragment of a TPNI protein sequence corresponding to one of the motifs mentioned hereinabove. Corresponding sequences may be found by alignment. Two such alignments are shown in the Examples in Figure 38 and Figure 39. Suitably therefore, the peptide may comprise a motif corresponding to one of the motifs mentioned hereinabove that is present in a homologue (suitably an orthologue) of human TPNI protein (SEQ ID NO: 4), mouse TPNI protein (SEQ ID NO: 5), rat TPNI protein (SEQ ID NO: 6), sheep TPNI protein (SEQ ID NO: 7) or pig TPNI protein (SEQ ID NO: 8).
[0307] Suitably, it will be understood that a peptide comprising the motifs outlined above may have any particular length outlined above. For example, the peptide may comprise the motif DLRGKFK (SEQ ID NO: 9), wherein up to four, three, two or one amino acid in the motif may be independently substituted for another amino acid, such as a positively charged amino acid, and the peptide may have a length of 6-14 amino acids.
[0308] The peptide is a non-naturally occurring peptide. The peptide may be considered to be a synthetic peptide. The peptide does not comprise or consist of a full or wild type TPNI sequence. The peptide lacks the functionality of wild type TPNI.
[0309] Peptide sequencesSuitably the peptide of the invention may comprise or consist of any of the peptide sequences provided herein, suitably wherein any peptide sequence listed herein may be considered to refer to the amino acid sequence given, or to any other sequence having a high identity thereto, suitably having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0310] The peptide may comprise or consist of any sequence listed in Table 1 below, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0311] Table 1. Peptide sequences.
[0312] No. of No. of positively negatively
[0313] charged charged Net Name Sequence Core motif Length residues residues charge P1 FDLRGKFKRP DLR(G / R)KFK 10 4 1 3
[0314] (SEQ ID NO: 49) (SEQ ID NO: 44)
[0315] P2 KIFDLRGKFK DLR(G / R)KFK 10 4 1 3
[0316] (SEQ ID NO: 50) (SEQ ID NO: 44)
[0317] P2-1 KIFDLRRKFK DLR(G / R)KFK 10 5 1 4
[0318] (SEQ ID NO: 51) (SEQ ID NO: 44)
[0319] P2-2 KIFDLRRKFKR DLR(G / R)KFK 11 6 1 5
[0320] (SEQ ID NO: 52) (SEQ ID NO: 44)
[0321] P2-3 KIFDLRRKFKRR DLR(G / R)KFK 12 7 1 6
[0322] (SEQ ID NO: 53) (SEQ ID NO: 44)
[0323] P2-4 KIFDLRGKFKR DLR(G / R)KFK 11 5 1 4
[0324] (SEQ ID NO: 54) (SEQ ID NO: 44)
[0325] P2-5 KIFDLRGKFKRR DLR(G / R)KFK 12 6 1 5
[0326] (SEQ ID NO: 55) (SEQ ID NO: 44)
[0327] P8 IFDLRGKFKR DLR(G / R)KFK 10 4 1 3
[0328] (SEQ ID NO: 56) (SEQ ID NO: 44)
[0329] P14 KIFDLRGKFKRP DLR(G / R)KFK 12 5 1 4
[0330] (SEQ ID NO: 57) (SEQ ID NO: 44)
[0331] P6 PRPAPAPIRR PAPAP 10 3 0 3
[0332] (SEQ ID NO: 58) (SEQ ID NO: 11)
[0333] P7 RPAPAPIRRR PAPAP 10 4 0 4
[0334] (SEQ ID NO: 59) (SEQ ID NO: 11)
[0335] P9 EPRPAPAPIR PAPAP 10 2 1 1
[0336] (SEQ ID NO: 60) (SEQ ID NO: 11)
[0337] P10 REPRPAPAPI PAPAP 10 2 1 1
[0338] (SEQ ID NO: 61) (SEQ ID NO: 11)
[0339] P15 REPRPAPAPIRRR PAPAP 13 5 1 4(SEQ ID NO: 62) (SEQ ID NO: 11)
[0340] P3 KKEDIEKENR KKED(I / T)EK 10 4 4 0 (SEQ ID NO: 63) (SEQ ID NO: 10)
[0341] P3-1 KQVKKEDIEKENRR KKED(I / T)EK 14 6 4 2 (SEQ ID NO: 64) (SEQ ID NO: 10)
[0342] P4 KQVKKEDIEK KKED(I / T)EK 10 4 3 1 (SEQ ID NO: 65) (SEQ ID NO: 10)
[0343] P13 VKKEDIEKEN KKED(I / T)EK 10 3 4 -1 (SEQ ID NO: 66) (SEQ ID NO: 10)
[0344] P33 GTRAKESLDLRAHL KKED(I / T)EK 25 8 6 2 KQVKKEDIEKE (SEQ ID NO: 10)
[0345] (SEQ ID NO: 67)
[0346] P16 KQVKKEDIEKENR KKED(I / T)EK 13 5 4 1 (SEQ ID NO: 68) (SEQ ID NO: 10)
[0347] P11 KKKSKISASR KKSKISASR 10 5 0 5 (SEQ ID NO: 69) (SEQ ID NO: 13)
[0348] P12 KKSKISASRK KKSKISASR 10 5 0 5 (SEQ ID NO: 70) (SEQ ID NO: 13)
[0349] P17 KKKSKISASRK KKSKISASR 11 6 0 6 (SEQ ID NO: 71) (SEQ ID NO: 13)
[0350] P5 KKDENRIEEK 10 4 4 0 (SEQ ID NO: 72)
[0351] In other words, the peptide may comprise or consist of any of the following sequences, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% thereto:
[0352] KIFDLRRKFKR (SEQ ID NO: 52, P2-2);
[0353] FDLRGKFKRP (SEQ ID NO: 49, P1);
[0354] KIFDLRGKFK (SEQ ID NO: 50, P2);
[0355] KIFDLRRKFK (SEQ ID NO: 51, P2-1);
[0356] KIFDLRRKFKRR (SEQ ID NO: 53, P2-3);
[0357] KIFDLRGKFKR (SEQ ID NO: 54, P2-4);
[0358] KIFDLRGKFKRR (SEQ ID NO: 55, P2-5);
[0359] PRPAPAPIRR (SEQ ID NO: 58, P6);
[0360] KKEDIEKENR (SEQ ID NO: 63, P3);
[0361] KQVKKEDIEKENRR (SEQ ID NO: 64, P3-1);
[0362] RPAPAPIRRR (SEQ ID NO: 59, P7);
[0363] IFDLRGKFKR (SEQ ID NO: 56, P8);
[0364] EPRPAPAPIR (SEQ ID NO: 60, P9);
[0365] REPRPAPAPI (SEQ ID NO: 61, P10);KKKSKISASR (SEQ ID NO: 69, P11);
[0366] KKSKISASRK (SEQ ID NO: 70, P12);
[0367] KQVKKEDIEK (SEQ ID NO: 65, P4);
[0368] VKKEDIEKEN (SEQ ID NO: 66, P13);
[0369] KKDENRIEEK (SEQ ID NO: 72, P5);
[0370] GTRAKESLDLRAHLKQVKKEDIEKE (SEQ ID NO: 67, P33);
[0371] KIFDLRGKFKRP (SEQ ID NO: 57, P14);
[0372] REPRPAPAPIRRR (SEQ ID NO: 62, P15);
[0373] KQVKKEDIEKENR (SEQ ID NO: 68, P16); or
[0374] KKKSKISASRK (SEQ ID NO: 71, P17)’.
[0375] The peptide may also comprise or consist of any sequence listed in Table 2 below, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0376] Table 2. 25mer sequences of rat (Rattus norvegicus) TPNI.
[0377] Activity in Activity in Name Sequence human TPNI rat TPNI assay assay Peptide L1 MADESSDAAGEPQPAPAPVRRRSSA
[0378] (SEQ ID NO: 73)
[0379] Peptide L2 SDAAGEPQPAPAPVRRRSSANYRAY
[0380] (SEQ ID NO: 74)
[0381] Peptide L3 EPQPAPAPVRRRSSANYRAYATEPH
[0382] (SEQ ID NO: 75)
[0383] Peptide L4 PAPVRRRSSANYRAYATEPHAKKKS
[0384] (SEQ ID NO: 76)
[0385] Peptide L5 RRSSANYRAYATEPHAKKKSKISAS
[0386] (SEQ ID NO: 77)
[0387] Peptide L6 NYRAYATEPHAKKKSKISASRKLQL
[0388] (SEQ ID NO: 78)
[0389] Peptide L7 ATEPHAKKKSKISASRKLQLKTLML
[0390] (SEQ ID NO: 79)
[0391] Peptide L8 AKKKSKISASRKLQLKTLMLQIAKQ
[0392] (SEQ ID NO: 80)
[0393] Peptide L9 KISASRKLQLKTLM LQIAKQEM ERE
[0394] (SEQ ID NO: 81)
[0395] Peptide L10 RKLQLKTLM LQIAKQEM EREAEERR
[0396] (SEQ ID NO: 82)Peptide L11 KTLMLQIAKQEMEREAEERRGEKGR
[0397] (SEQ ID NO: 83)
[0398] Peptide L12 QIAKQEMEREAEERRGEKGRVLSTR
[0399] (SEQ ID NO: 84)
[0400] Peptide L13 EMEREAEERRGEKGRVLSTRCQPLV
[0401] (SEQ ID NO: 85)
[0402] Peptide L14 AEERRGEKGRVLSTRCQPLVLDGLG
[0403] (SEQ ID NO: 86)
[0404] Peptide L15 GEKGRVLSTRCQPLVLDGLGFEELQ
[0405] (SEQ ID NO: 87)
[0406] Peptide L16 VLSTRCQPLVLDGLGFEELQDLCRQ
[0407] (SEQ ID NO: 88)
[0408] Peptide L17 CQPLVLDGLGFEELQDLCRQLHARV
[0409] (SEQ ID NO: 89)
[0410] Peptide L18 LDGLGFEELQDLCRQLHARVDKVDE
[0411] (SEQ ID NO: 90)
[0412] Peptide L19 FEELQDLCRQLHARVDKVDEERYDV
[0413] (SEQ ID NO: 91)
[0414] Peptide L20 DLCRQLHARVDKVDEERYDVEAKVT
[0415] (SEQ ID NO: 92)
[0416] Peptide L21 LHARVDKVDEERYDVEAKVTKNITE
[0417] (SEQ ID NO: 93)
[0418] Peptide L22 DKVDEERYDVEAKVTKNITEIADLT
[0419] (SEQ ID NO: 94)
[0420] Peptide L23 ERYDVEAKVTKNITEIADLTQKIYD
[0421] (SEQ ID NO: 95)
[0422] Peptide L24 EAKVTKNITEIADLTQKIYDLRGKF
[0423] (SEQ ID NO: 96)
[0424] Peptide L25 KNITEIADLTQKIYDLRGKFKRPTL High High (SEQ ID NO: 97)
[0425] Peptide L26 IADLTQKIYDLRGKFKRPTLRRVRI High High (SEQ ID NO: 98)
[0426] Peptide L27 QKIYDLRGKFKRPTLRRVRISADAM High (SEQ ID NO: 99)
[0427] Peptide L28 LRGKFKRPTLRRVRISADAMMQALL High High (SEQ ID NO: 100)
[0428] Peptide L29 KRPTLRRVRISADAMMQALLGTRAK High
[0429] (SEQ ID NO: 101)
[0430] Peptide L30 RRVRISADAMMQALLGTRAKESLDL High High (SEQ ID NO: 102)
[0431] Peptide L31 SADAMMQALLGTRAKESLDLRAHLK High High (SEQ ID NO: 103)
[0432] Peptide L32 MQALLGTRAKESLDLRAHLKQVKKE
[0433] (SEQ ID NO: 104)Peptide L33 (i.e., GTRAKESLDLRAHLKQVKKEDIEKE High High P33) (SEQ ID NO: 67)
[0434] Peptide L34 ESLDLRAHLKQVKKEDIEKENREVG High High (SEQ ID NO: 106)
[0435] Peptide L35 RAHLKQVKKEDIEKENREVGDWRKN
[0436] (SEQ ID NO: 107)
[0437] Peptide L36 QVKKEDIEKENREVGDWRKNIDALS High High (SEQ ID NO: 108)
[0438] Peptide L37 DIEKENREVGDWRKNIDALSGMEGR
[0439] (SEQ ID NO: 109)
[0440] Peptide L38 NREVGDWRKNIDALSGMEGRKKKFE
[0441] (SEQ ID NO: 110)
[0442] Peptide L39 DWRKNIDALSGMEGRKKKFEG High (SEQ ID NO: 111)
[0443] In other words, the peptide may comprise or consist of any of the following sequences, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% thereto:
[0444] MADESSDAAGEPQPAPAPVRRRSSA (SEQ ID NO: 73, Peptide L1);
[0445] SDAAGEPQPAPAPVRRRSSANYRAY (SEQ ID NO: 74, Peptide L2);
[0446] EPQPAPAPVRRRSSANYRAYATEPH (SEQ ID NO: 75, Peptide L3);
[0447] PAPVRRRSSANYRAYATEPHAKKKS (SEQ ID NO: 76, Peptide L4);
[0448] RRSSANYRAYATEPHAKKKSKISAS (SEQ ID NO: 77, Peptide L5);
[0449] NYRAYATEPHAKKKSKISASRKLQL (SEQ ID NO: 78, Peptide L6);
[0450] ATEPHAKKKSKISASRKLQLKTLML (SEQ ID NO: 79, Peptide L7);
[0451] AKKKSKISASRKLQLKTLMLQIAKQ (SEQ ID NO: 80, Peptide L8);
[0452] KISASRKLQLKTLMLQIAKQEMERE (SEQ ID NO: 81, Peptide L9);
[0453] RKLQLKTLMLQIAKQEMEREAEERR (SEQ ID NO: 82, Peptide L10);
[0454] KTLMLQIAKQEMEREAEERRGEKGR (SEQ ID NO: 83, Peptide L11);
[0455] QIAKQEMEREAEERRGEKGRVLSTR (SEQ ID NO: 84, Peptide L12);
[0456] EMEREAEERRGEKGRVLSTRCQPLV (SEQ ID NO: 85, Peptide L13);
[0457] AEERRGEKGRVLSTRCQPLVLDGLG (SEQ ID NO: 86, Peptide L14);
[0458] GEKGRVLSTRCQPLVLDGLGFEELQ (SEQ ID NO: 87, Peptide L15);
[0459] VLSTRCQPLVLDGLGFEELQDLCRQ (SEQ ID NO: 88, Peptide L16);
[0460] CQPLVLDGLGFEELQDLCRQLHARV (SEQ ID NO: 89, Peptide L17);
[0461] LDGLGFEELQDLCRQLHARVDKVDE (SEQ ID NO: 90, Peptide L18);
[0462] FEELQDLCRQLHARVDKVDEERYDV (SEQ ID NO: 91, Peptide L19);
[0463] DLCRQLHARVDKVDEERYDVEAKVT (SEQ ID NO: 92, Peptide L20);LHARVDKVDEERYDVEAKVTKNITE (SEQ ID NO: 93, Peptide L21); DKVDEERYDVEAKVTKNITEIADLT (SEQ ID NO: 94, Peptide L22);
[0464] ERYDVEAKVTKNITEIADLTQKIYD (SEQ ID NO: 95, Peptide L23);
[0465] EAKVTKNITEIADLTQKIYDLRGKF (SEQ ID NO: 96, Peptide L24);
[0466] KNITEIADLTQKIYDLRGKFKRPTL (SEQ ID NO: 97, Peptide L25);
[0467] IADLTQKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 98, Peptide L26);
[0468] QKIYDLRGKFKRPTLRRVRISADAM (SEQ ID NO: 99, Peptide L27);
[0469] LRGKFKRPTLRRVRISADAMMQALL (SEQ ID NO: 100, Peptide L28);
[0470] KRPTLRRVRISADAMMQALLGTRAK (SEQ ID NO: 101, Peptide L29);
[0471] RRVRISADAMMQALLGTRAKESLDL (SEQ ID NO: 102, Peptide L30);
[0472] SADAMMQALLGTRAKESLDLRAHLK (SEQ ID NO: 103, Peptide L31);
[0473] MQALLGTRAKESLDLRAHLKQVKKE (SEQ ID NO: 104, Peptide L32);
[0474] GTRAKESLDLRAHLKQVKKEDIEKE (SEQ ID NO: 67, Peptide L33, i.e., P33);
[0475] ESLDLRAHLKQVKKEDIEKENREVG (SEQ ID NO: 106, Peptide L34);
[0476] RAHLKQVKKEDIEKENREVGDWRKN (SEQ ID NO: 107, Peptide L35);
[0477] QVKKEDIEKENREVGDWRKNIDALS (SEQ ID NO: 108, Peptide L36);
[0478] DIEKENREVGDWRKNIDALSGMEGR (SEQ ID NO: 109, Peptide L37);
[0479] NREVGDWRKNIDALSGMEGRKKKFE (SEQ ID NO: 110, Peptide L38); or DWRKNIDALSGMEGRKKKFEG (SEQ ID NO: 111, Peptide L39).
[0480] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide L1, Peptide L2, Peptide L3, Peptide L25, Peptide L26, Peptide L27, Peptide L28, Peptide L29, Peptide L30, Peptide L31, Peptide L33 (i.e., P33), Peptide L34, Peptide L35, and / or Peptide L36, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0481] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide L1, Peptide L2, and / or Peptide L3, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0482] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide L25, Peptide L26 and / or Peptide L27, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%,82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0483] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide L28, Peptide L29, Peptide L30 and / or Peptide L31, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0484] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide L33 (i.e. , P33), Peptide L34, Peptide L35, and / or Peptide L36, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0485] In one embodiment, the peptide may comprise or consist of the sequence of Peptide L33 (i.e., P33), as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto. In one embodiment, the peptide may comprise or consist of the sequence of Peptide L33 (i.e., P33), as defined in the table above, or a sequence having at least 70% identity thereto. In one embodiment, the peptide may comprise the sequence of Peptide L33 (i.e., P33), as defined in the table above. In one embodiment, the peptide may consist of the sequence of Peptide L33 (i.e., P33), as defined in the table above.
[0486] The peptide may also comprise or consist of any sequence listed in Table 3 below, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0487] Table 3. 20mer sequences of rat (Rattus norvegicus) TPNI.
[0488] Name Sequence
[0489] Peptide Z1 MADESSDAAGEPQPAPAPVR (SEQ ID NO: 112)
[0490]
[0491] Peptide Z2 SDAAGEPQPAPAPVRRRSSA (SEQ ID NO: 113) Peptide Z3 EPQPAPAPVRRRSSANYRAY (SEQ ID NO: 114) Peptide Z4 PAPVRRRSSANYRAYATEPH (SEQ ID NO: 115) Peptide Z5 RRSSANYRAYATEPHAKKKS (SEQ ID NO: 116) Peptide Z6 NYRAYATEPHAKKKSKISAS (SEQ ID NO: 117) Peptide Z7 ATEPHAKKKSKISASRKLQL (SEQ ID NO: 118) Peptide Z8 AKKKSKISASRKLQLKTLML (SEQ ID NO: 119) Peptide Z9 KISASRKLQLKTLMLQIAKQ (SEQ ID NO: 120) Peptide Z10 RKLQLKTLMLQIAKQEMERE (SEQ ID NO: 121) Peptide Z11 KTLMLQIAKQEMEREAEERR (SEQ ID NO: 122) Peptide Z12 QIAKQEMEREAEERRGEKGR (SEQ ID NO: 123) Peptide Z13 EMEREAEERRGEKGRVLSTR (SEQ ID NO: 124) Peptide Z14 AEERRGEKGRVLSTRCQPLV (SEQ ID NO: 125) Peptide Z15 GEKGRVLSTRCQPLVLDGLG (SEQ ID NO: 126) Peptide Z16 VLSTRCQPLVLDGLGFEELQ (SEQ ID NO: 127) Peptide Z17 CQPLVLDGLGFEELQDLCRQ (SEQ ID NO: 128) Peptide Z18 LDGLGFEELQDLCRQLHARV (SEQ ID NO: 129) Peptide Z19 FEELQDLCRQLHARVDKVDE (SEQ ID NO: 130) Peptide Z20 DLCRQLHARVDKVDEERYDV (SEQ ID NO: 131) Peptide Z21 LHARVDKVDEERYDVEAKVT (SEQ ID NO: 132) Peptide Z22 DKVDEERYDVEAKVTKNITE (SEQ ID NO: 133) Peptide Z23 ERYDVEAKVTKNITEIADLT (SEQ ID NO: 134) Peptide Z24 EAKVTKNITEIADLTQKIYD (SEQ ID NO: 135) Peptide Z25 KNITEIADLTQKIYDLRGKF (SEQ ID NO: 136) Peptide Z26 IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137) Peptide Z27 QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138) Peptide Z28 LRGKFKRPTLRRVRISADAM (SEQ ID NO: 139)
[0492]
[0493] Peptide Z29 KRPTLRRVRISADAMMQALL (SEQ ID NO: 140)
[0494] Peptide Z30 RRVRISADAMMQALLGTRAK (SEQ ID NO: 141)
[0495] Peptide Z31 SADAMMQALLGTRAKESLDL (SEQ ID NO: 142)
[0496] Peptide Z32 MQALLGTRAKESLDLRAHLK (SEQ ID NO: 143)
[0497] Peptide Z33 GTRAKESLDLRAHLKQVKKE (SEQ ID NO: 144)
[0498] Peptide Z34 ESLDLRAHLKQVKKEDIEKE (SEQ ID NO: 145)
[0499] Peptide Z35 RAHLKQVKKEDIEKENREVG (SEQ ID NO: 146)
[0500] Peptide Z36 QVKKEDIEKENREVGDWRKN (SEQ ID NO: 147)
[0501] Peptide Z37 DIEKENREVGDWRKNIDALS (SEQ ID NO: 148)
[0502] Peptide Z38 NREVGDWRKNIDALSGMEGR (SEQ ID NO: 149)
[0503] Peptide Z39 DWRKNIDALSGMEGRKKKFE (SEQ ID NO: 150)
[0504] Peptide Z40 WRKNIDALSGMEGRKKKFEG (SEQ ID NO: 151)
[0505]
[0506] In other words, the peptide may comprise or consist of any of the following sequences, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% thereto:
[0507] MADESSDAAGEPQPAPAPVR (SEQ ID NO: 112, Peptide Z1);
[0508] SDAAGEPQPAPAPVRRRSSA (SEQ ID NO: 113, Peptide Z2);
[0509] EPQPAPAPVRRRSSANYRAY (SEQ ID NO: 114, Peptide Z3);
[0510] PAPVRRRSSANYRAYATEPH (SEQ ID NO: 115, Peptide Z4);
[0511] RRSSANYRAYATEPHAKKKS (SEQ ID NO: 116, Peptide Z5);
[0512] NYRAYATEPHAKKKSKISAS (SEQ ID NO: 117, Peptide Z6);
[0513] ATEPHAKKKSKISASRKLQL (SEQ ID NO: 118, Peptide Z7);
[0514] AKKKSKISASRKLQLKTLML (SEQ ID NO: 119, Peptide Z8);
[0515] KISASRKLQLKTLMLQIAKQ (SEQ ID NO: 120, Peptide Z9);
[0516] RKLQLKTLMLQIAKQEMERE (SEQ ID NO: 121, Peptide Z10);
[0517] KTLMLQIAKQEMEREAEERR (SEQ ID NO: 122, Peptide Z11);
[0518] QIAKQEMEREAEERRGEKGR (SEQ ID NO: 123, Peptide Z12);
[0519] EMEREAEERRGEKGRVLSTR (SEQ ID NO: 124, Peptide Z13);
[0520] AEERRGEKGRVLSTRCQPLV (SEQ ID NO: 125, Peptide Z14);
[0521] GEKGRVLSTRCQPLVLDGLG (SEQ ID NO: 126, Peptide Z15);
[0522] VLSTRCQPLVLDGLGFEELQ (SEQ ID NO: 127, Peptide Z16);CQPLVLDGLGFEELQDLCRQ (SEQ ID NO: 128, Peptide Z17);
[0523] LDGLGFEELQDLCRQLHARV (SEQ ID NO: 129, Peptide Z18);
[0524] FEELQDLCRQLHARVDKVDE (SEQ ID NO: 130, Peptide Z19);
[0525] DLCRQLHARVDKVDEERYDV (SEQ ID NO: 131, Peptide Z20);
[0526] LHARVDKVDEERYDVEAKVT (SEQ ID NO: 132, Peptide Z21);
[0527] DKVDEERYDVEAKVTKNITE (SEQ ID NO: 133, Peptide Z22);
[0528] ERYDVEAKVTKNITEIADLT (SEQ ID NO: 134, Peptide Z23);
[0529] EAKVTKNITEIADLTQKIYD (SEQ ID NO: 135, Peptide Z24);
[0530] KNITEIADLTQKIYDLRGKF (SEQ ID NO: 136, Peptide Z25);
[0531] IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137, Peptide Z26);
[0532] QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138, Peptide Z27);
[0533] LRGKFKRPTLRRVRISADAM (SEQ ID NO: 139, Peptide Z28);
[0534] KRPTLRRVRISADAMMQALL (SEQ ID NO: 140, Peptide Z29);
[0535] RRVRISADAMMQALLGTRAK (SEQ ID NO: 141, Peptide Z30);
[0536] SADAMMQALLGTRAKESLDL (SEQ ID NO: 142, Peptide Z31);
[0537] MQALLGTRAKESLDLRAHLK (SEQ ID NO: 143, Peptide Z32);
[0538] GTRAKESLDLRAHLKQVKKE (SEQ ID NO: 144, Peptide Z33);
[0539] ESLDLRAHLKQVKKEDIEKE (SEQ ID NO: 145, Peptide Z34);
[0540] RAH LKQVKKEDI EKEN REVG (SEQ ID NO: 146, Peptide Z35);
[0541] QVKKEDIEKENREVGDWRKN (SEQ ID NO: 147, Peptide Z36);
[0542] DIEKENREVGDWRKNIDALS (SEQ ID NO: 148, Peptide Z37);
[0543] NREVGDWRKNIDALSGMEGR (SEQ ID NO: 149, Peptide Z38);
[0544] DWRKNIDALSGMEGRKKKFE (SEQ ID NO: 150, Peptide Z39); or WRKNIDALSGMEGRKKKFEG (SEQ ID NO: 151, Peptide Z40).
[0545] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z1, Peptide Z2, Peptide Z3, Peptide Z5, Peptide Z6, Peptide Z7, Peptide Z8, Peptide Z9, Peptide Z12, Peptide Z13, Peptide Z25, Peptide Z26, Peptide Z27, Peptide Z29, Peptide Z30, Peptide Z31, Peptide Z32, Peptide Z33, Peptide Z34, Peptide Z35, Peptide Z36, Peptide Z39, and / or Peptide Z40 as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0546] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z1, Peptide Z2, Peptide Z3, Peptide Z5, Peptide Z6, Peptide Z7, Peptide Z8, Peptide Z9, Peptide Z12, Peptide Z13, Peptide Z25, Peptide Z26, Peptide Z27, Peptide Z29,Peptide Z30, Peptide Z31 , Peptide Z32, Peptide Z34, Peptide Z35, Peptide Z36, and / or as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0547] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z1, Peptide Z2, and / or Peptide Z3, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0548] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z2, and / or Peptide Z3, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0549] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z5, Peptide Z6, Peptide Z7, Peptide Z8, and / or Peptide Z9, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0550] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z5, Peptide Z6, and / or Peptide Z7, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0551] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z7 and / or Peptide Z8, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z12 and / or Peptide Z13, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0552] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z25, Peptide Z26, and / or Peptide Z27, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0553] In such embodiments, the peptide may comprise or consist of the sequence of Peptide Z26, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0554] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z29, Peptide Z30, Peptide Z31, and / or Peptide Z32, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0555] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z29, Peptide Z30, and / or Peptide Z31, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0556] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z30, Peptide Z31, and / or Peptide Z32, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z30, and / or Peptide Z31 , as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0557] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z30, and / or Peptide Z32, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0558] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z30, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0559] In some embodiments, the peptide may comprise or consist of the sequence of Peptide Z36, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0560] In such embodiments, the peptide may comprise or consist of the sequence of Peptide Z34, Peptide Z35, and / or Peptide Z36, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0561] In some embodiments, the peptide may comprise or consist of the sequence of Peptide Z33, as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.In some embodiments, the peptide may comprise or consist of the sequence of any one or more of Peptide Z39, and / or Peptide Z40 as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0562] The peptides mentioned hereinabove may correspond to sequence fragments present in human (Homo sapiens) or rodent (e.g., rat, Rattus norveg icus, or mouse, Mus musculus) TPNI protein. Accordingly, the peptide may comprise or consist of a sequence corresponding to any of these species, or any other (non-human, non-rat, non-mouse) species. Suitably therefore, the peptide may comprise a motif that is a fragment of a TPNI protein sequence corresponding to one of the peptides mentioned hereinabove. Corresponding sequences may be found by alignment. Two such alignments are shown in the Examples in Figure 38 and Figure 39.
[0563] Suitably therefore, the peptide may comprise or consist of a sequence corresponding to any one or more of the peptides mentioned hereinabove that is present in a homologue (suitably an orthologue) of human TPNI protein (SEQ ID NO: 4), mouse TPNI protein (SEQ ID NO: 5), rat TPNI protein (SEQ ID NO: 6), sheep TPNI protein (SEQ ID NO: 7) or pig TPNI protein (SEQ ID NO: 8).
[0564] Motif DLRGKFK (SEQ ID NO: 9) embodiments
[0565] In some embodiments, the peptide comprises the motif DLRGKFK (SEQ ID NO: 9), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid. In one embodiment, up to one amino acid in the motif may be substituted for another amino acid. In one embodiment therefore, the peptide may comprise the motif DLR(G / R)KFK (SEQ ID NO: 44).
[0566] In some embodiments, the peptide may comprise the motif (F / Y)DLRGKFK (SEQ ID NO: 31), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid. In one embodiment, up to one amino acid in the motif may be substituted for another amino acid. In one embodiment therefore, the peptide may comprise the motif (F / Y)DLR(G / R)KFK (SEQ ID NO: 46).
[0567] In such embodiments, the peptide may comprise the motif (F / Y)DLR(G / R)KFK (SEQ ID NO: 46) or (F / Y)DLRRKFK (SEQ ID NO: 105) or (F / Y)DLRGKFK (SEQ ID NO: 31). For examplethe peptide may comprise the motif FDLRGKFK (SEQ ID NO: 34), YDLRGKFK (SEQ ID NO: 35), FDLRRKFK (SEQ ID NO: 47), or YDLRRKFK (SEQ ID NO: 48).
[0568] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P1 , P2, P2-1, P2-2, P2-3, P2-4, P2-5, P8, P14, Peptide Z26, Peptide Z27, Peptide L25, Peptide L26 and / or Peptide L27, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. Such peptides may be included in medical aspects of the present invention.
[0569] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P1, P2, P2-1, P2-2, P2-3, P2-4, P2-5, P8, P14, Peptide Z26, and / or Peptide Z27, as defined in the tables above, ora sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0570] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P1 , P2, P2-1 , P2-2, P2-3, P2-4, P2-5, P8 and / or P14, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0571] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P1, P2, P2-1, P2-2, P2-3, P2-4, P2-5 and / or P8, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0572] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P1 , P2, P8 and / or P14, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P1 , P2 and / or P8, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0573] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P1 and / or P2, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0574] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P2, P2-1, P2-2, P2-3, P2-4 and / or P2-5 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0575] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P1 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0576] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P2 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0577] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P2-2 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P2-3 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0578] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P2-4 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0579] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P2-5 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0580] In such embodiments, the peptide may comprise or consist of a continuous sequence of at least 4, 5, 6, 7, 8, 9, 10 or 11 amino acids present in the sequence of P14, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. In such embodiments, the peptide may comprise or consist of the sequence of P14 as defined in the tables above.
[0581] In some embodiments, the peptide comprises or consists of the sequence of P1 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P2 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P2-1 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P2-2 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P2-3 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P2-4 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P2-5 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P8 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P14 as defined in thetables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L25 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L26 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L27 as defined in the tables above.
[0582] Motif KKED(l T) EK (SEQ ID NO: 10) embodiments
[0583] In some embodiments, the peptide comprises the motif KKED(I / T)EK (SEQ ID NO: 10), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid.
[0584] In such embodiments, the peptide may comprise the motif KKEDIEK (SEQ ID NO: 14) or KKEDTEK (SEQ ID NO: 15).
[0585] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3, P3-1, P4, P13, P33 (i.e. Peptide L33), Peptide Z34, Peptide Z35, Peptide Z36, Peptide L34, Peptide L35, Peptide L36 and / or P16, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. Such peptides may be included in medical aspects of the present invention.
[0586] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3, P3-1, P4, P13, Peptide Z34, Peptide Z35 and / or Peptide Z36, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0587] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3, P3-1, P4, P13, and / or Peptide Z36, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3, P3-1, P4, P13 and / or P16, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0588] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3, P3-1, P4 and / or P13, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0589] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3, P4, P13 and / or P16, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0590] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3, P4 and / or P13, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0591] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P3 and / or P4, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0592] In such embodiments, the peptide may comprise or consist the sequence of any one or more of peptides P3 and / or P3-1 , as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.In such embodiments, the peptide may comprise or consist a continuous sequence of at least 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acids present in the sequence of P16, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. In such embodiments, the peptide may comprise or consist the sequence of P16 as defined in the tables above.
[0593] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P3 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0594] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P3-1 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0595] In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P4 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0596] In some embodiments, the peptide comprises or consists of the sequence of P3 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P3-1 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P4 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P13 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P33 (i.e. Peptide L33) as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P16 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L34 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L35 as definedin the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L36 as defined in the tables above.
[0597] Motif PAPAP (SEQ ID NO: 11) embodiments
[0598] In some embodiments, the peptide comprises the motif PAPAP (SEQ ID NO: 11), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid.
[0599] In some embodiments, the peptide may comprise the motif (Q / R)PAPAP(V / I) (SEQ ID NO: 32), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid.
[0600] In such embodiments, the peptide may comprise the motif RPAPAPI (SEQ ID NO: 36), RPAPAPV (SEQ ID NO: 38), QPAPAPV (SEQ ID NO: 37), or QPAPAPI SEQ ID NO: 39).
[0601] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P6, P7, P9, P10, P15, Peptide Z1, Peptide Z2, Peptide Z3, Peptide L1, Peptide L2 and / or Peptide L3 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. Such peptides may be included in medical aspects of the present invention.
[0602] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P6, P7, P9, P10, P15, Peptide Z1, Peptide Z2 and / or Peptide Z3, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0603] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P6, P7, P9, P10, P15, Peptide Z2 and / or Peptide Z3, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%,80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0604] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P6, P7, P9, P10 and / or P15 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0605] In such embodiments, the peptide may comprise the sequence of any one or more of peptides P6, P7, P9 and / or P10 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0606] Suitably, the peptide may consist of the sequence of any one or more of peptides P6, P7, P9 and / or P10 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0607] In such embodiments, the peptide may comprise a continuous sequence of at least 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acids present in the sequence of P15, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. In some embodiments, the peptide may comprise or consist of the sequence of P15 as defined in the tables above.
[0608] In some embodiments, the peptide comprises or consists of the sequence of P6 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P7 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P9 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P10 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P15 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L1 as defined in the tables above. In some embodiments, the peptide comprises orconsists of the sequence of Peptide L2 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L3 as defined in the tables above.
[0609] Motif ADAM MQAL (SEQ ID NO: 12) embodiments
[0610] In some embodiments, the peptide comprises the motif ADAM MQAL (SEQ ID NO: 12), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid.
[0611] In some embodiments, the peptide may comprise the motif SADAMMQALL (SEQ ID NO: 33), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid.
[0612] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides Peptide L28, Peptide L29, Peptide Z29, Peptide Z30, Peptide Z31, Peptide L30 and / or Peptide L31 , as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. Such peptides may be included in medical aspects of the present invention.
[0613] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides Peptide Z29, Peptide Z30 and / or Peptide Z31 , as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0614] In such embodiments, the peptide may comprise or consist of the sequence of peptide Peptide Z30, as defined in the tables above, ora sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0615] In some embodiments, the peptide comprises or consists of the sequence of Peptide L28 as defined in the tables above. In some embodiments, the peptide comprises or consists of thesequence of Peptide L29 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L30 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of Peptide L31 as defined in the tables above.
[0616] Motif KKSKISASR (SEQ ID NO: 13) embodiments
[0617] In some embodiments, the peptide comprises the motif KKSKISASR (SEQ ID NO: 13), suitably wherein up to four, three, two or one amino acids in the motif may be independently substituted for another amino acid. Suitably, wherein up to four amino acids in the motif may be independently substituted for another amino acid.
[0618] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P11 , P12, Peptide Z7, and / or Peptide Z8, and / or P17 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. Such peptides may be included in medical aspects of the present invention.
[0619] In such embodiments, the peptide may comprise or consist of the sequence of any one or more of peptides P11 , P12, P17, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto. Such peptides may be included in medical aspects of the present invention.
[0620] In such embodiments, the peptide may comprise or consist of the sequence of peptide P11 and / or P12, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0621] In such embodiments, the peptide may comprise or consist of a continuous sequence of at least 4, 5, 6, 7, 8, 9 or 10 amino acids present in the sequence of P17, as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.In such embodiments, the peptide may comprise or consist of the sequence of P17 as defined in the tables above.
[0622] In some embodiments, the peptide comprises or consists of the sequence of P11 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P12 as defined in the tables above. In some embodiments, the peptide comprises or consists of the sequence of P17 as defined in the tables above.
[0623] Various embodiments
[0624] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of P2-2, P1, P2, P2-1, P2-3, P2-4, P2-5, P3, P3-1, P4, P5, Peptide Z1, Peptide Z2, Peptide Z3, Peptide Z5, Peptide Z6, Peptide Z7, Peptide Z8, Peptide Z9, Peptide Z12, Peptide Z13, Peptide Z25, Peptide Z26, Peptide Z27, Peptide Z29, Peptide Z30, Peptide Z31, Peptide Z32, Peptide Z33, Peptide Z34, Peptide Z35, Peptide Z36, Peptide Z39, and / or Peptide Z40 as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0625] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of P2-2, P1, P2, P2-1, P2-3, P2-4, P2-5, P3, P3-1, P4, P5, Peptide Z2, Peptide Z3, Peptide Z5, Peptide Z6, Peptide Z7, Peptide Z8, Peptide Z9, Peptide Z12, Peptide Z13, Peptide Z25, Peptide Z26, Peptide Z27, Peptide Z30, Peptide Z32, Peptide Z33, Peptide Z36, Peptide Z39, and / or Peptide Z40 as defined in the table above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.
[0626] In some embodiments, the peptide may comprise or consist of the sequence of any one or more of P2-2, P1, P2, P2-1, P2-3, P2-4, P2-5, P3, P3-1, P4, P5, Peptide Z1, Peptide Z2, Peptide Z3, Peptide Z5, Peptide Z6, Peptide Z7, Peptide Z8, Peptide Z9, Peptide Z12, Peptide Z13, Peptide Z25, Peptide Z26, Peptide Z27, Peptide Z29, Peptide Z30, Peptide Z31, Peptide Z32, Peptide Z34, Peptide Z35, and / or Peptide Z36 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, suitably a sequence having at least 70% identity thereto.In one particular embodiment, the peptide may comprise or consist of the sequence of peptide P5 as defined in the tables above, or a sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity thereto, preferably having at least 70% identity thereto.
[0627] Binding to a PDE4 protein
[0628] The peptide is capable of binding to a phosphodiesterase-4 (PDE4) protein. It is believed that the binding of the peptide to a PDE4 protein inhibits the PDE4 protein from binding to a TPNI protein, as described further hereinbelow. Suitably therefore the peptide inhibits the binding of a PDE4 protein to a TPNI protein. Suitably the peptide binds to the PDE4 protein and inhibits the binding thereof to a TPNI protein.
[0629] The peptide may be capable of binding to any region of a PDE4 protein. The peptide may be capable of binding at least in part to Upstream Conserved Region 1 (UCR1), Linker Region 1 (LR1), Upstream Conserved Region 2 (UCR2), Linker Region 2 (LR2) and / or the catalytic region of a PDE4 protein. The peptide may be capable of binding to any one or more of these regions. Suitably, the peptide may be capable of binding at least in part to LR1.
[0630] In one embodiment, the peptide is capable of binding at least in part to LR1 of the PDE4 protein. In one embodiment, the peptide is capable of binding to any one or more of the following PDE4 residues: A111, L116, Q117, D118, R119, C128, T137, 1138, T139, E140 and / or E141 according to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. Suitably according to SEQ ID NO: 1. Suitably according to SEQ ID NO: 2. Suitably according to SEQ ID NO 3. Suitably, the peptide may be capable of binding at least in part to LR1 of the PDE4 protein and to any one or more of the following PDE4 residues A111, L116, Q117, D118, R119, C128, T137, 1138, T139, E140 and / or E141.
[0631] In such embodiments, the peptide may comprise any motif mentioned hereinabove. In such embodiments, the peptide may comprise the motif KKED(I / T)EK (SEQ ID NO: 10), KKEDIEK (SEQ ID NO: 14), or KKEDTEK (SEQ ID NO: 15), suitably wherein up to four, three, two or one amino acid in the motif may be independently substituted for another amino acid.
[0632] Suitably therefore, the peptide that is capable of binding at least in part to LR1 of the PDE4 protein, or the peptide that is capable of binding to any one or more of the following PDE4residues: A111, L116, Q117, D118, R119, C128, T137, 1138, T139, E140 and / or E141, may comprise or consist of any one or more of peptides P3, P3-1, P4, P13, P33 (i.e. Peptide L33), Peptide Z34, Peptide Z35, Peptide Z36, Peptide L34, Peptide L35, Peptide L36 and / or P16 as defined hereinabove. Suitably, such a peptide may comprise or consist of P33 (i.e. Peptide L33).
[0633] Suitably therefore, the peptide that is capable of binding at least in part to LR1 of the PDE4 protein, or the peptide that is capable of binding to any one or more of the following PDE4 residues A111, L116, Q117, D118, R119, C128, T137, 1138, T139, E140 and / or E141, may be included in medical aspects of the present invention.
[0634] The binding between the peptide and the PDE4 protein may be non-covalent. Non-covalent binding may include hydrogen bonds, electrostatic interactions, van der Waals interactions, hydrophobic interactions, dipole-dipole interactions, and / or any other non-covalent interaction.
[0635] PDE4 protein
[0636] The PDE4 protein may be any PDE4 protein. Suitably therefore, the peptide may be capable of binding to any PDE4 protein. Suitably therefore, the peptide may be capable of inhibiting any PDE4 protein from binding to a TPNI protein.
[0637] The PDE4 protein may be a PDE4 protein from any species. Suitably therefore, the peptide may be capable of binding to a PDE4 protein from any species. Suitably therefore, the peptide may be capable of inhibiting a PDE4 protein from any species from binding to a TPNI protein.
[0638] The PDE4 protein may be a human (Homo sapiens) or a rodent (Rodentia) such as a rat (Rattus sp.) or mouse (Mus sp.) PDE4 protein. Suitably therefore, the peptide may be capable of binding to a human (Homo sapiens) or a rodent (Rodentia) such as a rat (Rattus sp.) or mouse (Mus sp.) PDE4 protein. Suitably therefore, the peptide may be capable of inhibiting a human (Homo sapiens) or a rodent (Rodentia) such as a rat (Rattus sp.) or mouse (Mus sp.) PDE4 protein from binding to a TPNI protein.
[0639] In some embodiments, the PDE4 protein is a human (Homo sapiens) PDE4 protein. In such embodiments, the peptide is capable of binding to a human (Homo sapiens) PDE4 protein. In such embodiments, the peptide is capable of inhibiting a human (Homo sapiens) PDE4 protein from binding to a TPNI protein.In such embodiments, the PDE4 protein may be human (Homo sapiens) PDE4D9 according to SEQ ID NO: 1, or a homologous protein (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto. Suitably a sequence with at least 98% identity thereto.
[0640] In some embodiments, the PDE4 protein is a rat (Rattus norvegicus) PDE4 protein. In such embodiments, the peptide is capable of binding to a rat (Rattus norvegicus) PDE4 protein. In such embodiments, the peptide is capable of inhibiting a rat (Rattus norvegicus) PDE4 protein from binding to a TPNI protein.
[0641] In such embodiments, the PDE4 protein may be rat (Rattus norvegicus) PDE4D9 according to SEQ ID NO: 3, or a homologous protein (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto. Suitably a sequence with at least 98% identity thereto.
[0642] In some embodiments, the PDE4 protein is a mouse (Mus musculus) PDE4 protein. In such embodiments, the peptide is capable of binding to a mouse (Mus musculus) PDE4 protein. In such embodiments, the peptide is capable of inhibiting a mouse (Mus musculus) PDE4 protein from binding to a TPNI protein.
[0643] In such embodiments, the PDE4 protein may be mouse (Mus musculus) PDE4D9 according to SEQ ID NO: 2, or a homologous protein (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto. Suitably a sequence with at least 98% identity thereto.
[0644] The PDE4 protein may be any PDE4 subfamily protein. The PDE protein may be a PDE4 subfamily A, B, C and / or D protein, or suitably any isoform thereof. Suitably therefore, the PDE protein may be a PDE4A subfamily protein, a PDE4B subfamily protein, a PDE4C subfamily protein, and / or a PDE4D subfamily protein. Suitably therefore, the peptide may be capable of binding to a PDE4 subfamily A, B, C and / or D protein. Suitably therefore, the peptide may be capable of inhibiting a PDE4 subfamily A, B, C and / or D protein from binding to a TPNI protein.Suitably therefore, the peptide may be capable of inhibiting the binding of a PDE4 subfamily A, B, C and / or D protein to a TPNI protein.
[0645] The PDE protein may be a PDE4 subfamily A, C and / or D protein, or suitably any isoform thereof. Suitably therefore, the PDE protein may be a PDE4A subfamily protein, a PDE4C subfamily protein, and / or a PDE4D subfamily protein. Suitably therefore, the peptide may be capable of binding to a PDE4 subfamily A, C and / or D protein. Suitably therefore, the peptide may be capable of inhibiting a PDE4 subfamily A, C and / or D protein from binding to a TPNI protein. Suitably therefore, the peptide may be capable of inhibiting the binding of a PDE4 subfamily A, C and / or D protein to a TPNI protein. Suitably in some embodiments the PDE protein is not PDE4B.
[0646] In some embodiments, the PDE4 protein is a PDE4 subfamily A protein (i.e., a PDE4A protein). In such embodiments, the protein is capable of binding to a PDE4A subfamily protein. In such embodiments, the peptide is capable of inhibiting a PDE4A subfamily protein from binding to TPNI protein. In such embodiments, the peptide is capable of inhibiting the binding of PDE4A to a TPNI protein.
[0647] The PDE4 protein may be any PDE4A subfamily protein isoform. The PDE4 protein may be PDE4A1, PDE4A2, PDE4A3, PDE4A4, PDE4A5, PDE4A6 and / or PDE4A7. The sequences of these PDE4A isoforms may be found in publicly available databases. For example, their sequences as present in humans may be found on UniProt under accession numbers P27815-1, P27815-2, P27815-3, P27815-4, P27815-5, P27815-6 and P27815-7, respectively, incorporated herein by reference.
[0648] In some embodiments, the PDE4 protein is a PDE4 subfamily B protein (i.e., a PDE4B protein). In such embodiments, the protein is capable of binding to a PDE4B subfamily protein. In such embodiments, the peptide is capable of inhibiting a PDE4B subfamily protein from binding to TPNI protein. In such embodiments, the peptide is capable of inhibiting the binding of PDE4B to a TPNI protein.
[0649] The PDE4 protein may be any PDE4B subfamily protein isoform. The PDE4 protein may be PDE4B1, PDE4B2, PDE4B3, PDE4B4 and / or PDE4B5. The sequences of these PDE4B isoforms may be found in publicly available databases. For example, their sequences as present in humans may be found on UniProt under accession numbers Q07343-1, Q07343-2, Q07343-3 and Q07343-4, respectively, incorporated herein by reference.In some embodiments, the PDE4 protein is a PDE4 subfamily C protein (i.e., a PDE4C protein). In such embodiments, the protein is capable of binding to a PDE4C subfamily protein. In such embodiments, the peptide is capable of inhibiting a PDE4C subfamily protein from binding to TPNI protein. In such embodiments, the peptide is capable of inhibiting the binding of PDE4C to a TPNI protein.
[0650] The PDE4 protein may be any PDE4C subfamily protein isoform. The PDE4 protein may be PDE4C1, PDE4C2, PDE4C3, PDE4C4, PDE4C5, PDE4C6 and / or PDE4C7. The sequences of these PDE4C isoforms may be found in publicly available databases. For example, their sequences as present in humans may be found on UniProt under accession numbers Q08493-1, Q08493-2, Q08493-3, Q08493-4, Q08493-5, Q08493-6 and Q08493-7, respectively, incorporated herein by reference.
[0651] In some embodiments, the PDE4 protein is a PDE4 subfamily D protein (i.e., a PDE4D protein). In such embodiments, the protein is capable of binding to a PDE4D subfamily protein. In such embodiments, the peptide is capable of inhibiting a PDE4D subfamily protein from binding to TPNI protein. In such embodiments, the peptide is capable of inhibiting the binding of PDE4D to a TPNI protein.
[0652] The PDE4 protein may be any PDE4D subfamily protein isoform. The PDE4 protein may be PDE4D1. The sequences of PDE4D1 may be found in publicly available databases. For example, its sequences as present in humans may be found on UniProt under accession number A0A140VJR0, incorporated herein by reference.
[0653] In some embodiments, the PDE4 protein is a PDE4 subfamily D protein (i.e., a PDE4D protein). In such embodiments, the protein is capable of binding to a PDE4D subfamily protein. In such embodiments, the peptide is capable of inhibiting a PDE4D subfamily protein from binding to TPNI protein. In such embodiments, the peptide is capable of inhibiting the binding of PDE4D to a TPNI protein.
[0654] The PDE4 protein may be any PDE4D subfamily protein isoform. The PDE4 protein may be PDE4D1, PDE4D2, PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D7, PDE4D8 and / or PDE4D9. The PDE4 protein may be PDE4D3, PDE4D8 and / or PDE4D9. The PDE4 protein may PDE4D1 , PDE4D2, PDE4D5 and / or PDE4D9. The PDE4 protein may PDE4D1 , PDE4D2, and / or PDE4D9. The PDE4 protein may be PDE4D1. The PDE4 protein may be PDE4D2. The PDE4 protein may be PDE4D3. The PDE4 protein may be PDE4D4. The PDE4 protein may be PDE4D5. The PDE4 protein may be PDE4D6. The PDE4 protein may be PDE4D7.The PDE4 protein may be PDE4D8. The PDE4 protein may be PDE4D9. In one embodiment, the PDE4 protein is PDE4D9. In some embodiments the PDE4 protein may be PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D7, PDE4D8, and / or PDE4D9. In some embodiments the PDE4 protein may be PDE4D3, PDE4D4, PDE4D5, PDE4D7, PDE4D8, and / or PDE4D9. In some embodiments the PDE4 protein may be PDE4D3, PDE4D4, PDE4D5, PDE4D7, and / or PDE4D9 In some embodiments the PDE4 protein may be PDE4D3, PDE4D5, PDE4D7, and / or PDE4D9.
[0655] Without wishing to be bound by theory, PDE4B and PDE4D are believed to be the most abundantly expressed subfamilies of PDE4 in cardiomyocytes. Specifically, PDE4D1, PDE4D2, PDE4D5 and PDE4D9 are believed to be the most abundantly expressed isoforms of PDE4 in cardiomyocytes, suitably ventricular cardiomyocytes, suitably neonatal ventricular cardiomyocytes, of which PDE4D1, PDE4D2 and PDE4D9 are believed to be the most highly expressed.
[0656] Without wishing to be bound by theory, PDE4D subfamily proteins (i.e. , PDE4D isoforms) are believed to be upregulated in patients with heart failure, suitably in the cardiomyocytes of patients with heart failure, suitably in the ventricular cardiomyocytes of patients with heart failure, as compared to healthy subjects. Without wishing to be bound by theory, a larger amount of PDE4D9 is associated with TPNI in patients with heart failure, suitably in the cardiomyocytes of patients with heart failure, as compared to healthy subjects.
[0657] Suitably therefore, the peptide may be capable of inhibiting a PDE4 protein from binding to a TPNI protein in a myocyte. The peptide may be capable of inhibiting a PDE4 protein from binding to a TPNI protein in a cardiomyocyte. The peptide may be capable of inhibiting a PDE4 protein from binding to a TPNI protein in a ventricular cardiomyocyte.
[0658] Suitably therefore, the peptide may be capable of inhibiting PDE4D1, PDE4D2 and / or PDE4D9 from binding to a TPNI protein in a myocyte. The peptide may be capable of inhibiting PDE4D1, PDE4D2 and / or PDE4D9 from binding to a TPNI protein in a cardiomyocyte. The peptide may be capable of inhibiting PDE4D1, PDE4D2 and / or PDE4D9 from binding to a TPNI protein in a ventricular cardiomyocyte.
[0659] In some embodiments, the PDE4 protein is PDE4D9. In such embodiments, the protein is capable of binding to PDE4D9. In such embodiments, the peptide is capable of inhibiting PDE4D9 from binding to a TPNI protein. In such embodiments, the peptide is capable of inhibiting the binding of PDE4D9 to a TPNI protein.In such embodiment, the peptide may be capable of inhibiting PDE4D9 from binding to a TPNI protein in a myocyte. In such embodiment, the peptide may be capable of inhibiting PDE4D9 from binding to a TPNI protein in a cardiomyocyte. In such embodiment, the peptide may be capable of inhibiting PDE4D9 from binding to a TPNI protein in a ventricular cardiomyocyte.
[0660] Effects of binding to a PDE4 protein
[0661] The peptide is capable of binding to a phosphodiesterase-4 (PDE4) protein, suitably any PDE4 protein as described, such as PDE4D9. Such binding may have a number of effects.
[0662] Inhibition of PDE binding to a TPNI protein
[0663] It has been discovered that, typically PDE4 binds to TPNI proteins in myocytes and causes the hydrolysis of cAMP in the proximity of TPNI, which in turn prevents the phosphorylation of TPNI, which is in complex with TPNC as part of the troponin complex, which in turn increases the affinity of Ca2+ for TPNC, which in turn reduces myocyte relaxation.
[0664] Binding of the peptide to a PDE4 protein may inhibit the PDE4 protein from binding to a TPNI protein. Suitably therefore, binding of the peptide to a PDE4 protein may inhibit or be capable of inhibiting the formation of a TPNI / PDE4 complex.
[0665] For example, binding of the peptide to a PDE4D9 protein may inhibit the PDE4D9 protein from binding to a TPNI protein. Suitably therefore, binding of the peptide to the PDE4D9 protein may inhibit or be capable of inhibiting the formation of a TPNI / PDE4D9 complex.
[0666] The peptide’s ability to inhibit the binding of a PDE4 protein to a TPNI protein may be assayed using for example co-immunoprecipitation as described in the Examples.
[0667] It is believed that the peptide is an allosteric inhibitor of a PDE4 protein, suitably with respect to the phosphodiesterase activity of the PDE4 protein.
[0668] Increase in cAMP
[0669] Binding of the peptide to a PDE4 protein may lead to an increase in the concentration of cAMP in the proximity of a TPNI protein, suitably it may lead to an increase in the concentration of cAMP in the proximity of a troponin complex comprising a TPNI protein, suitably it may leadto an increase in the concentration of cAMP in the proximity of a myofilament complex comprising a TPNI protein, suitably it may lead to an increase in the concentration of cAMP in the proximity of a myofibril complex comprising a TPNI protein, or in a cell that comprises a TPNI protein.
[0670] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may lead to an increase in the concentration of cAMP in the proximity of the TPNI protein, suitably it may lead to an increase in the concentration of cAMP in the proximity of a troponin complex comprising the TPNI protein, suitably it may lead to an increase in the concentration of cAMP in the proximity of a myofilament complex comprising the TPNI protein, suitably it may lead to an increase in the concentration of cAMP in the proximity of a myofibril complex comprising the TPNI protein, or in a cell that comprises the TPNI protein.
[0671] The term “proximity” refers to proximity on a molecular level, suitably nanometre-sized proximity. Suitably, “in the proximity of” may mean within 100, 50, 30, 25, 20, 15, 10 or 5 nm.
[0672] Cells that comprise a TPNI protein may include muscle cells (i.e. , myocytes) such as heart muscle cells (i.e., cardiomyocyte), preferably ventricular cardiomyocytes.
[0673] Suitably therefore, binding of the peptide to a PDE4 protein may lead to an increase in the concentration of cAMP within 100, 50, 30, 25, 20, 15, 10 or 5 nm of a TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 100, 50, 30, 25, 20, 15, 10 or 5 nm of a troponin complex comprising a TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 100, 50, 30, 25, 20, 15, 10 or 5 nm of a myofilament complex comprising a TPNI protein, or of a myofibril complex comprising a TPNI protein.
[0674] In one embodiment, binding of the peptide to a PDE4 protein may lead to an increase in the concentration of cAMP within 30 nm of a TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 30 nm of a troponin complex comprising a TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 30 nm of a myofilament complex comprising a TPNI protein, or of a myofibril complex comprising a TPNI protein.
[0675] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may lead to an increase in the concentration of cAMP within 100, 50, 30, 25, 20, 15, 10 or 5 nm of the TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 100, 50, 30, 25, 20, 15, 10 or 5 nm of a troponin complex comprising the TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 100, 50, 30, 25, 20, 15, 10 or 5 nm of amyofilament complex comprising the TPNI protein, or of a myofibril complex comprising the TPNI protein
[0676] In one embodiment, the inhibition of binding of a PDE4 protein to a TPNI protein may lead to an increase in the concentration of cAMP within 30 nm of the TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 30 nm of a troponin complex comprising the TPNI protein, suitably it may lead to an increase in the concentration of cAMP within 30 nm of a myofilament complex comprising the TPNI protein, or of a myofibril complex comprising the TPNI protein
[0677] Binding of the peptide to a PDE4 protein may lead to an increase in the concentration of cAMP within the cAMP nanodomain surrounding a TPNI protein or the troponin complex comprising a TPNI protein.
[0678] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may lead to an increase in the concentration of cAMP within the cAMP nanodomain surrounding the TPNI protein or the troponin complex comprising the TPNI protein.
[0679] An increase in the concentration of cAMP within the cAMP nanodomain surrounding a TPNI protein, or an increase in the concentration of cAMP in the proximity of a TPNI protein, troponin complex, myofilament, myofibril, or in a cell, may be measured using techniques described in the Examples herein such as the CLITie assay.
[0680] Increase in phosphorylation
[0681] Binding of the peptide to a PDE4 protein may promote or increase the phosphorylation of a TPNI protein, suitably it may promote or increase the phosphorylation of a troponin complex comprising a TPNI protein, suitably it may promote or increase the phosphorylation of a myofilament comprising a TPNI protein, or of a myofibril complex comprising a TPNI protein. Suitably, the phosphorylation may be protein kinase A (PKA)-dependent.
[0682] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may promote or increase the phosphorylation of the TPNI protein, suitably it may promote or increase the phosphorylation of a troponin complex comprising the TPNI protein, suitably it may promote or increase the phosphorylation of a myofilament comprising the TPNI protein, or of a myofibril complex comprising the TPNI protein. Suitably, the phosphorylation may be protein kinase A (PKA)-dependent.Binding of the peptide to a PDE4 protein suitably does not to affect the phosphorylation of other PKA targets, such as those in a myofilament, such as myosin binding protein C (MyBPC), phospholamban or cAMP response element binding protein (CREB) and / or suitably does not affect phosphorylation in the bulk cytosol of the cell comprising a TPNI protein or the TPNI protein, suitably in the bulk cytosol of myocytes, cardiomyocytes and / or ventricular cardiomyocytes.
[0683] The phosphorylation of TPNI and / or PKA targets may be assayed for example by immunostaining for the desired phosphorylation as described in the Examples herein.
[0684] Dissociation of Ca2+
[0685] Binding of the peptide to a PDE4 protein may promote or increase the dissociation or release of calcium (Ca2+) from a troponin complex comprising a TPNI protein, suitably it may promote or increase the dissociation or release of calcium (Ca2+) from a TPNC protein that is complexed with a TPNI protein as part of a troponin complex, or from a myofilament comprising a TPNI protein.
[0686] Suitably therefore, binding of the peptide to a PDE4 protein may desensitise or decrease the sensitivity of a TPNC protein to Ca2+, suitably it may desensitise or decrease the sensitivity of a TPNC protein that is complexed with a TPNI protein as part of a troponin complex to Ca2+.
[0687] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may promote or increase the dissociation or release of calcium (Ca2+) from a troponin complex comprising the TPNI protein, or from a TPNC protein that is complexed with the TPNI protein as part of a troponin complex, or from a myofilament comprising the TPNI protein.
[0688] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may desensitise or decrease the sensitivity of a TPNC protein to Ca2+, suitably it may desensitise or decrease the sensitivity of a TPNC protein that is complexed with a TPNI protein as part of a troponin complex to Ca2+.
[0689] The affinity of TPNC for calcium (Ca2+) may be measured by techniques known in the art such as skinned cardiac muscle preparations, as described for example in Hofmann, Polly A., and Franklin Fuchs. "Bound calcium and force development in skinned cardiac musclebundles: effect of sarcomere length." Journal of molecular and cellular cardiology 20.8 (1988): 667-677, incorporated herein by reference.
[0690] Muscle relaxation
[0691] Binding of the peptide to a PDE4 protein may promote relaxation of a sarcomere comprising a TPNI protein, suitably it may promote relaxation of a myofibril comprising a TPNI protein, suitably it may promote relaxation of a muscle cell (i.e. , myocyte) comprising a TPNI protein, or muscle tissue comprising TPNI proteins. Suitably therefore, binding of the peptide to a PDE4 protein may promote relaxation of a sarcomere, myofibril, myocyte or muscle tissue.
[0692] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may promote relaxation of a sarcomere comprising the TPNI protein, suitably it may promote relaxation a myofibril comprising the TPNI protein, suitably it may promote relaxation a myocyte comprising the TPNI protein, or muscle tissue comprising TPNI proteins. Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may promote relaxation of a sarcomere, myofibril, myocyte or muscle tissue.
[0693] Binding of the peptide to a PDE4 protein may increase or enhance the isometric force capable of being generated by a sarcomere comprising a TPNI protein, suitably it may increase or enhance the isometric force capable of being generated by a myofibril comprising a TPNI protein, suitably it may increase or enhance the isometric force capable of being generated by a myocyte comprising a TPNI protein, or muscle tissue comprising TPNI proteins. Suitably therefore, binding of the peptide to a PDE4 protein may enhance the isometric force capable of being generated by a sarcomere, myofibril, myocyte or muscle tissue.
[0694] Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may increase or enhance the isometric force capable of being generated by a sarcomere comprising the TPNI protein, suitably it may increase or enhance the isometric force capable of being generated by a myofibril comprising the TPNI protein, suitably it may increase or enhance the isometric force capable of being generated by a myocyte comprising the TPNI protein, or muscle tissue comprising TPNI proteins. Suitably therefore, the inhibition of binding of a PDE4 protein to a TPNI protein may increase or enhance the isometric force capable of being generated by a sarcomere, myofibril, myocyte or muscle tissue.
[0695] Suitably the muscle cell (i.e., myocyte) may be a heart muscle cell (i.e., cardiomyocyte), in one embodiment the muscle cell is a ventricular cardiomyocyte.Suitably therefore, the peptide may promote or enhance lusitropy. The peptide may be lusitropic.
[0696] The relaxation of a sarcomere, myofibril, myocyte or muscle tissue may be assayed using techniques described in the Examples such as the cardiac work-loop technique or visual microscopic imaging (e.g., SarcTrack).
[0697] TPNI
[0698] The peptide is capable of inhibiting a PDE4 protein from binding to a TPNI protein. Suitably therefore, the TPNI protein may be in the same cell as the PDE4 protein. Suitably therefore, the peptide is capable of inhibiting the formation of a TPNI / PDE4 complex, suitably in a myocyte, suitably in a cardiomyocyte, suitably in a ventricular cardiomyocyte.
[0699] The TPNI protein may be a TPNI protein from any species. Suitably TPNI may also be known as TNNI3.
[0700] The TPNI may be human (Homo sapiens) TPNI according to SEQ ID NO: 4, or a homologous (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto.
[0701] The TPNI may be rat (Rattus norvegicus) TPNI according to SEQ ID NO: 6, or a homologous (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto.
[0702] The TPNI may be mouse (Mus musculus) TPNI according to SEQ ID NO: 5, or a homologous (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto.The TPNI may be sheep (Ovis aries) TPNI according to SEQ ID NO: 7, or a homologous (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto.
[0703] The TPNI may be pig (Sus scrofa) TPNI according to SEQ ID NO: 8, or a homologous (such as an orthologue or paralogue) thereof, or a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, preferably a sequence with at least 70% identity thereto.
[0704] Nucleic acid sequence
[0705] The present invention also relates to a nucleic acid sequence encoding the peptide of the invention. This may be referred to herein as “the nucleic acid sequence” or “the nucleic acid sequence of the invention”. Suitably the nucleic acid sequence may encode any version of the peptide described hereinabove.
[0706] Nucleic acid sequences of the present invention may be provided by reference to the standard genetic code, which may be used to design such nucleic acid sequences. As such, it is within the scope of a skilled person’s abilities to provide a nucleic acid sequence encoding the peptide of the invention.
[0707] The nucleic acid sequence may be any type of nucleic acid capable of encoding the peptide of the invention. In one embodiment, the nucleic acid sequence is RNA. In one embodiment, the nucleic acid sequence is DNA.
[0708] The nucleic acid sequence may be a mRNA sequence. Suitably the mRNA sequence may comprise an open reading frame encoding the peptide. By ‘open reading frame’ is meant a sequence which can be translated into amino acids of a peptide. Suitably the mRNA sequence may further comprise a sequence encoding a signal peptide. Suitably a nucleotide sequence encoding a signal peptide. Suitably the nucleotide sequence may encode a signal peptide which targets the peptide to the secretory pathway. Suitably the sequence encoding the signal peptide may be operably linked to the open reading frame. Suitably the sequence encoding the signal peptide may be positioned at the 5’ or the 3’ of the open reading frame. Suitably the sequence encoding the signal peptide may be contiguous with the open reading frame,suitably such that the peptide is translated as a fusion protein with the signal peptide. Suitably the signal peptide may be fused to the C or N-terminus of the peptide. Suitably the mRNA sequence may further comprise a linker located between the open reading frame and the sequence encoding a signal peptide. Suitably said linker may be a cleavable linker, such that the signal peptide may be cleaved from the peptide once secreted. Suitable linkers may be self cleaving peptide linkers such as T2A, E2A, P2A for example.
[0709] Suitably the mRNA sequence may further comprise one or more additional elements to aid in expression. The mRNA sequence may comprise a 5’IITR or a 3’IITR. Suitably the UTRs may be heterologous to the open reading frame encoding the peptide, suitably they may be derived from naturally occurring genes or may be synthetically engineered. A “5'untranslated region” (5'IITR) refers to a region of an mRNA that is directly upstream (i.e. , 5') from the start codon (i.e. , the first codon of an mRNA transcript translated by a ribosome) that does not encode a polypeptide. A “3' untranslated region” (3'IITR) refers to a region of an mRNA that is directly downstream (i.e., 3') from the stop codon (i.e., the codon of an mRNA transcript that signals a termination of translation) that does not encode a polypeptide.
[0710] The mRNA sequence may also comprise a cap structure and / or a tail structure and / or include one or more nonstandard nucleotide residues to render the mRNA sequence more stable in a in vitro or in vivo environment. Suitably, the mRNA sequence may comprise a 5’ cap, or a 5’ cap analogue such as GA, 7mG(5')ppp(5')NlmpNp, capO (methylation of the first nucleobase, e.g. m7GpppN), cap1 (additional methylation of the ribose of the adjacent nucleotide of m7GpppN), cap2 (additional methylation of the ribose of the 2nd nucleotide downstream of the m7GpppN), cap3 (additional methylation of the ribose of the 3rd nucleotide downstream of the m7GpppN), cap4 (additional methylation of the ribose of the 4th nucleotide downstream of the m7GpppN), ARCA (anti-reverse cap analogue), modified ARCA (e.g. phosphothioate modified ARCA), inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine. Further cap analogues have been described previously (W02008 / 016473, W02008 / 157688, WG2009 / 149253, WO2011 / 015347, and WO2013 / 059475).
[0711] The mRNA sequence may comprise a 3’ poy(A) tail. A polyA tail may contain 10 to 300 adenosine monophosphates. For example, a polyA tail may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosine monophosphates. In a relevant biological setting (e.g., in cells, in vivo) the poly(A) tail functions to protect mRNA from enzymatic degradation, e.g., in thecytoplasm, and aids in transcription termination, export of the mRNA from the nucleus and translation.
[0712] Suitably the nucleic acid may further comprise a ribosome binding site, also referred to as “Kozak sequence”.
[0713] The nucleic acid may comprise one or more modified nucleotides. Suitably the modifications may comprise chemical modifications. The terms “chemical modification” and “chemically modified” with respect to the nucleic acid of the invention refer to modification with respect to adenosine (A), guanosine (G), uridine (II), thymidine (T) or cytidine (C) ribonucleosides. The modifications may be present on an internucleotide linkages, purine or pyrimidine bases, or sugars. The modification may be introduced with chemical synthesis or with a polymerase enzyme at the terminal of a chain or anywhere else in the chain. Any of the regions of a polynucleotide may be chemically modified.
[0714] In some examples, the phosphate backbone of the nucleic acid may be modified. A backbone modification in connection with the present invention is a modification in which phosphates of the backbone of the nucleotides contained in the nucleic acid are chemically modified. For example, the nucleic acid may comprise a phosphorothioate-modified phosphate backbone, preferably at least one of the phosphate oxygens contained in the phosphate backbone being replaced by a sulfur atom. Suitably the nucleic acid may further include, for example: non-ionic phosphate analogues, such as, for example, alkyl and aryl phosphonates, in which the charged phosphonate oxygen is replaced by an alkyl or aryl group, or phosphodiesters and alkylphosphotriesters, in which the charged oxygen residue is present in alkylated form. Such backbone modifications typically include, modifications from the group consisting of methylphosphonates, phosphoramidates and phosphorothioates (e.g. cytidine-5' -O-(1-thiophosphate)).
[0715] Expression construct
[0716] The present invention also relates to an expression construct comprising the nucleic acid sequence of the invention or encoding the peptide of the invention. This may be referred to herein as “the expression construct” or “the expression construct of the invention”.
[0717] The expression construct may be any nucleic acid sequence capable of directing expression of the nucleic acid sequence of the invention in an appropriate host or host cell, such as in asubject or patient, or in a cell of a subject or patient, to provide the peptide of the invention. Suitable host cells may include myocytes, cardiomyocytes or ventricular cardiomyocytes.
[0718] The expression construct may include one or more regulatory sequences operably linked to the nucleic acid sequence of the invention. For example, the expression vectors may contain a promoter, transcription initiation site, ribosome binding site, RNA processing signal, transcription termination site, a polyadenylation signal, and / or any sequence required for proper translation of the nucleic acid sequence of the invention. For example, the expression construct may comprise a promoter operably linked to the nucleic acid sequence of the invention, which is optionally further operably linked to a termination signal sequence.
[0719] The expression construct may include one or more regulatory sequences that are functional in host cells such as myocytes, cardiomyocytes and / or ventricular cardiomyocytes. The expression construct may thus allow expression of the nucleic acid sequence of the invention in a host cell such as a human host cell and / or a myocyte, cardiomyocyte, or ventricular cardiomyocyte.
[0720] The term “operably linked” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control element “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with or dictated by the control element.
[0721] The expression construct may include transcriptional and translational regulatory sequences, and may provide for inducible or constitutive expression, where the coding region of the nucleic acid sequence of the invention is operably linked under the transcriptional control of the transcriptional initiation region and a transcriptional and translational termination region. These control regions may derived from exogenous sources, including species-specific endogenous promoters. In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In addition to constitutive and inducible promoters, strong promoters find use in the expression constructs described herein, particularly where high expression levels are desired in an in vivo (cell-based) or in an in vitro expression system. Exemplary promoters include mouse mammary tumour virus (MMTV) promoters, Rous sarcoma virus (RSV) promoters, human cytomegalovirus (CMV) promoters, simian virus 40 (SV40) promoters, adenovirus promoters, or the cardiac troponin promoter for example. Alternative promoters can also be used.The expression construct may comprise, as necessary, an enhancer, a silencer, a selection marker gene (for example, a drug resistance gene such as a neomycin resistance gene), an SV40 replication origin, a Woodchuck hepatitis posttranscriptional regulatory element 3 (WPRE3) and the like. Those skilled in the art are able to construct an expression construct capable of inducing expression of the peptide of the invention at a desired expression level by appropriately selecting a combination of known enhancers, silencers, selection marker genes, terminators, and so forth in consideration of the type of the promoter utilised and so on.
[0722] Expression constructs generally have convenient restriction sites located near the promoter sequence to provide for the insertion of a nucleic acid sequence (such as, in the present invention, the nucleic acid sequence of the invention). A selectable marker operative in the host cell may be present to facilitate selection of cells containing the expression construct. In addition, the expression construct may include additional elements. For example, the expression vector may have one or two replication systems, thus allowing it to be maintained in different organisms, for example in mammalian cells for expression and in a prokaryotic host for cloning and amplification. In addition the expression construct may contain a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.
[0723] The expression constructs may also comprise transcription termination regions. Where transcription terminations regions are used, any termination region may be used in the preparation of the expression constructs. For example, the termination region may be native to the transcriptional initiation region, may be native to the nucleic acid sequence of the invention, may be native to the host cell, or may be derived from another source.
[0724] In addition, other sequence modifications can be made to the nucleic acid sequence of the invention, such as additional sequence modifications that are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon / intron splice site signals, transposon-like repeats, and other such well-characterised sequences that may be deleterious to gene expression.
[0725] The expression construct may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components.
[0726] The expression construct may be heterologous with respect to the host, i.e. , the nucleic acid sequence of the invention of the expression construct does not occur naturally in the host celland must have been introduced into the host cell or an ancestor thereof by a transformation, transduction, or transfection event. The expression of the nucleic acid sequence in the expression construct may be under the control of, for example, a constitutive promoter or of an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus.
[0727] Vector
[0728] The present invention also relates to a vector comprising the expression construct of the invention or the nucleic acid sequence of the invention. This may be referred to herein as “the vector” or “the vector of the invention”.
[0729] A “vector” is a replicon, such as plasmid, phage, viral construct, cosmid, bacterial artificial chromosome, derived artificial chromosome or yeast artificial chromosome to which another heterologous DNA segment (such as, in the present case, the expression construct or the nucleic acid sequence of the invention) may be inserted. Vectors are typically used to transduce (e.g. transform or transfect) and express a DNA segment, such as in the present case the expression construct or the nucleic acid sequence of the invention, in a host cell.
[0730] The expression vector may be introduced into a suitable host cell, which may be a host cell in a subject or patient to whom the vector has been administered. Thus, a nucleic acid sequence encoding the peptide of the invention may be inserted into an expression construct, said expression construct included in a vector, and said expression vector introduced into a compatible host cell for example by administering it to a subject, and conditions may be present or induced which bring about expression of the nucleic acid sequence encoding the peptide of the invention.
[0731] Bacterial host cells may be used for propagation of the vector as is conventionally done in molecular biology. Accordingly therefore, there is provided a host cell, suitably a bacterial or eukaryotic host cell, comprising the vector of the invention.
[0732] One of skill in the art would be well-equipped to construct the vector of the invention through standard recombinant techniques (see, for example, Sambrooketal., 2001 and Ausubel et al., 1996, both incorporated herein by reference). Exemplary vectors that may be used include but are not limited to those derived from recombinant bacteriophage DNA, plasmid DNA or cosmid DNA. For example, plasmid vectors such as pZEM-hTHPO, pD649, pBR322, plIC 19 / 18, plIC 118, 119 and the M 13 mp series of vectors may be used. Bacteriophage vectorsmay include Agt10, Agt11 , Agt18-23, AZAP / R and the EM BL series of bacteriophage vectors. Cosmid vectors that may be utilised include, but are not limited to, pJB8, pCV 103, pCV 107, pCV 108, pTM, pMCS, pNNL, pHSG274, COS202, COS203, pWE15, pWE16 and the charomid 9 series of vectors. Additional vectors include bacterial artificial chromosomes (BACs) based on a functional fertility plasmid (F-plasmid), yeast artificial chromosomes (YACs), and P1-derived artificial chromosomes, DNA constructs derived from the DNA of P1 bacteriophage (PACS). Alternatively, recombinant virus vectors may be engineered, including but not limited to those derived from viruses such as herpes virus, retroviruses, vaccinia virus, poxviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses, adeno-associated viruses or bovine papilloma virus. In one embodiment, the vector is an AAV vector. In one embodiment, the vector is an AAV9 vector. In one embodiment, the vector is a scAAV9 vector.
[0733] Methods for introducing vectors into host cells are known and include, as non-limiting examples stable transformation methods, transient transformation methods, and virus mediated methods. The vectors described herein may be introduced into the host cell by for example, recombinant viral vectors (e.g., retroviruses, adenoviruses), liposomes and the like. For example, transient transformation methods include microinjection, electroporation, or particle bombardment.
[0734] Vectors may also include selectable markers. The phrase “selectable marker” refers to a protein that enables the separation of host cells expressing the marker from those that lack or do not express it. The selectable marker may be a fluorescent marker, for instance.
[0735] Expression of the marker by host cells having successfully integrated the vector allows the isolation of these cells using methods such as, for example, FACS (fluorescent activated cell sorting). Alternatively, expression of a selectable marker may confer an advantageous property to the host cell that allows survival of only those cells carrying the gene. For example, the marker protein may allow for the selection of the host cell by conferring an antibiotic resistance to the host cell. Consequently, when host cells are cultured in medium containing said antibiotic, only cell clones expressing the marker protein that mediates antibiotic resistance are capable of propagating, indicating the successful integration of the intended nucleic acid, expression construct, or vector.
[0736] Conjugate
[0737] The present invention also relates to a conjugate comprising the peptide of the invention, nucleic acid sequence of the invention, expression construct of the invention, or the vector ofthe invention, wherein the peptide, nucleic acid, expression construct or vector is covalently linked to a delivery group. This may be referred to herein as “the conjugate” or “the conjugate of the invention”.
[0738] The conjugate of the invention may comprise any delivery group capable of aiding delivery or uptake of the peptide, nucleic acid sequence, expression construct, or vector into a target cell. Suitable such delivery groups may include: antibodies, peptides, small molecule chemicals, polymers, lipids, or the like. Suitably therefore, the peptide, nucleic acid sequence, expression construct, or vector may be conjugated to a delivery group.
[0739] Suitably the delivery group may be a peptide. Suitably, the peptide may be selected from viral proteins such as VP22 (derived from herpes virus tegument protein), snake venom protein such as CyLOP-1 (derived from crotamin), cell adhesion glycoproteins such as pVEC (derived from murine vascular endothelial-cadherin protein), Penetratin (Antennapedia homeodomain), Tat (human immunodeficiency virus transactivating regulatory protein), cell penetrating peptide (CPP), or reverse Tat, for example. In some embodiments, the peptide, nucleic acid sequence, expression construct, or vector is conjugated to a delivery group wherein the delivery group is a cell penetrating peptide (CPP), suitably to enhance therapeutic uptake of the peptide, nucleic acid sequence, expression construct, or vector into the cells of a host such as a patient or subject. Suitably in such embodiments, it is the peptide of the invention which is conjugated to a delivery group, suitably to a cell penetrating peptide (CPP).
[0740] Cell penetrating peptides (CPPs) are typically short peptides primarily composed of basic residues and are typically rich in lysine and arginine residues. CPPs are believed to interact with negatively charged cell surface molecules through these positively charged amino acid residues, thereby help the peptides naturally cross the cell membrane commonly by endocytosis.
[0741] Suitable CPPs are known in the art. The use of arginine-rich peptide carriers may be particularly useful. Certain arginine based peptide carriers have been shown to be highly effective at delivery of antisense compounds into primary cells including muscle cells (Marshall, Oda et al. 2007; Jearawiriyapaisarn, Moulton et al. 2008; Wu, Moulton et al. 2008). Furthermore, compared to other peptides, the arginine peptide carriers, when conjugated to a payload, demonstrate an enhanced ability to alter transcript levels (Marshall, Oda et al. 2007). Suitably, the cell penetrating peptide may be selected from those peptides described in WO2015075747, WO2013030569, W02009147368, US20120289457, or US20160237426, for example.By conjugated it is meant that the peptide, nucleic acid sequence, expression construct, or vector is covalently linked to the delivery group. Suitably therefore, conjugate comprises the peptide, nucleic acid sequence, expression construct, or vector covalently linked to a delivery group.
[0742] For example, the delivery group may be conjugated to the 3' end of the nucleic acid sequence, expression construct, or vector of the invention. Alternatively, conjugation of a delivery group to the nucleic acid sequence, expression construct, or vector of the invention may be at the 5' end of the nucleic acid sequence, expression construct, or vector.
[0743] For example, the delivery group may be conjugated to the C-terminus of the peptide of the invention. Alternatively, the delivery group may be conjugated to the N-terminus of the peptide of the invention.
[0744] Optionally, the delivery group may be conjugated to the nucleic acid sequence, expression construct, or vector of the invention via a linker. Optionally, the linker may be any linker known in the art, suitably the linker may comprise one or more of: an optionally substituted piperazinyl moiety, a beta alanine, glycine, serine, threonine, a hydrocarbon chain, proline, 6-aminohexanoic acid residue, lysine and / or arginine in any combination. A typically linker may be a short chain of glycine and serine residues, for example. Alternatively, the delivery group may be conjugated directly to the nucleic acid sequence, expression construct, or vector of the invention without a linker.
[0745] Suitably the conjugate may comprise or further comprise a homing moiety i.e. tissue targeting moiety. Suitably, the homing moiety is selective for a selected tissue such as a mammalian tissue, i.e., the same tissue being targeted by the peptide of the invention. Suitably, the homing moiety may be selective for muscle tissue, heart tissue, or heart muscle tissue.
[0746] Suitably, the homing moiety may be a homing peptide. Suitable homing peptides are disclosed in 'Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient mdx Mice' Gao et al. Mol Ther. 2014 Jul; 22(7): 1333-1341, for example.
[0747] Suitably, where the conjugate comprises both a delivery peptide and a homing peptide, the delivery peptide and the homing peptide may be formed as a chimeric fusion protein. Suitably, the conjugate may comprise a chimeric peptide formed from a cell penetrating peptide and for example a hart muscle tissue-specific homing peptide. For example, the conjugate may be ofthe form: delivery peptide-homing peptide-peptide of the invention, or of the form: homing peptide-carrier peptide- peptide of the invention. Optionally such forms of the conjugate may comprise linkers located between each element.
[0748] Suitably, the peptide, nucleic acid sequence, expression construct, or the vector of the invention may be conjugated to a delivery group that enhances the solubility of the peptide, nucleic acid sequence, expression construct, or vector. Suitably the solubility in an aqueous medium. Suitably, a delivery group that enhances solubility may for example be conjugated to the peptide, nucleic acid sequence, expression construct, or the vector of the invention in addition to a delivery group operable to transport the peptide, nucleic acid sequence, expression construct, or the vector of the invention into a cell. Suitable delivery groups that enhance the solubility of a oligonucleotide are known in the art and include polymers, such as polyethylene glycol, or triethylene glycol.
[0749] Delivery particle
[0750] The present invention also relates to a delivery particle comprising the peptide of the invention, nucleic acid sequence of the invention, expression construct of the invention, vector of the invention, or the conjugate of the invention. This may be referred to herein as “the delivery particle” or “the delivery particle of the invention”.
[0751] Suitably the delivery particle may be capable of aiding delivery or uptake of the peptide, nucleic acid sequence, expression construct, vector or conjugate of the invention into a host (such as a subject or a patient) or a host cell (such as a myocyte, cardiomyocyte, or a ventricular cardiomyocyte).
[0752] Suitable delivery particles may include: nanoparticles including polymeric nanoparticles such as lipid nanoparticles, nanocarriers including supramolecular nanocarriers, virus particles, vesicles and the like.
[0753] Supramolecular nanocarriers may include cationic polymer complexes and various polymeric compounds. Complexation of nucleic acids with various polycations is another approach for intracellular delivery. This includes use of PEGylated polycations, polyethyleneamine (PEI) complexes, cationic block co-polymers, and dendrimers. Several cationic nanocarriers, including PEI and polyamidoamine dendrimers help to release contents from endosomes.Other approaches include use of microspheres including biodegradable microspheres, dendrimers, biodegradable polymers, prodrugs, inorganic colloids such as sulphur or iron, antibodies, implants including biodegradable implants and osmotically controlled implants, lipid nanoparticles, emulsions, oily solutions, aqueous solutions, biodegradable polymers, poly(lactide-coglycolic acid), poly(lactic acid), liquid depot, polymer micelles, quantum dots and lipoplexes. In some embodiments, an oligonucleotide is conjugated to another molecule which is known in the art to act as a carrier.
[0754] Vesicles may include extracellular vesicles, liposomes, lipid vesicles, lipid nanoparticles (LNPs), exosomes or the like. Vesicles such as LPNs for example are typically capable of being endocytosed by cells, and may be decorated with targeting moieties to target these to specific tissues of interest.
[0755] Virus particles may include adeno-associated virus (AAV) virus particles such as AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11. In some embodiments, the virus particle may be AAV9. In some embodiments, the virus particle may be scAAV9.
[0756] In some embodiments, the peptide, nucleic acid sequence, expression construct, vector, or conjugate of the invention may be comprised within a liposome.
[0757] In some embodiments, the peptide, nucleic acid sequence, expression construct, vector, or conjugate of the invention may be comprised within a lipid nanoparticle.
[0758] In some embodiments, the peptide, nucleic acid sequence, expression construct, vector, or conjugate of the invention may be comprised within a virus particle.
[0759] Pharmaceutical composition
[0760] The present invention also relates to a pharmaceutical composition comprising the peptide of the invention, nucleic acid sequence of the invention, expression construct of the invention, vector of the invention, the conjugate of the invention, or the delivery particle of the invention, and one or more pharmaceutically acceptable excipients. This may be referred to herein as “the pharmaceutical composition” or “the pharmaceutical composition of the invention”.
[0761] As used herein, “pharmaceutical composition” refers to a composition comprising one or more compounds that is formulated for administration to a subject, and the term may be used interchangeably with “therapeutic composition” herein. Pharmaceutical compositions typicallycomprise one or more active ingredients (e.g. one or more peptides, nucleic acid sequences, expression constructs, vectors, conjugates, and / or delivery particles of the invention) and one or more pharmaceutically acceptable materials. The pharmaceutical compositions described herein may therefore comprise one or more peptides of the invention and one or more other components. For example, the pharmaceutical composition may comprise one or more peptides of the invention and one or more pharmaceutically acceptable excipients, diluents and / or carriers.
[0762] Pharmaceutical compositions may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents or compounds.
[0763] As used herein, "pharmaceutically acceptable" refers to a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected compound (e.g. one or more peptides, nucleic acid sequences, expression constructs, vectors, conjugates, and / or delivery particles of the invention) without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
[0764] Suitably, the pharmaceutical composition comprises a pharmaceutically acceptable diluent. Diluents are diluting agents. Pharmaceutically acceptable diluents are well known in the art. A suitable diluent is therefore easily identifiable by one of ordinary skill in the art.
[0765] Suitably, the pharmaceutical composition comprises a pharmaceutically acceptable excipient. Excipients are natural or synthetic substances formulated alongside an active ingredient included for the purpose of bulking-up the formulation or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption or solubility. Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance concerned such as by facilitating flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation over the expected shelf life. Pharmaceutically acceptable excipients are well known in the art. A suitable excipient is therefore easily identifiable by one of ordinary skill in the art. By way of example, suitable pharmaceutically acceptable excipients include water, saline, aqueous dextrose, glycerol, ethanol, and the like.Suitably, the pharmaceutical composition may comprise one or more one or more peptides, nucleic acid sequences, expression constructs, vectors, conjugates, and / or delivery particles of the invention and a pharmaceutically acceptable carrier. Carriers are non-toxicto recipients at the dosages and concentrations employed and are compatible with other ingredients of the formulation. The term “carrier” denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. Pharmaceutically acceptable carriers are well known in the art. A suitable carrier is therefore easily identifiable by one of ordinary skill in the art. Suitably, pharmaceutical compositions are formulated to comprise an acceptable, non-toxic, sterile carrier such as physiological saline, non-toxic buffers, preservatives and the like. Suitable formulations for use in the therapeutic methods disclosed herein are described in Remington's Pharmaceutical Sciences (Mack Publishing Co.) 16th ed. (1980).
[0766] Medical uses
[0767] The peptide of the invention is useful in the treatment of diseases or conditions, as therapies.
[0768] The present invention therefore also relates to the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention for use as a medicament.
[0769] For such uses, the peptide may be any peptide described hereinabove. In one embodiment, the peptide for use as a medicament is a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein. In one embodiment, the peptide for use as a medicament is a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein, wherein the peptide has a maximum length of 24 amino acids.
[0770] The present invention therefore also relates to the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention for use in the manufacture of a medicament.
[0771] For such uses, the peptide may be any peptide described hereinabove. In one embodiment, the peptide for use in the manufacture of a medicament is a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein. In one embodiment, the peptide for use in themanufacture of a medicament is a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein, wherein the peptide has a maximum length of 24 amino acids.
[0772] The present invention therefore also relates to a method of treating a subject having a disease or condition, or preventing a disease or condition in a subject, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention. Suitably, the subject may be a subject in need of said treatment or preventative therapy.
[0773] For such methods, the peptide may be any peptide described hereinabove. In one embodiment, the peptide used in the method is a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein. In one embodiment, the peptide used in the method is a peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein, wherein the peptide has a maximum length of 24 amino acids.
[0774] The peptide may be used as a medicament effective for treating a number of diseases or conditions outlined below. Accordingly, peptide may be for use in the manufacture of a medicament effective for treating the diseases or conditions outlined below. Accordingly, the peptide may be used for treating a subject having the diseases or conditions outlined below, or for preventing said diseases or conditions in a subject.
[0775] The disease or condition that may be treated or prevented may be any disease or condition involving impaired heart muscle relaxation or involving a hypercontracted state of the heart muscle compared to a healthy or control subject or patient. A “healthy” or “control” subject or patient may be one who does not have the same mentioned disease or condition, and is otherwise healthy or without any other relevant or confounding conditions or ailments.
[0776] The disease or condition that may be treated or prevented may be any disease or condition involving reduced fractional shortening of the left ventricle compared to a healthy or control subject or patient.
[0777] The disease or condition that may be treated or prevented may be any disease or condition involving elevation of E / E’ (calculated by dividing the peak early mitral inflow velocity (E) by the peak early diastolic mitral annular velocity (E1) as derivable from Pulse-wave Doppler and Tissue Doppler imaging) compared to a healthy or control subject or patient.The disease or condition that may be treated or prevented may be any disease or condition involving elevated end systolic pressure (ESP) compared to a healthy or control subject or patient.
[0778] The disease or condition that may be treated or prevented may be any disease or condition involving elevated end diastolic pressure (EDP) compared to a healthy or control subject or patient.
[0779] The disease or condition that may be treated or prevented may be any disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4, such as any one or more PDE4D isoforms, are upregulated compared to a healthy or control subject or patient. Suitably, wherein the upregulation is in myocytes. Suitably, wherein the upregulation is in cardiomyocytes. Suitably, wherein the upregulation is in ventricular cardiomyocytes.
[0780] The disease or condition that may be treated or prevented may be any disease or condition in which the expression of PDE4D9 is upregulated compared to a healthy or control subject or patient. Suitably, wherein the upregulation is in myocytes. Suitably, wherein the upregulation is in cardiomyocytes. Suitably, wherein the upregulation is in ventricular cardiomyocytes.
[0781] The disease or condition that may be treated or prevented may be any disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4, such as any one or more PDE4D isoforms with TPNI protein compared to a healthy or control subject or patient. Suitably, wherein the increased association is in myocytes. Suitably, wherein the increased association is in cardiomyocytes. Suitably, wherein the increased association is in ventricular cardiomyocytes.
[0782] The disease or condition that may be treated or prevented may be any disease or condition involving an increased association of PDE4D9 with TPNI protein compared to a healthy or control subject or patient. Suitably, wherein the increased association is in myocytes. Suitably, wherein the increased association is in cardiomyocytes. Suitably, wherein the increased association is in ventricular cardiomyocytes.
[0783] The disease or condition that may be treated or prevented may be any disease or condition involving a lower level of TPNI protein phosphorylation compared to a healthy or control subject or patient. Suitably, wherein the lower level of TPNI protein phosphorylation is in myocytes. Suitably, wherein the lower level of TPNI protein phosphorylation is incardiomyocytes. Suitably, wherein the lower level of TPNI protein phosphorylation is in ventricular cardiomyocytes.
[0784] The disease or condition that may be treated or prevented may be selected from any one of: heart failure, diabetic cardiomyopathy, diastolic dysfunction (including sepsis-induced or septic-shock induced diastolic dysfunction), heart failure involving diastolic dysfunction, heart failure involving diabetic cardiomyopathy, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), hypercontracture, and / or hypertrophic cardiomyopathy (including genetic hypertrophic cardiomyopathy).
[0785] There is therefore provided the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention for use in the treatment or prevention of a disease or condition selected from any one of the following: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction (including sepsis-induced or septic-shock induced diastolic dysfunction), heart failure involving diastolic dysfunction, heart failure involving diabetic cardiomyopathy, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), hypercontracture, and hypertrophic cardiomyopathy (including genetic hypertrophic cardiomyopathy).
[0786] In one embodiment, there is provided the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention for use in the treatment or prevention of heart failure. In some embodiments, the heart failure involves diastolic dysfunction such as heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).There is therefore provided the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention for use in the manufacture of a medicament for the treatment or prevention of a disease or condition selected from any one of the following: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction (including sepsis-induced or septic-shock induced diastolic dysfunction), heart failure involving diastolic dysfunction, heart failure involving diabetic cardiomyopathy, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), hypercontracture, and hypertrophic cardiomyopathy (including genetic hypertrophic cardiomyopathy).
[0787] In one embodiment, there is therefore provided the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention for use in the manufacture of a medicament for the treatment or prevention of heart failure. In some embodiments, the heart failure involves diastolic dysfunction such as heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
[0788] There is therefore provided a method of treating a subject having a disease, or preventing a disease in a subject, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention, wherein the subject has (i.e. has been diagnosed with or suffers from) a disease or condition selected from any one of the following: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of anyone or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction (including sepsis-induced or septic-shock induced diastolic dysfunction), heart failure involving diastolic dysfunction, heart failure involving diabetic cardiomyopathy, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), hypercontracture, and hypertrophic cardiomyopathy (including genetic hypertrophic cardiomyopathy).
[0789] In one embodiment, there is provided a method of treating a subject having a disease, or preventing a disease in a subject, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention, wherein the subject has heart failure. In some embodiments, the heart failure involves diastolic dysfunction such as heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
[0790] Treatment with the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may have any one or more of the following effects listed below. Therefore, the prevention or treatment of any of the diseases or conditions mentioned above may be carried out by causing one or more of the following effects. For example, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in the treatment or prevention of any disease or condition listed above by: increasing or promoting heart muscle relaxation, increasing or promoting fractional shortening of the left ventricle, reducing E / E’, reducing end systolic pressure (ESP), reducing end diastolic pressure (EDP), increasing ejection fraction, increasing cardiac output, reducing the association of PDE4D isoforms and / or specifically PDE4D9 with TPNI, and / or by increasing the level of TPNI phosphorylation in a subject.
[0791] Treatment may increase heart muscle relaxation as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore heart muscle function to a healthy or acceptable state.Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in increasing or promoting heart muscle relaxation, and / or restoring heart muscle function to a healthy or acceptable state. There is therefore also provided a method of increasing or promoting heart muscle relaxation in a subject in need thereof, or preventing impaired heart muscle relaxation in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention.
[0792] Treatment may increase or promote fractional shortening of the left ventricle as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore fractional shortening of the left ventricle to a healthy or acceptable state.
[0793] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in increasing or promoting fractional shortening of the left ventricle. There is therefore also provided a method of increasing or promoting fractional shortening in a subject in need thereof, or preventing a reduction of or an impairment in fractional shortening in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention.
[0794] Treatment may reduce E / E’ as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore E / E’ to a healthy or acceptable state.
[0795] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in reducing E / E’. There is therefore also provided a method of reducing E / E’ in a subject in need thereof, or preventing an increase in E / E’ in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention.Treatment may reduce end systolic pressure (ESP) as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore end systolic pressure (ESP) to a healthy or acceptable state.
[0796] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in reducing end systolic pressure (ESP). There is therefore also provided a method of reducing end systolic pressure (ESP) in a subject in need thereof, or preventing an increase in end systolic pressure (ESP) in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention.
[0797] Treatment may reduce end diastolic pressure (EDP) as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore end diastolic pressure (EDP) to a healthy or acceptable state.
[0798] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in reducing end diastolic pressure (EDP). There is therefore also provided a method of reducing end diastolic pressure (EDP) in a subject in need thereof, or preventing an increase in end diastolic pressure (EDP) in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention.
[0799] Treatment may increase heart ejection fraction as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore heart ejection fraction to a healthy or acceptable state.
[0800] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in increasing ejection fraction. There is therefore also provided a method of increasing ejection fraction in a subject in needthereof, or preventing a decrease in ejection fraction in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention.
[0801] Treatment may increase cardiac output as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore cardiac output to a healthy or acceptable state.
[0802] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in increasing cardiac output. There is therefore also provided a method of increasing cardiac output in a subject in need thereof, or preventing a decrease in cardiac output in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention.
[0803] Treatment may reduce the association of PDE4 proteins, PDE4D isoforms and / or specifically PDE4D9 with TPNI as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore the level of association of PDE4D isoforms and / or specifically PDE4D9 with TPNI to a healthy or acceptable state. Suitably, this may be reduced or restored in cardiomyocytes, suitably ventricular cardiomyocytes.
[0804] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in reducing the association of PDE4 proteins, PDE4D isoforms and / or specifically PDE4D9 with TPNI. There is therefore also provided a method of reducing the association of PDE4 proteins, PDE4D isoforms and / or specifically PDE4D9 with TPNI in a subject in need thereof, or preventing an increase in the association of PDE4 proteins, PDE4D isoforms and / or specifically PDE4D9 with TPNI in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention. Suitably, the reduction or prevention may be in cardiomyocytes, suitably ventricular cardiomyocytes.Treatment may increase the level of TPNI phosphorylation as compared to the state or condition of the subject or patient before treatment, and / or treatment may restore the level of TPNI phosphorylation to a healthy or acceptable state. Suitably, this may be increased in cardiomyocytes, suitably ventricular cardiomyocytes.
[0805] Suitably therefore, the peptide of the invention, the nucleic acid sequence of the invention, the vector of the invention, the conjugate of the invention, the delivery particle of the invention, or the pharmaceutical composition of the invention may be for use in increasing the level of TPNI phosphorylation in a subject. There is therefore also provided a method of increasing the level of TPNI phosphorylation in a subject in need thereof, or preventing a reduction in the level of TPNI phosphorylation in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the peptide of the invention, nucleic acid sequence of the invention, vector of the invention, conjugate of the invention, delivery particle of the invention, or the pharmaceutical composition of the invention. Suitably, the reduction or prevention may be in cardiomyocytes, suitably ventricular cardiomyocytes.
[0806] Administration of the treatment is in an "effective amount" which may be considered as a “prophylactically effective amount” or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual, e.g. an effective amount to prevent or delay onset of the disease or condition, to ameliorate one or more symptoms of the disease or condition, to induce or prolong remission, or to delay relapse or recurrence of the disease or condition.
[0807] The amount of peptide, nucleic acid sequence, expression construct, vector, conjugate, deliver particle, or pharmaceutical composition of the invention may be administered as a single dosage form depending upon the subject treated and the particular mode of administration. Suitably, the peptide, nucleic acid sequence, expression construct, vector, conjugate, deliver particle, or pharmaceutical composition may be administered as a single dose, multiple doses or over an established period of time for example by repeated injection. Suitably, dosage regimens also may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response).
[0808] Suitably the peptide, nucleic acid sequence, expression construct, vector, conjugate, deliver particle, or pharmaceutical composition of the invention may be administered once per day, once every two days, once every three days, once per week, twice per week, once every two weeks, once per month, once every two months, once every 6 months, for example.For example, treatment may slow the progression of disease or condition. In some embodiments, wherein treatment is commenced in an early stage heart failure for example, treatment may delay the onset of middle and / or late stage heart failure. In some embodiments, wherein treatment is commenced during middle stage heart failure, treatment may delay the onset of late stage heart failure.
[0809] In some embodiments, the present disclosure pertains to: a method of ameliorating, reducing the severity of, or slowing the onset or progression of a disease or condition selected from: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 such as any one or more PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction (including sepsis-induced or septic-shock induced diastolic dysfunction), heart failure involving diastolic dysfunction, heart failure involving diastolic dysfunction associated with cardiac developmental defects, including paediatric and adult manifestations, heart failure involving diabetic cardiomyopathy, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), hypercontracture, and hypertrophic cardiomyopathy (including genetic hypertrophic cardiomyopathy).
[0810] Treatment may further comprise administering an additional therapeutic agent to the subject. The additional therapeutic agent may be comprised within the pharmaceutical composition as described above, or may be separate. Suitably the additional therapeutic agent may be administered at the same time, simultaneously with the peptide, nucleic acid sequence, expression construct, vector, conjugate, deliver particle, or pharmaceutical composition of the invention, or at a different time. Suitably the additional therapeutic agent may act synergistically with the peptide, nucleic acid sequence, expression construct, vector, conjugate, deliver particle, or pharmaceutical composition of the invention.
[0811] Suitably, the subject may be mammalian. Suitably the subject may be an animal such as a primate (e.g., a rhesus monkey or chimpanzee), horse, dog, cat, pig, mouse, rat, rabbit, sheep,goat, ferret, or a guinea pig. Suitably the subject may be human. Suitably the subject may be male or female. Suitably the subject may be of any age.
[0812] All documents mentioned herein are incorporated herein by reference in their entirety.
[0813] Examples of the invention will now be described in relation to the following figures.
[0814] BRIEF DESCRIPTION OF THE DRAWINGS
[0815] Figure 1: (a) A diagram of cAMP-dependent PKA-mediated phosphorylation of TPNI. (b) A diagram showing the discovery that phosphodiesterase (PDE) associates with TPNI (i.e. TN-I) thus locally hydrolysing cAMP and thereby decreasing PKA-mediated phosphorylation of TPNI. A peptide which binds to PDE can inhibit the interaction between PDE and TPNI and promote phosphorylation of TPNI.
[0816] Figure 2: Unique cAMP regulation at TPNI. (a) Representative kinetics of normalised FRET change recorded in ARVM expressing the targeted CUTie reporters treated with p-adrenergic receptor agonist isoproterenol (ISO, 5nM) and followed by application of the adenylyl cyclase activator forskolin (FRSK, 25 pM) and the phosphodiesterase inhibitor 3-isobutyl-1-methxylxanine (IBMX, 100 pM), a treatment that generates an intracellular amount of cAMP that saturates the CUTie sensors, (b) Summary of cAMP response at 1 min and 5 min after application of 5 nM ISO in different targeted sensors. Mann-Whitney U test with Holm-sidak correction for multiple comparison, (c) Delay in the cAMP response after ISO application. Nonparametric Kruskal-Wallis test with Dunn’s correction for multiple comparison, (d) Representative western blot and (e) quantification showing time course of MyBPC, TPNI and PLB phosphorylation in ARVM at 1 min, 5 min and 10 min after application of 5 nM ISO with / without in the presence of 100 nM phosphatase inhibitor calyculin A. One-Way ANOVA with Bonferroni correction for multiple comparison, n > 4 biological replicates. Values are means ± s.e.m. *P<0.05, **P<0.01.
[0817] Figure3: PDE4D specifically regulates cAMP at TPNI (a) Representative western blot of TPNI immunoprecipitate (IP) probed with a pan PDE4D antibody. Molecular weight markers for PDE4D isoforms are on the right, (b) Immunoprecipitation of TPNI and detection of PDE4D and PDE4B in NRVM treat with ISO (1 pM) at different time point, as indicated, (c) Representative kinetics and summary of FRET change recorded in NRVM expressing TPNI-CUTie and expressing PDE4D9-mcherry dominant negative construct treated with 1nM ISO and followed by saturating treatment, (d) Representative kinetics and summary of FRETchange recorded in NRVM expressing MyBPC-CUTie and transfected with RFP-DE4D9 dominant negative constructs treated with 1nM ISO and followed by saturating treatment, (e) Representative kinetics and summary of FRET change recorded in NRVM overexpressing TPNI-, TPNImut-, and TPNlKi78E-CUTie sensor and treated with 1nM ISO followed by Roli (10mM) and saturating stimulus. Mann-Whitney II test with Holm-Sidak correction for multiple comparison, n > 3 biological replicates. All values are means ± s.e.m. *P<0.05, **P<0.01.
[0818] Figure 4: P33 enhances the adrenergic response selectively at TPNI. (a) Representative western blot and (b) quantification of co-lmmunoprecipitation (Co-IP) experiments using lysates from NRVM overexpressing PDE4D9-mcherry treated with ISO (1 nM) and P33 peptide (10 pM) or control scrambled SC peptide (10 pM). Two-way ANOVA with Sidak correction for multiple comparisons. Values are mean ± s.d. Representative kinetics and summary of FRET change recorded in NRVM overexpressing (c) TPNI-CUTie, (d) MyBPC-CUTie or (e) AKAP18b-CUTie treated with treat with 1 nM ISO followed by Roli and saturating treatment of cells pre-treated with 10 mM P33 or SC. Mann-Whitney U test with Holm-Sidak correction for multiple comparison. Values are mean ± s.e.m. (f) Representative western blot and (g) quantification showing time course of TPNI and MyBPC phosphorylation in ARVM pretreated with 10 pM P33 peptide or control scrambled SC peptide and lysed 1 min, 5 min or 10 min after application of 5 nM ISO. Two-way ANOVA with Sidak correction for multiple comparisons. Values are mean ± s.d. n > 3 biological replicates. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0819] Figure 5: P33 improves cardiac contractile properties in a [Ca2+]j independent manner (a) Velocity of relaxation and maximal isometric force response recorded in isolated ARVM using the cardiac work-loop technique. All values are mean ± s.e.m. DMSO (N > 12) SP (10pM; N > 6), P33 (10pM; N > 9). Two-way ANOVA with Tukey (hsd) post-hoc test. **P < 0.05; *P < 0.05, respectively, (b) Representative microscope image of an intact, live cardiomyocyte glued in between two anchoring glass rods; one of the two glass rods is anchored to a free hanging cantilever end, the other to a piezoelectric transducer that allows cell length modulation, (c) Average calcium transient recorded in ARVM show response to 5 nM ISO in the presence of DMSO (left), SC (10 pM, middle), or P33 (10 pM, right). Exemplary average transient are obtained from paced transients only (at least 10 transients) from one measurement each, normalised to fluorescence ratio at time point 0s. N>4 biological replicates.
[0820] Figure 6: P33 prevents TAC-induced cardiac dilatation. Wild-type B6 mice (male) were administered with scAAV9-SC or scAAV9-P33 via tail vein one week after sham or transverseaortic banding (TAC) surgeries. Organ weights, Echocardiographic parameters derived from 2-D parasternal short-axis, and Left ventricular (LV) haemodynamics obtained three weeks post-injection, (a) Left ventricle and (b) lung weights obtained post-mortem and normalized to tibial length. Echocardiography measurements showing (c,d) systolic functions and (e) diastolic functions. LV haemodynamic measured under basal (no dobutamine) for (f) heart rates, (g) LV end-systolic pressure (LVESP), (h) LV end-diastolic pressure (LVEDP), (i) the rate of pressure rise maximum / minimum (dP / dtmax / min) as a measure of contractility, and (j) isovolumetric constant, tau, as a measure of relaxation. LV haemodynamic measured cardiac stressor dobutamine (32 ng / g BW / min) for (k) heart rates, (I) LVESP, (m) LVEDP, (n) dP / dtmax / min and (o) tau. Values are mean ± s.d. Sham-SC N> 5, Sham-P33 N > 4, TAC-SC > 12, TAC-P33> 10. One-way ANOVA with Sidak correction for multiple comparison, Kruskal-Wallis with Dunn’s correction would be used if the values failed the normality test.
[0821] Figure 7: (a) Representative image of human adult left ventricular myocyte expressing TPNI-CUTie (green) and probe with a-actinin (red), (b) Representative kinetics and (c) summary of FRET change in response to PDE4 inhibitor Rolipram (Roli, 10 pM) recorded in human ventricular myocytes isolated from patients with heart failure with reduced ejection fraction (HFrEF) and expressing TPNI-CUTie or the cytosolic Epad-camps sensor. The kinetics also show the response to PDE3 inhibition with Cilostamide, (10 pM) and IBMX (100 pM). Each compound was added to the bath in sequence without washout between additions. Arrows indicate the time of compound addition. Two-tailed unpaired t-test with Welch’s correction, (d) Representative kinetics and (e) summary of the FRET change at 0.5 min and 5 min after the application of ISO (1 nM) recorded in human ventricular myocyte isolated from HFrEF patients and expressing TPNI-CUTie or MyBPC-CUTie targeted sensors. The effect of applying Rolipram (10 pM) and IBMX (100 pM) is also shown. Two-tailed paired t-test. Each data point represents an independent experiment. Cells are from 4 different individuals, (f) Representative western blot using the lysates from human patient heart tissues probe with PDE4D and phosphorylated TPNI. (g) Summary of the TPNI phosphorylation in the healthy human donor and patients with low EF. (h) Representative western blot and (i) summary of TPNI immunoprecipitation probed with PDE4D antibody, using lysates from healthy human donor and patients with low EF. Representative kinetics (j) and summary of FRET change at 0.5 min and 5 min after application of ISO (5 nM) recorded in human ventricular myocytes isolated from HFrEF patients, pre-treated with SC or P33 peptides and expressing the TPNI-CUTie targeted sensor (k) A typical response to Rolipram (10 pM) and IBMX (100 pM) application is also shown. Two tailed paired t-test for comparisons between 0.5 min and 5 min. Two-tailed unpaired t-test with Welch’s corrections for comparison between SC and P33 at 5 min. Each data point represents an independent experiment. For both treatments, data arefrom six different patients. Number of cells is also indicated under the graphs. All values are means ± SD.
[0822] Figure 8: (a) Schematic representation of the TPNI-, MyBPC-, myomesin- and AKAP18d-CLITie targeted sensors used in this study and (b) depiction showing their different localization in cardiac myocytes, (c) Representative kinetics and average of maximal FRET change displayed by the TPNI-, MyBPC-, myomesin-CUTie sensors expressed in HEK293 cells treated with saturating stimulus (25 pM FRSK + 100 pM IBMX). One-way Anova with Bonferroni correction for multiple comparison, n > 3 biological replicates, (d) Representative confocal images of ARVM expressing TPNI-CUTie, MyBPC-CUTie and myomesin-CUTie showing the localisation of the sensor relative to the localisation of a-actinin. A merged image of signals from the sensor (green) and a-actinin signal (red) and a magnified detailed are also shown. The panel on the right shows fluorescence intensity profiles measured across a single sarcomere along the line indicated in the zoomed-in images. Dotted lines indicate the position of the highest intensity for the a-actinin and sensor signal used to determine the distance (d) of the sensor localization from the Z line, (e) Quantification of the distance between the sensor intensity peak and the closest a-actinin intensity peak (see methods). Two-tailed unpaired t-test. n > 2 biological replicates, (f) Representative western blot of GFP immunoprecipitation from lysates obtained from NRVM expressing TPNI-, MyBPC-, or AKAP18b-CUTie targeted sensor and probe with Troponin T or MYH7. All value are ± s.e.m. *P<0.05, **P<0.01, ***P<0.001.
[0823] Figure 9: a) Representative kinetics of FRET change recorded in NRVM expressing the different targeted sensors and treated with 1nM ISO followed by saturating treatment (FRSK+IBMX). (b) Summary of cAMP responses measured from data shown in (a) at 1 min and 5 min after application of 1 nM ISO. Mann-Whitney U test with Holm-sidak correction for multiple comparison, (c) Average time to achieve 5% of FRET change after ISO application (delay). Nonparametric Kruskal-Wallis test with Dunn’s correction for multiple comparison, n = 4 biological replicates. All Values are means ± s.e.m. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0824] Figure 10: (a) Representative kinetics of FRET changes recorded in NRVM expressing TPNI-or MyBPC-CUTie targeted sensors treated with 1nM ISO followed by either PDE2 inhibitor (BAY, 10 nM), (b) the PDE3 inhibitor cilostamide (Cilo, 10 mM), or (c) their combination, (d) Representative kinetics of FRET changes recorded in NRVM expressing TPNI- or MyBPC-CUTie targeted sensors treated with 1nM ISO followed by PDE4 inhibitor Rolipram (Roli,10pM) and saturating treatment (SAT), (e) Summary of cAMP responses to different PDE inhibitors after ISO treatment. Mann-Whitney II test with Holm-Sidak correction for multiple correction, (f) Western blot analysis of cell lysates from NRVM treated with siRNA for PDE4D, PDE4B or cyclin B (cyclB) as control, (g) Representative kinetics and (h) summary of FRET change recorded in NRVM coexpressing TPNI-CUTie and PDE4D / 4B siRNA (100nM) treated with 1nM ISO followed by Roli (10 pM ) and saturating treatment (SAT). Two-way ANOVA with Sidak correction for multiple comparison, n > 3 biological replicates. All values are means ± s.e.m.. *P< 0.05, **P< 0.01, ***P< 0.001.
[0825] Figure 11: Quantitative PCR determination of relative PDE4D isoforms mRNA expression levels in NRVM. Data represents an n of 3 experiments on different cardiomyocyte preparations.
[0826] Figure 12: (a) PDE4D9 interacts directly with to TPNI. The interaction sites for PDE4D9 on TPNI was mapped to the C terminal using peptide array technology. Peptide array of the full-length sequence of rat cardiac TPNI was probed with GST-PDE4D9. (b) Alanine scanning of the peptide corresponding to spot 33 in (a) this sequence identified two key lysine residues, K178 and K179, as important in mediating this interaction, numbered spots on the TPNI peptide array, (c) Schematic representation showing the mutation sites and localization in NRVM of TPNImut- and TPNlKi78E-CUTie compared to TPNI-CUTie. Scale bar= 10 pm, (d) Representative western blot and (e) quantification showing co-immunoprecipitation in HEK293T cells overexpressed with TPNI-, TPNIKITSE-, or TPNImut-CUTie and PDE4D9-mcherry. Nonparametric Kruskal-Wallis test with Dunn’s correction for multiple comparison, (f) Representative western blot and (g) quantification showing GFP-pulldown and detection of phosphorylation level of the TPNI moiety in NRVM cells overexpressed with TPNI-, or TPNImut-CUTie. Two-way ANOVA with sidak multiple comparison. Values are mean ± s.d. n > 4 biological replicates. *P<0.05, **P< 0.01. (h,i) A peptide array of 25mers of the full-length sequence of human or rat cardiac TPNI was probed with GST-PDE4D9. In this experiment, the strongest binding occurred at spot 32 (corresponding to peptide P33). Alanine scanning of a 25mer encompassing P33 identified three key lysine residues, K178, K179, and K184, as important in mediating this interaction, numbered spots on the TPNI peptide array (h, bottom panel).
[0827] Figure 13: (a) Representative kinetics of FRET change recorded in NRVM expressing the plasma membrane-targeted cAMP reporter AKAP79-CUTie and treated with ISO (1 nM) followed by rolipram (10 pM) and saturating treatment in the presence of P33, SC peptides (10 pM) or DMSO as control (b) Summary of data collected as in (a). Data points are valuesrecorded at 5 min after treatment, (c) Representative kinetics of FRET change recorded in NRVM expressing the cytosolic cAMP reporter Cytosolic-CUTie and treated with ISO (1 nM) followed by rolipram (10 pM) and saturating treatment in the presence of P33, SC peptides (10 pM) or DMSO as control, (d) Summary of data collected as in (C). Data points are values recorded at 5 min after treatment, (e) Representative kinetics of FRET change recorded in NRVM expressing the cytosolic cAMP reporter Epac-H187 and treated with Rolipram (10 pM) followed by IBMX (100 pM) and saturating treatment in the presence of P33, SC peptides (10 pM) or DMSO as control, (f) Summary of data collected as in (e). Data points are values recorded at 5 min after treatment. All value are ± s.e.m. N > 3 biological replicates. P<0.05.
[0828] Figure 14: (a) Representative western blot and (b) summary quantification of coImmunoprecipitation experiments using lysates from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) treated with ISO (1nM) and P33 peptide (10 pM) or control scrambled SC peptide (10 pM) showing the PDE4D / TPNI interaction and phosphorylation level of TPNI. Values are mean ± s.d. n = 2 biological replicates.
[0829] Figure 15: (a) Representative image of hiPSC-CM expressing fluorescently-tagged tropomyosin used for CalTrack and SarcTrack experiments (see methods), (b) Average Calcium transients recorded form CalTrack using hiPSC-CM expressing the Ca2+probe RGECO and (c) sarcomere length at diastole and (d) sarcomere shortening determined by SarcTrack in the presence of DMSO, SC peptide (10 pM), or P33 peptide (10 pM).
[0830] Figure 16: : (a-e) Calcium transient characteristics in the basal condition in the presence of DMSO, SC peptide (10 pM), or P33 peptide (10 pM). Electrically evoked calcium transients were measured in monolayers under control conditions for 2 min. Monotonic transient analysis was performed to evaluate transient parameters for the peak (a), departure (b, c), and return phase (d, e) of the calcium transients, (f-j) Electrically evoked calcium transients were measured in monolayers under basal conditions for 2 min, and after ISO (5 nM) application for further 2 min in the presence of SC peptide (10 pM) or P33 peptide (10 pM). Following monotonic transient analysis, the ISO effect was calculated as ratio of mean transient parameter under ISO exposure divided by mean transient parameter under basal conditions for each monolayer. Therefore, data are shown as x-fold of basal. ISO effect is shown for parameters describing peak (f), departure (g, h), and return phase (i, j) of calcium transients. All values are in min to max whiskers box, N>4 biological replicates.
[0831] Figure 17: (a) Representative western blot and (b) quantification of phosphorylation of TPNI and MyBPC using lysates from myocardial infarcted ARVM in the responses to ISO (5 nM)application, (c) Representative western blot and (d) quantification of co-lmmunoprecipitation (Co-IP) experiments using lysates from normal or myocardial infarction ARVM and probed with PDE4D9 in the response to ISO (5 nM) application, (e) Representative western blot and (f) quantification of phosphorylation of TPNI and MyBPC using lysates from myocardial infarcted ARVM in the responses to ISO (5 nM) application in the presence of SC peptide (10 pM) or P33 peptide (10 pM). n > 2 biological replicates.
[0832] Figure 18: (a) Schematic of the self-complementary (sc) AAV9 vector, scAAV9-SC / P33. The construct contains the SC or P33 gene sequence and an internal ribosomal entry site (IRES) followed by the mcherry protein and short form of Woodchuck hepatitis posttranscriptional regulatory element 3 (WPRE3) under the control of the cardiac troponin promoter, (b) Schematic of experimental design for the in vivo TAC experiment depicting surgeries, scAAV9 delivery, and subsequent evaluation.
[0833] Figure 19: (a) Representative echocardiography M-mode images from the parasternal shortaxis view from all four experimental groups obtained 5 weeks after transverse aortic constriction (TAC) or sham surgery and injected at week 1 post-surgery with scAAV9-SC or scAAV9-P32. (b) Representative pulsed-wave Doppler (PWD, left) and Tissue Doppler imaging (TDI, right) recordings in a sham-SC mouse. PWD provides mitral inflow velocity patterns, from which early (E) and late (A) diastolic velocities, as well as the E / A ratio were derived. TDI provides the myocardial motion, from which the E' wave corresponds to the motion of the mitral annulus during early diastolic filling of the left ventricle, and the A' wave originates from atrial systole during late filling, (c) Representative M-mode echocardiography scans (top) and Masson’s trichrome staining at week 4 after TAC (bottom; scale bar = 100 pm), (d) Quantification of the normalized fibrotic area (%). Sham-SC n = 4, sham-P33 n =4, TAC+SC n = 6 and TAC+P33 n = 6.
[0834] Figure 20: (a) Representative western blot of whole cell lysates (WCL) and coImmunoprecipitation (IP) experiments using ventricular tissues lysates generated from mouse hearts at 6.5 weeks post-sham or transverse aortic banding (TAC) surgery, (b) Quantification of PDE4D9 co-immunoprecipitation with TPNI. Values are XXX. N=5 biological replicates (c) Representative western blot and (d) quantification of PDE4D9 co-immunoprecipitation with TPNI using lysates from the ventricular tissues obtained from TAC-operated mice 5 weeks after scAAV9-SC or scAAV9-P32 injection and subjected to dobutamine stimulus for X min before tissue collection. PDE4D9 co-immunoprecipitation with TPNI in mice injected with scAAV9-SC but not treated with dobutamine is also shown. N=4 biological repolicates. (e) Representative western blot and (f) quantification of phospho-TPNI level detected inventricular tissue lysates obtained from TAC-operated mice 5 weeks after scAAV9-SC or scAAV9-P32 injection and subjected to dobutamine stimulus for X min before tissue collection. N=6 biological replicates. Basal TPNI phosphorylation level in the absence of dobutamine for N=3 biological replicates is also shown.
[0835] Figure 21: Computational docking model of PDE4D9 and P33. LR1: linker region 1. LR2: linker region 2: PKA site: protein kinase A site.
[0836] Figure 22: Peptides P1-P13 designed to have high computationally predicted binding potential to TPNI. The start and end positions refer to the positions of the first and last amino acid of each peptide within the TPNI sequence (as shown in Figure 38 and Figure 39). Net charge is the number of positively charged residues (R, H, K) minus the number of negatively charged residues (D, E).
[0837] Figure 23: TPNI-CUTie assay with P33 at various concentrations plotted individually (a) or all on one plot (b).
[0838] Figure 24: TPNI-CUTie assay with P1 to P5 and P33 1 pM plotted individually (a) or all on one plot (b).
[0839] Figure 25: TPNI-CUTie assay with P2 and P33 at 1 pM and 3 pM with and without error bars.
[0840] Figure 26: Five P2 peptide variants (P2-1 to P2-5) and one P3 peptide variant (P3-1).
[0841] Figure 27: TPNI-CUTie assay with peptides P2-1 to P2-5 with P2 and P33 for reference plotted individually (a) or all on one plot (b).
[0842] Figure 28: TPNI-CUTie assay with peptide P3-1 with P3 and P33 for reference plotted individual (a) or all on one plot (b).
[0843] Figure 29: Wild-type B6 mice (male) were administered with scAAV9-SC or scAAV9-P2-2 via tail vein one week after sham or transverse aortic banding (TAC) surgeries. Organ weights, Echocardiographic parameters derived from 2-D parasternal short-axis, and Left ventricular (LV) heamodynamics obtained three weeks post-injection, (a) Left ventricle and (b) lung weights obtained post-mortem and normalized to tibial length. Echocardiography measurements showing (c-f) systolic functions and (g) Diastolic function.Figure 30: Right ventricle normalised to tibial length in TAC operated mice treated with P2-2.
[0844] Figure 31: Diastolic parameters in TAC operated mice treated with P2-2.
[0845] Figure 32: echocardiographic long axis view (l_AX) dataset gathered from TAC operated mice treated with P2-2.
[0846] Figure 33: echocardiographic short axis view (SAX) dataset gathered from TAC operated mice treated with P2-2.
[0847] Figure 34: echocardiographic pulmonary dataset gathered from in TAC operated mice treated with P2-2.
[0848] Figure 35: haemodynamic measurements taken of TAC operated mice treated with P2-2.
[0849] Figure 36: haemodynamic measurements taken of TAC operated mice treated with P2-2 under maximal p-adrenergic stimulation with dobutamine.
[0850] Figure 37: further haemodynamic measurements taken of TAC operated mice treated with P2-2.
[0851] Figure 38: An alignment between human, mouse (Mus musculus) and rat (Rattus norvegicus) TPNI. Peptides P1-P4 are annotated. A square box highlights peptide P33 in which lysine (K) residues important for binding to TPNI are marked with as asterisk (*). Charged residues are shaded.
[0852] Figure 39: An alignment between human, mouse (Mus musculus), rat (Rattus norvegicus), sheep (Ovis aries) and pig (Sus scrofa) TPNI.
[0853] Figure 40: An alignment between human, mouse (Mus musculus) and rat (Rattus norvegicus) PDE4D9.
[0854] Figure 41 : A series of overlapping peptides are generated from the amino acid sequence of the protein of interest. Individual amino acids are then precisely spotted onto a cellulose membrane to generate each of these overlapping peptides (1, 2, 3, etc). The array is then incubated with a purified protein that is thought to interact with the protein of interest. Primary antibody against the potential interacting protein is then added, followed by HRP-linkedsecondary antibody, and immunoblots are developed using the ECL method. Dark spots on the film indicate potential interaction sites on the protein of interest.
[0855] Figure 42: Western blot analysis of lysates from mouse left ventricular (LV) tissues harvested 10 weeks after scAAV9-cTNT-SC / P2-2-IRES-mcherry were systemically administered (1x1010vg) via the temporal vein in 1-day-old MYBPC KI mice, probed with mCherry antibody.
[0856] Figure 43: Pathological parameters and echocardiography parameters measured 10 weeks after scAAV9-cTNT-SC / P2-2-IRES-mcherry were systemically administered (1x1010vg) via the temporal vein in 1-day-old MYBPC KI mice. WT, wild type; Hetero, heterozygous KI; Homo, homozygous KI; LV, left ventricle weight; RV, right ventricle weight; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; FAC, fractional area change; E, early diastolic peak filling velocity; E', peak early relaxation velocity of myocardial diastolic motion. Data is mean ± standard deviation. Analysis by two tailed unpaired t-test with Welch's correction for comparison between SC and P2-2 group within different genotypes. N number: WT SC, n=17 (10 male, 7 female); WT P2-2, n=8 (4 male, 4 female); Hetero SC, n=14 (7 male, 7 female); Hetero P2-2, n=14 (8 male, 6 female); Homo SC, n=10 (5 male, 5 female); Homo P2-2, n=8 (4 male, 4 female). A total of 71 mice across all genotypes were assessed. AAV9-mediated delivery of P2-2 improved ejection fraction and normalised DD in both heterozygous and homozygous MyBPC3-KI mice. In heterozygous animals, beneficial effects were also observed in selected functional parameters, consistent with their slower disease progression and milder baseline phenotype. Overall, these findings provide strong in vivo evidence that P2-2 can ameliorate cardiac dysfunction in a genetic HCM model.
[0857] Figure 44: Validation of PDE4D9-TPNI direct interaction using microscale thermophoresis (MST) showing that PDE4D9 and TPNI interact with a binding affinity (KD) of approximately 3 pM.
[0858] Figure 45: shows P33 and P2-2 binding affinity for PDE4D9 using MST.
[0859] Figure 46: shows the efficacy of P33 and P2-2 in disrupting the PDE4D9-TPNI determined by MST.
[0860] Figure 47: A dose response curve showing the potency of P33 and P2-2 in disrupting the PDE4D9-TPNI interaction.Figure 48: sequence alignment of PDE4D isoforms.
[0861] Figure 49: sequence alignment of PDE4A, B, C and D isoforms.
[0862] Figure 50: Pathological parameters and echocardiography parameters measured 4 weeks after sham or TAC surgery following with scAAV9-SC / P33 injections 1-week post-surgery. BW, body weight; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; EF, ejection fraction; FS, fraction shortening; SV, stroke volume; CO, cardiac output; Myo CSA, myocardial cross-sectional area; FAC, fractional area change; E, early diastolic peak filling velocity; A, late diastolic peak filling velocity; E’, peak early diastolic myocardial relaxation velocity; A’, peak myocardial velocity associated with atrial contraction. Data is mean ± standard deviation. Analysis by Welch t-test with Benjamini-Hochberg correction for multiple testing, p-values represent the comparison between following groups: ip = Sham SC vs. Sham P33; # = sham SC vs. TAC SC; * = TAC SC vs TAC P33.
[0863] Figure 51 : P33 improves cardiac haemodynamics and relaxation following pressure overload. LV ventricular haemodynamic parameters measured 4 weeks after sham or TAC surgery following with scAAV9-SC / P33 injections 1-week post-surgery. dP / dtmax, a measure of contractility; Tau, a measure of isovolumetric relaxation. Data is mean ± standard deviation. Analysis by Welch t-test with Benjamini-Hochberg correction for multiple testing, p-values represent the comparison between following groups: ip = Sham SC vs. Sham P33; # = sham SC vs. TAC SC; * = TAC SC vs TAC P33.
[0864] Figure 52: Targeting the PDE4D9-TPNI interaction with P2-2 attenuates pathological cardiac remodelling and dysfunction. Pathological parameters and echocardiography parameters measured 4 weeks after sham or TAC surgery followed by scAAV9-SC / P2-2 injections 1 week post-surgery. BW, body weight; ; LV, left ventricle weight; RV, right ventricle weight; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; EF, ejection fraction; FS, fraction shortening; SV, stroke volume; CO, cardiac output; Myo CSA, myocardial cross-sectional area; FAC, fractional area change; E, early diastolic peak filing velocity; E’, peak early relaxation velocity of myocardial diastolic motion. Data is mean ± standard deviation. Analysis by Welch t-test with Benjamini-Hochberg correction for multiple testing. The different p-values represent the comparison between the following groups: ip, sham vs. TAC SC; #, sham vs TAC P2-2; *, TAC SC vs TAC P2-2. Method and protocol: C57BL / 6J wildtype mice were treated with scAAV9-SC or scAAV9-P2-2 via tail vein injection of scAAV9-cTnT-SC-IRES-mCherry-WPRE3 or scAAV9-cTnT-P2-2-IRES-mCherry-WPRE3 one weekafter sham or transverse aortic banding (TAC) surgery. Organ weights, echocardiographic parameters and left ventricular (LV) haemodynamics were obtained three weeks post-injection.
[0865] Figure 53: P2-2 improves cardiac haemodynamics and relaxation following pressure overload. LV ventricular haemodynamic parameters measured 4 weeks after sham or TAC surgery followed by scAAV9-SC / P2-2 injection 1 week post-surgery. dP / dtmax, a measure of contractility; Tau, a measure of relaxation. Data is mean ± standard deviation. One-way ANOVA with Sidak’s multiple comparisons correction was applied. The different p-values represent the comparison between the following groups:i , sham vs. TAC SC; #, sham vs TAC P2-2; *, TAC SC vs TAC P2-2. Method and protocol: as in Figure 52.
[0866] EXAMPLES
[0867] Example 1
[0868] A diagram of cAMP-dependent PKA-mediated phosphorylation of TPNI in shown in Figure 1.
[0869] Example 2
[0870] Background Abstract
[0871] Defective cardiac relaxation, or diastolic dysfunction, is common in heart failure, particularly when associated with diabetes, obesity, hypertension and ageing, and leads to increased mortality1. Currently there is no effective treatment that specifically targets diastolic dysfunction2. Cardiac relaxation requires detachment of calcium from contractile myofilaments, a process facilitated by the phosphorylation of troponin I by the 3’,5’-cyclic adenosine monophosphate (cAM P)-activated protein kinase A (PKA)3. In this study, we explored whether troponin I phosphorylation can be selectively enhanced to improve cardiac relaxation. The inventors uncovered a novel mechanism that attenuates PKA-dependent phosphorylation of troponin I through the direct association of the cAMP-hydrolysing enzyme PDE4D9 with troponin I leading to local cAMP degradation. The troponin l-associated PDE4D9 operates within a tightly confined range and selectively modulates troponin I phosphorylation without affecting phosphorylation of other PKA targets. The inventors demonstrate that a disrupting peptide that interferes with the PDE4D9 / troponin I interaction displaces the enzyme from troponin I, selectively increasing troponin I phosphorylation and improving cardiac myocyte relaxation. The inventors found that the association of PDE4D9 with troponin I is markedlyupregulated in cardiac disease, both in rodents and in human tissue, and that displacement of PDE4D9 from troponin I completely normalises diastolic dysfunction and significantly improves cardiac performance in a mouse model of heart failure. These findings hold promise for developing a novel approach to treat cardiac disease.
[0872] Introduction
[0873] Cardiac contraction (systole) and relaxation (diastole) are driven by contractile proteins arranged in sarcomeres consisting of interdigitated thick myosin filaments and thin actin filaments. The sliding of thick and thin filaments past each other causes the sarcomeres to shorten during contraction and re-lengthen during relaxation. This process is regulated by the binding and unbinding of calcium ions to and from troponin C (TPNC) which, together with troponin T (TPNT) and troponin I (TPNI), forms the regulatory troponin complex associated with the thin filament. The p-adrenergic receptor (P-AR) / cAMP / PKA pathway is a core regulator of cardiac function. During sympathetic stimulation, increased cAMP levels activate PKA, which phosphorylates specific proteins to enhance both contraction and relaxation, allowing the heart to adapt to higher workload demands. PKA phosphorylates phospholamban (PLB) at the sarcoplasmic reticulum (SR), enhancing the activity of the sarco-endoplasmic reticulum calcium ATPase (SERCA). This promotes calcium reuptake into the SR, ensuring a greater calcium reserve is available for release during the next contraction. PKA phosphorylation of the thick filament protein myosin-binding protein C (MyBPC) enhances contraction by extending the force-generating state of the sarcomere. Meanwhile, phosphorylation of troponin I (Tnl, a.k.a., TPNI) facilitates relaxation by lowering the affinity of troponin C (TnC, a.k.a., TPNC) for calcium, ensuring timely deactivation of myofilaments to match the faster contraction rate3. In pathological conditions, such as heart failure (HF), chronic p-AR overstimulation disrupts cAMP signaling, impairing contractility and relaxation4. P-blockers mitigate these effects and improve cardiac efficiency by reducing oxygen demand and preventing further myocardial damage5. However, p-blockers are ineffective when the primary issue is not impaired contraction but impaired cardiac relaxation6.
[0874] The cAMP / PKA signalling pathway operates through a complex network of subcellular signalling nanodomains7. cAMP elevation in response to p-AR activation is not homogeneous across the cardiomyocyte but cAMP forms nanometer-sized gradients shaped by cAMP-hydrolysing phosphodiesterases (PDEs)8. The spatially confined cAMP pools activate a selected subset of PKA enzymes, typically tethered in proximity of specific phosphorylation targets via scaffolding proteins9. This spatial organization enables selective phosphorylation of local PKA targets, resulting in specific cellular effects10. While drugs targeting receptors atthe plasma membrane influence the entire intracellular network of cAMP nanodomains, the compartmentalized nature of cAMP signalling offers an opportunity for more precise interventions11. Such approaches could selectively modulate cAMP levels within individual compartments achieving nanometer subcellular precision and stringent functional selectivity7.
[0875] Results
[0876] Distinct cAMP regulation at TPNI
[0877] The inventors first sought to confirm whether TPNI designates a nanodomain at the myofilament where cAMP is uniquely regulated. For this, the inventors used the cAMP FRET-based reporter TPNI-CUTie8and the newly developed MyBPC-CUTie (Figure 8a, b) . Correct localization of TPNI-CUTie and MyBPC-CUTie was confirmed by immunostaining (Figure 8c, d) and co-immunoprecipitation (Figure 8e). Overlapping kinetics and maximal amplitude of FRET change at saturating cAMP was confirmed in HEK293 cells (Figure 8f), allowing direct comparison of the cAMP signals reported by the two sensors. Adult rat ventricular myocytes (ARVM) expressing TPNI-CUTie, MyBPC-CUTie orAKAP183-CUTie8, a sensor targeted to the SR and forming a complex with PLB and SERCA, were then challenged with the p-AR agonist isoproterenol (ISO, 5nM). Consistent with our previous findings8, the cAMP response at AKAP188 was faster, significantly larger and sustained for at least 5 min compared to the cAMP response at TPNI, where cAMP elevation was slower and transient, with peak at 1 min after addition of ISO and return to basal after 5min (Figure 2a-c).
[0878] Remarkably, the cAMP response at TPNI was also clearly distinct from the response detected at MyBPC where the amplitude of the response was similar to that detected at TPNI but the response kinetics were strikingly distinct, with the cAMP level remaining sustained at MyBPC for at least 5 minutes (Figure 2a-b) Similar differences were detected in neonatal rat ventricular myocytes (NRVM) (Figure 9). Thus, p-AR activation generates a cAMP signal at TPNI that is distinct from the signal generated at approximately 30 nm away where MyBPC-CUTie localises. Consistent with the measured cAMP kinetics, PKA-dependent phosphorylation of TPNI peaked at about 5 min after the application of 5 nM ISO and declined significantly after 10 min, whereas phosphorylation of MyBPC and PLB showed a steady increase up to 10 min after ISO application (Figure 2d-e).
[0879] PDE4D uniquely modulates cAMP at TPNIThe inventors previously demonstrated that inhibiting PDE with IBMX abolishes the transient cAMP response at TPNI, leading to a sustained elevation of the second messenger at this site8. Proteomics studies indicate that both PDE2A and PDE3A isoforms are associated with myofilaments12. To assess whether either of this enzyme family is responsible for the unique transient nature of the cAMP signal at TPNI, NRVM expressing either TPNI-CUTie or MyBPC-CLITie were treated with 1 nM ISO and either the PDE2A inhibitor BAY 60-7550 (BAY, 1 .M) or the PDE3 inhibitor cilostamide (Cilo 10 .M) and the local cAMP changes were recorded over time. While both PDE2A and PDE3A contribute to cAMP hydrolysis at both locations, their inhibition does not eliminate the transient nature of the response at TPNI (Figure 10a,b,e), even when the two enzymes are inhibited simultaneously (Figure 10c). By contrast, inhibition of PDE4 with rolipram (Rol 10 .M) results in sustained response at TPNI (Figure 10d,e), suggesting a PDE4 isoform is implicated.
[0880] The PDE4 family consists of four subfamilies (PDE4A, PDE4B, PDE4C, and PDE4D), with PDE4B and PDE4D being the most abundantly expressed in rat cardiac myocytes13. To identify the PDE4 subfamily involved, small interfering RNA to knock down (KD) either PDE4B or PDE4D subfamilies14was carried out in NRVM (Figure 10f). While the cAMP response to ISO at TPNI was not affected by PDE4B KD, the signal was significantly enhanced and sustained in PDE4D KD cardiac myocytes (Figure 10g, h).
[0881] Given the extremely localised nature of the cAMP regulation at TPNI, the inventors next investigated whether a PDE4D enzyme forming a complex with TPNI may be implicated. The inventors found that pull-down of TPNI from NRVM co-immunoprecipitates PDE4D enzymes with molecular weight consistent with PDE4D3 / 8 / 9 isoforms (Figure 3a). In contrast, no PDE4B isoforms were detected in the TPNI pull down (Figure 3b). Notably, the amount of PDE4D detected in the TPNI immunoprecipitate increased overtime after application of ISO, suggesting stimulus-dependent recruitment of the PDE to TPNI (Figure 3b). Consistently, the level of PKA-dependent phosphorylation of TPNI increased transiently, peaking at 3 min after ISO application, with a time-course consistent with the recruitment of PDE4D (Figure 3b).
[0882] Quantitative PCR showed that PDE4D9 is the most highly expressed PDE4D long isoform in NRVM (Figure 11), therefore the inventors next focused on this enzyme. To confirm whether PDE4D9 operates at the TPNI nanodomain, the inventors expressed in NRVM a catalytically-inactive mutant of PDE4D9. This mutant functions as a dominant negative (DN) construct that, by displacing the native active enzyme from its anchoring site, is expected to cause a greater increase in cAMP levels at the site where the endogenous cognate enzyme is normallyanchored15. As shown in Figure 3c, on expression of PDE4D9-DN a larger and sustained cAMP response to ISO is recorded atTPNI while no significant different is observed at MyBPC (Figure 3d).
[0883] PDE4D9 directly interacts with TPNI
[0884] To confirm whether TPNI directly interacts with PDE4D9 and to define the interacting surface, the inventors used peptide array technology. TPNI arrays consisting of 20- (Figure 12a-b) or 25-mers (Figure 12h-i) covering the entire sequence of rat TPNI, were probed with purified GST-PDE4D9. A strong signal was found in correspondence of several peptides that were further analysed by alanine scanning, where each of the amino acids in the selected peptide is substituted with an alanine or, if originally an alanine, with a glycine. Peptide alanine scanning identified lysine residues at position K175, K178, K179 (Figure 12b) and K184 (Figure 12h) as required for interaction with GST-PDE4D9. Interestingly, a lysine to glutamate mutation in position 178 of human TPNI (corresponding to K179 in the rat sequence), causes a restrictive cardiomyopathy characterised by Ca2+ hypersensitivity and impaired relaxation16. To confirm the role of this residue in the TPNI / PDE4D9 interaction, the inventors introduced the K178A mutation in TPNI-CUTie (TPNI Ki78A-CUTie) (Figure 12c) and probed its ability to interact with PDE4D9 by coimmunoprecipitation and western blotting. As shown in Figure 12d-e, the K178A mutation significantly reduced the interaction of PDE4D9 with TPNI. As expected, when used to measure cAMP levels at the troponin complex, TPNlKi78A-CUTie detected a significantly larger and sustained cAMP signal in response to ISO stimulation compared to TPNI-CUTie (Figure 3e). Comparable results were found using a TPNI-CUTie mutant (TPNImut-CUTie) carrying the mutations K177A, K178A and K183A (Figure 3e and Figure 12d-e). Consistent with the inhibitory effect of the alanine substitutions on the TPNI / PDE4D9 interaction, when expressed in NRVM treated with ISO, TPNImut-CUTie showed sustained phosphorylation of the TPNI moiety, in clear contrast to the transient phosphorylation of TPNI-CUTie (Figure 12f-g). The peptide P33 with sequence G161TRAKESLDLRAHLKQVKKEDIEKE185 was selected for further studies.
[0885] P33 boosts local cAMP & TPNI
[0886]
[0887] To test whether P33 can displace PDE4D9 from TPNI, NRVM were treated with stearylated P33 (10 jiM) before pull-down of TPNI. The inventors found a significant reduction in PDE4D9 association with TPNI after ISO stimulation as compared to cells treated with a control peptide (SC, 10 jiM) (Figure 4a, b). Consistently, cAMP levels measured in NRVM expressing Tpnl-CLITie and pre-treated with P33 showed increased amplitude and duration of the cAMP signal compared to cells pretreated with vehicle DMSO or SC peptide (Figure 4c). The effect of P33 was highly specific, as no change in cAMP levels were detected at MyBP-C (Figure 4d) or AKAP188 (Figure 4e). Treatment with P33 also did not affect the cAMP response to ISO measured at the plasmalemma in proximity of the L-type calcium channel with the AKAP79-CLITie sensor8, or in the bulk cytosol using the CLITie sensor8(Figure 13a-d). Moreover, P33 had no impact on the cell overall PDE4 or PDE activity, as detected with the cytosolic cAMP sensor EPAC-H187 upon application of Rol or IBMX, respectively (Figure 13c-f). Notably, treatment with P33 resulted in a sustained phosphorylation of TPNI in response to ISO, while had no effect on the phosphorylation of MyBPC or phospholamban (Figure 4f,g). The ability of P33 to reduce the TPNI / PDE4D interaction and to enhance TPNI phosphorylation was confirmed also in cardiac myocytes differentiated from human inducible pluripotent stem cells (hiPSC-CM) (Figure 14).
[0888] P33 enhances relaxation and contraction in vitro
[0889] Given the localised effect of displacing PDE4D9 from TPNI, the inventors expected treatment with P33 to enhance relaxation and, possibly, force generation17. To verify this, the inventors treated rat cardiomyocyte with 10 pM P33 or SC or with vehicle as control, and measured the velocity of relaxation and maximal isometric force responses upon pacing at 1 Hz, by using the work-loop technique in single isolated cardiomyocytes undergoing a physiological work-loop cycle akin to the in-vivo pressure volume loop / cardiac cycle1819. The inventors found significantly enhanced relaxation and maximal isometric force generated in samples treated with P33 compared to SC and to vehicle control (Figure 5a, b). Enhanced sarcomere length at relaxation and enhanced contraction on application of P33 were also confirmed in hiPSC-CM (Figure 15c-d). Notably, the effects of P33 on lusitropy and force generation were independent of changes in the amplitude and duration of the calcium transient (Figure 5b, Figure 15b and Figure 16a-j).
[0890] PDE4D9 / TPNI interaction is excessive in disease and is normalised by P33
[0891] Defective phosphorylation of TPNI has been reported in animal models of cardiac disease20-23and in samples obtained from patients suffering from cardiomyopathies24-27. The inventors therefore explored whether the novel mechanism the inventors uncovered for the selective regulation of TPNI phosphorylation may be altered in disease. The inventors found significantly larger amount of PDE4D9 associated with TPNI in unstimulated cells obtained from failing cardiac myocytes obtained from a rat model of myocardial infarction (Ml) comparedto healthy controls (Figure 17c,d) and no additional PDE4D9 recruitment on ISO stimulation was visible in the diseased cells (Figure 17c,d). Consistently, the inventors found that treatment of failing cardiac myocytes with 5 nM ISO results in attenuated TPNI phosphorylation compared with cells from age-matched healthy controls while no difference was found in the phosphorylation of MyBPC Is (Figure 17a,b). Notably, treating the failing cardiac myocytes with P33, but not with SC peptide, lead to enhanced TPNI phosphorylation upon ISO stimulation, while no difference between SC control and P33 was observed on the phosphorylation of MyBPC (Figure 17e-f).
[0892] P33 prevents diastolic dysfunction in vivo
[0893] To test whether P33 may attenuate diastolic dysfunction, heart failure was induced in adult male C57BL / 6J mice at 2 months of age using a well-established surgical model of transverse aortic constriction (TAC), which promotes cardiac remodelling and dysfunction due to pressure overload. At 1 week after sham or TAC surgery, animals were subjected to tail vein injection of 1012vector genomes of the adeno-associated virus scAAV9-SC or scAAV9-P33, carrying the sequence for the control SC or P33 peptides, respectively (Figure 18a). Four weeks after infection the cardiac phenotype was studied (Figure 18b). Left ventricular (LV) weight (Figure 6a), but not lung weight (Figure 6b) normalised to tibial length was significantly higher in the TAC-SC group compared to sham-SC, suggesting robust cardiac hypertrophy in the absence of pulmonary congestion. Echocardiographic analysis of systolic parameters derived from 2-D parasternal long-axis view showed a trend for LV dilatation along with significantly reduced ejection fraction in TAC-SC compared to Sham-SC (Figure 6d), indicating contractile dysfunction consistent with early-stage heart failure. Injection of scAAV9-P33 resulted in significantly less LV hypertrophy (TAC-P33 vs TAC-SC, Figure 6a and Figure 19a) and P33 reduces fibrosis, a key parameter in cardiac remodeling associated with heart failure (Figure 19c, d) and acted to preserve ejection fraction (Figure 6d). In addition, echocardiographic diastolic parameters derived from combining Pulse-wave Doppler (PWD) and Tissue Doppler imaging (TDI) showed significant elevation of E / e’ only in TAC mice treated with SC, suggesting an increase in diastolic filling pressure that was not observed in P33 treated mice (Figure 6e). Haemodynamic measurements confirmed the beneficial effect of P33 in TAC operated mice. As expected, LV end-systolic pressure was greatly elevated in both TAC groups, although to a slightly lesser extent in P33 treated mice (Figure 6g). This difference disappeared upon maximal p-adrenergic stimulation with dobutamine (Figure 6I), suggesting it was not due to divergence in the surgical placement of the aortic band. Treatment with P33, but not SC, completely normalized LV end-diastolic pressure, in agreement with the echocardiographic E / e’ findings (Figure 6m). Baseline values for the maximal rate of pressurerise (dP / dtmax) were not significantly different between groups, however, this parameter is sensitive to preload, so an elevated LVEDP in the TAC SC group may have maintained a deceptively high dP / dtmax. A further measure of diastolic function is Tau, the time constant of isovolumetric relaxation, which was significantly prolonged only in the TAC SC group (Figure 6j). The beneficial effect of P33 remained evident when mice were subjected to dobutamine stress (32 ng / g BWt / minute), with complete normalisation of LVEDP (Figure 6m) and normal values for tau (Figure 6o). Notably, all group were capable of increasing dP / dtmax upon dobutamine stimulation, indicating that P33 treatment did not blunt contractile reserve (Figure 6n). Mechanistically, the observed beneficial effect of P33 could be explained by the finding that, while in TAC mice the interaction of PDE4D9 with TPNI is significantly elevated relative to sham controls (Figure 20a-b), treatment with P33 significantly reduced this interaction compared to treatment with SC peptide (Figure 20e,f), resulting in significantly enhanced phosphorylation of TPNI (Figure 20c, d).
[0894] Translational potential of P33
[0895] Compared to rodents, human cardiac myocytes express predominantly PDE3 and relatively less PDE4 isoforms25. To confirm a role of PDE4 isoforms in the regulation of cAMP at TPNI in human myocytes the inventors expressed the TPNI-CUTie sensor in freshly isolated ventricular myocytes from HF patients (Figure 7a) and found a clearly detectable cAMP response on application of Rol (Figure 7b, c). To assess whether the mechanism the inventors discovered also operates in human hearts and can potentially be targeted to treat diastolic dysfunction in patients, the inventors analysed snap frozen left ventricular tissue obtained from HF patients or healthy donors (Table 4). As previously reported, the inventors found that the level of TPNI phosphorylation is significantly lower in cardiac tissue from diseased hearts relative to healthy controls (Figure 7f,g). Co-immunoprecipitation of PDE4 isoforms with TPNI was detectable in both healthy controls and HF samples with a significant enhancement of the interaction of PDE4D isoforms with TPNI in failing myocytes (Figure 7h,i). It is also shown that the tight local control on cAMP levels TPNI depends on a PDE4 in human cardiac myocytes (Figure 7d,e) and that P33 has the same effect in human cardiac myocytes as shown in rat cardiac myocytes (Figure 7j,k).
[0896] Table 4. SR: sinus rhythm. pAF: paroxysmal atrial fibrillation. cAF: persistent (chronic) atrial fibrillation. HLP: hyperlipidaemia. HTX: heart transplantation.
[0897] Sex Age BMI, Diagnosis Procedure ECG LVEF (%) Medication kg / m2 pre OP
[0898]
[0899] LV I F 49 24 LV control N.A.LVX F 50 26 (o.w.) LV control N.A.
[0900] H8429 / 5 M 47 N.A. LV control N.A.
[0901] HAM-0078 F 63 23.3 HFrEF, ICM HTX pAF 22 ACE inhibitors, Beta-blockers, Diuretics, Lipidsen (statins).
[0902] HAM-119 M 51 25.6 (o.w.) HFrEF HTX cAF 18 Beta-blockers, Diuretics HAM-0058 M 52 26.1 (o.w.) CCM HTX SR 35 ACE inhibitors, Beta-blockers, Diuretics HAM-0083 M 58 27.1 (o.w.) DCM HTX N.A. 25 ACE inhibitors, Beta-blockers, Diuretics HAM-0094 M 66 25.2 (o.w.) HFrEF, ICM HTX cAF 21 Beta-blockers, Diuretics, Lipidsen (statins).
[0903] HAM-0097 M 62 24.3 HFrEF, ICM HTX SR 18 Beta-blockers, Diuretics.
[0904] 131020 F 64 33.4 HFrEF, ICM HTX SR 25 ATI blockers, (obesity) Beta-blockers, Calcium antagonists,
[0905]
[0906] Lipidsen (statins).
[0907] Discussion
[0908] Limited understanding of HF pathophysiology has so far hampered development of therapeutics that target the molecular mechanisms underpinning this condition. This is particularly true for diastolic dysfunction, where current medications are often ineffective. Extensive literature reports that the sensitivity of the contractile apparatus to Ca2+is heightened during end-stages HF24, making a strong case for targeting directly myofilament Ca2+sensitivity to treat this condition. However, progress has been limited by the lack of specific Ca2+desensitizers. Here, the inventors uncovered a novel mechanism that modulates Ca2+sensitivity by precisely regulating cAMP / PKA-dependent phosphorylation of TPNI with nanometer subcellular precision. This mechanism involves the direct interaction of PDE4D9 with TPNI, leading to localized cAMP degradation and reduced TPNI phosphorylation by PKA. The action range of the TPNI-anchored PDE4D9 is tightly confined, with its hydrolytic activity becoming ineffective beyond approximately 30 nm from the TPNI / PDE4D9 complex. Our findings align with the current understanding that cAMP signaling is highly compartmentalized and functions through the formation of localized signalosomes. In these structures, PKA is anchored near specific targets and is activated by confined pools of cAMP. TPNT, functioning as an AKAP29, is likely the local docking site for PKA.The inventors demonstrate that, by selectively displacing PDE4D9 from TPNI, the highly localized nature of this regulatory mechanism can be leveraged to achieve local elevation of cAMP, local activation of PKA, and selective phosphorylation of TPNI. As expected, this phosphorylation promotes cardiac myocyte relaxation, as the inventors observe in isolated cells. In addition, the inventors observed enhanced inotropy, possibly as a consequence of increased crossbridge cycling rate and shortening velocity1730'32. In vivo, PDE4D9 displacement from TPNI normalises ventricular end diastolic pressure and ejection fraction in a TAC model of heart failure.
[0909] Our findings suggest a strategy to correct diastolic dysfunction and improve cardiac performance in heart disease. A key advantage of locally elevating cAMP by displacing PDE4D9 from the myofilament is the exquisite selectivity at this intervention both at the cellular and subcellular level. Given that TPNI is exclusively expressed in striated muscle and phosphorylated by PKA only in cardiac myocytes, the effects of disrupting the TPNI / PDE4D9 interaction are expected to be highly specific to cardiac myocytes. Furthermore, unlike with pharmacological inhibition, elevating cAMP through PDE4D9 displacement from TPNI does not affect the overall hydrolytic activity of PDE4 or other PDEs in the cell, avoiding off-target effects, as those seen with PDE3 inhibitors. The inventors find that displacing PDE4D9 from TPNI does not affect local cAMP signaling at the AKAP79-L-type Ca2+ channel complex at the plasmalemma or at the AKAP185-SERCA / PLB complex at the SR, as confirmed by no significant effect of P33 treatment on the amplitude of the calcium transient. Thus, unlike treatments that globally elevate cAMP in the cell, this selective displacement offers the additional benefit of improving cardiac performance without increasing SERCA activity and, consequently, ATP consumption. As evidenced by the response under dobutamine stress, it also preserves cardiac reserve, which instead is lowered by p-blockers.
[0910] The observation that the expression of PDE4D isoforms is elevated in human failing hearts is exciting and can explain the defective phosphorylation of TPNI widely reported in cardiac patients24-27. While PDE4 isoforms are relatively less abundant than PDE3 isoforms in human cardiac myocytes, the inventors show that they significantly contribute to the regulation of cAMP at TPNI. Currently, no effective treatment exists that selectively targets the mechanisms underpinning myofilament relaxation33. The high morbidity and mortality associated with diastolic dysfunction make this a major unmet medical need worldwide6. The results presented here support exploring the displacement of PDE4D9 from the myofilament as a novel avenue for heart disease treatment.Methods
[0911] Materials &
[0912] Isoproterenol, cilostamide, rolipram, forskolin, and 3-isobutyl-1 -methylxanthine (IBMX) were from Sigma-Aldrich; N-terminal stearic-scrambled peptide (SC, KTELKAERGIKSDVAKERELHDLGK, SEQ ID NO: 152) and disrupting peptide (P33, GTRAKESLDLRAHLKQVKKEDIEKE, SEQ ID NO: 67) were synthesised by GenScript. Collagenase A was from Roche; pancreatin was from Sigma; laminin (mouse) was from BD Biosciences; PBS, DMEM high glucose, MEM199, horse serum, newborn calf serum, penicillin / streptomycin (10 000 units of penicillin [base] and 10 OOOpg of streptomycin [base] / mL), and L-glutamine were from Invitrogen. Adenoviral vectors and self-complementary AAV vectors carrying the target reporter and sequences were generated by Vector Biolabs (Malvern, PA, USA).
[0913] Cloning of MyBPC-CUTie
[0914] Full length mouse cardiac myosin binding protein C (MyBPC, NM_008653.2) was PCR to incorporate Nhel restriction sites at both 5’ and 3’ ends. The resulting fragments was cloned, in frame, into the Nhel site sit of the CUTie sensor. Clones were screened for correct orientation of insert and selected clones were sequenced.
[0915] Primary cardiac myocyte isolation
[0916] ARVMs were isolated from 350-375 g male Sprague Dawley rats as described34. Briefly, hearts were perfused on a Langendorff apparatus at 37 °C for 4-5 min through the coronary arteries with an oxygenated Ca2+-free Tyrode Buffer solution (130 mM NaCI, 5 mM Hepes, 0.4 mM NaH2PO4, 5.6 mM KCI, 3.5 mM MgCh, 20 mM Taurine, 10mM Glucose), and subsequently digested with 0.06 mg / ml Liberase TH (Roche Diagnostics Limited, UK) in a 100 pM Ca2+Tyrode Buffer solution for a further 15-20 min until the heart became flaccid. After perfusion, the left ventricle was removed, minced, and resuspended in equal volume of 1% BSA Ca2+-free Tyrode Buffer solution. Extracellular Ca2+was added incrementally to reach a final concentration of 1.0 mM. Cells were cultured in Minimum Essential Medium (MEM) (Sigma-Aldrich, UK), supplemented with 2.5% foetal bovine serum (FBS), 1% penicillinstreptomycin, 1% L-Glutamine and 9 mM NaHCOs and plated on laminin (40 pg / ml) coated culture dishes. ARVMs were left to adhere for 2 h in a 5% CO2 atmosphere at 37 °C, before the medium was replaced with FBS-free MEM. Myocytes were infected for 3 h at multiplicityof infection (MOI) of 10-100 with adenovirus encoding for FRET reporters. The medium was then replaced with fresh FBS-free MEM including 0.5pM cytochalasin D (MP Biomedicals, UK). Infected cells were kept in culture for less than 36 h. NRVM were cultured as described before35.
[0917]
[0918] ARVMs plated on coverslips were infected for 2 hours at MOI of 10-100 with adenovirus encoding for CLITie sensors. After 48 hours of infection, washed 3x with PBS, and fixed with 4% PFA in PBS at room temperature for 15 minutes. After permeabilisation with PBS+0.2% Triton-X-100 (PBST) for 30 minutes, the coverslips were blocked in PBST+1% BSA for 1 hour at room temperature. Primary a-Actinin antibody (A7811, sigma-Aldrich, 1:2,000) incubation were performed overnight at 4°C, followed by 3 washes at room temperature with PBS+0.025% Tween 20 and detection with Alexa Fluor 647 (Invitrogen) conjugated secondary antibody for 1 hour. Coverslips were mounted in ibidi mounting medium (Thistle Scientific). Sequential confocal images were acquired on a confocal laser scanning microscope.
[0919]
[0920] FRET i
[0921] FRET imaging experiments were performed 24-48 h after transduction with adenovirus carrying each sensor, as described before36. Cells were maintained at room temperature in a modified Ringer solution (125 mM NaCI, 20 mM Hepes, 1 mM NasPC , 5 mM KCI, 1 mM MgSC , 5.5 mM Glucose, CaCh 1mM, pH 7.4). ARVMs were imaged 18 h after infection and kept at ~35 °C in Tyrode solution containing 1.4 mM Ca2+. An inverted microscope (Olympus 1X71) with a PlanApoN, 60X, NA 1.42 oil immersion objective, 0.17 / FN 26.5 (Olympus, UK), was used. The microscope was equipped with a CoolSNAP HQ2 monochrome camera (Photometries) and a DV2™ optical beam-splitter (MAG Biosystems, Photometries). Images were acquired and processed using MetaFluor® 7.1, (Meta imaging series, Molecular Devices). FRET changes were measured as changes in the background-subtracted 480nm / 545nm fluorescence emission intensity on excitation at 430 nm and expressed as R / Ro, where R is the ratio at time t and Ro is the average ratio of the first 8 frames.
[0922]
[0923] For pull-down experiments ARVM from one heart were suspended in Tyrode buffer with 1.4 pM Ca2+ and treated as describe above. 6x106NRVM were plated onto 3x10-cm Petri dishes coated with laminin (20 mgml-1) and infected with the indicated adenovirus for 36-48 hoursand treated as above. The cells were lysed in IP buffer (50 mM HEPES pH7.4, 150 mM NaCI, 2 mM EDTA, 10% glycerol, 0.5% Triton-X-100 or 50 mM Tris pH7.4, 150 mM NaCI, 1 mM EDTA, and 1% nonyl phenoxypolyethoxylethanol [NP40]) supplemented with Complete EDTA-free protease inhibitor cocktail tablets and PhosSTOP Phosphatase Inhibitor Cocktail Tablet (Roche Diagnostics Limited) for 5min on ice. The cells were then collected and placed on a rotating wheel for 20 min at 4°C. Insoluble material was removed by centrifugation at 9,600g for 10 min at 4 -C and total protein was quantified by Micro BCA Protein Assay Kit (Pierce Biotechnology Inc.). 500-1000 pg protein were rotated for 1 hours at 4°C with 20 pl Pierce protein A Plus agarose (Thermo Fisher Scientific, 22810). The precipitates were removed by centrifugation at 1,000g for 3 minutes. The supernatant were then rotated for overnight with a monoclonal anti-cardiac troponin I (Abeam, ab10231), followed by 30pl protein G agarose (Cell signalling, 37478) for 2-4 hours. The precipitates were than collected by centrifugation at 1,000g for 3 minutes and beads were washed three times with ice-cold IP buffer. Bound protein were then eluted in 60 pl of 2X SDS loading buffer (Life Technologies) and release from the beads at 96oC for 6 min to ready for western blotting.
[0924] Western blotting
[0925] Pull-down proteins and samples equivalent to 20-50 pg proteins were separated on NuPage 4-12% Bis-Tris gradient gel (Invitrogen) and transferred onto PVDF blotting membrane (Amersham Hybond P 0.45 PVDF, Cytiva). After transfer, the membrane are blocked for 1 hour at room temperature with 5% skim milk (VWR Chemicals) or 5% PhosphoBLOCKER blocking reagent (Cell Biolabs), and then incubated overnight at 4°C with the following primary antibodies: mouse-anti-cardiac TPNI (Abeam, ab10231, 1:2000), rabbit anti-Phospho TPNI (S22+23) (Abeam, ab190697, 1:2000), mouse anti-PLN (Badrilla, A010-14, 1:4000), rabbit anti-phospho PLN (pSer16) (Badrilla, A010-12AP, 1:4000), mouse anti-MyBPC (Santa Cruz, sc-137237, 1:500), rabbit anti-phospho MyBPC (pSer282) (kindly provide by Dr. Sakthivel Sadayappan, Department of Cellular & Molecular Medicine, University of Arizona College of Medicine, Tucson, USA, 1:5000), rabbit anti-PDE4D9, goat anti-PDE4B and goat anti-PDE4D (kindly provide by Dr. George Baillie, University of Glasgow, UK, 1:5000). The blots were washed and incubated with appropriate horseradish peroxidase-conjugated secondary antibodies for 1 hour at room temperature. Immunoreactive bands were visualized by ECL western blotting detection kit. Antibody dilutions and exposure times were adjusted to ensure that for each antibody the signal detected was within the linear range. Membranes were then stripped of bound antibodies by incubation with stripping buffer (Thermo Fisher Scientific,21059) for 30 min at room temperature with gentle agitation if necessary. Quantifications of the band intensity were accomplished by densitometry using Imaged software.
[0926] Quantitative PCR was conducted as previously described37. In brief, RNA extraction from cardiac tissue was performed using a mixed protocol using phenokchlorophorm extraction followed by Qiagen RNeasy kits for cleanup. qPCR reactions were conducted using the ABI Prism 7300 qPCR thermocycler and analysis software (60 °C 30 s, 95 °C 10 min followed by 40 cycles of 95 °C 15 s, 60 °C 1 min). Reactions were conducted in qPCR Fastmix (VWR, Lutterworth, UK), as previously described. Primers used are as in37.
[0927]
[0928] Peptide array experiments were performed by automatic SPOT synthesis as described38-40. Human TPNI peptides were synthesised onto PEG-derivatized continuous cellulose membrane supports via 9-fuorenylmethyloxycarbonyl chemistry (Fmoc) using the MultiPep 2 Robot (CEM). A far western blot approach was utilised to detect PDE4D9 (derived from lysate of PDE4D9 overexpressing HEK293 cells), whereby TPNI arrays (consisting of 20mers or 25mer peptides) were (i) blocked for 2 h at room temperature in 1X Intercept (TBS) Blocking Buffer (LI-COR), (ii) incubated overnight at 4 °C in [1000 pg] PDE4D9-HEK293 lysate (diluted in 1X TBS, pH 7.4), (iii) incubated overnight at 4 °C in aPDE4D9 rabbit primary antibody (1:1000, bespoke PDE4D9 antibody raised against unique N-term PDE4D9 sequence in rabbits), (iv) incubated for 1 h at room temperature in IRDye 800nm donkey a-rabbit secondary (1:10,000, LI-COR) and (v) visualised via Odyssey CLx (LI-COR). Arrays were washed three times in 1X TBS-T following protein, primary and secondary antibody incubation steps. No lysate, antibody only was used as a negative control. Antibodies were diluted in 1X Intercept (TBS-T) Antibody Diluent (LIC-COR).
[0929] Further information on peptide array method
[0930] Peptide arrays were generated by direct synthesis of peptides onto Whatman cellulose membranes. Arrays of overlapping 20- or 25-mer peptides, sequentially shifted by 5 amino acids, were generated, as shown in Figure 41. These arrays cover the entire sequence of the protein of interest (TPNI) and were able to bind purified fusion proteins (PDE4D9-GST) providing information on protein-protein interactions, and the sites critical for these interactions (Bolger et al 2006, Frank 2002). Peptide arrays were synthesised in-house, using anAutoSpot-Robot ASS 222 (Intavis Bioanalyical Instruments, Kohn, Germany). Arrays were stored dry at 4°C prior to use. To investigate possible protein-protein interactions, peptide arrays were first activated by rinsing for 1 minute in 100% ethanol, then washed in 1x TBST for 10 minutes.
[0931] Non-specific binding was blocked by incubating with 5% milk solution for 2 hours at room temperature with gentle agitation. The array was then incubated with 10pg / ml of the purified protein of interest in 1% milk solution at 4°C overnight. After 16 hours, the array was washed 3 times for 10 minutes in TBST and incubated with primary antibody to the purified protein of interest at the appropriate dilution for 2 hours at room temperature.
[0932] After a further 3 washes in TBST, the appropriate HRP-conjugated secondary antibody was added for 1 hour at room temperature. Finally, the array was washed 3 times in TBST, and exposed to ECL and film.
[0933] For each peptide array experiment with a GST-tagged fusion protein, the array was first incubated with GST alone as a control to identify sites which might bind the GST tag rather than the protein of interest. Where potential binding sites were identified on film as spots, the 20- or 25-mer amino acid sequence corresponding to the spot was identified and an “Alanine Scan” of the region generated by producing a peptide array consisting of the wildtype spot, and then each residue sequentially mutated to alanine. If the original residue was alanine, it was mutated to glycine instead. The resulting alanine scan was then probed with the protein of interest as above. If mutation of a residue to alanine abolished binding of the fusion protein of interest, this provided evidence for it being involved in the interaction between the two proteins.
[0934] In vitro work-
[0935]
[0936] Sprague- Dawley Rats: Sex; Male: Body Mass; 250 - 400g: Number of animals: (5 for P33, 4 for Sc, 6 for controls) animals were be purchased from Charles River (Margate, UK) and housed at Warwick University Biomedical Services Unit (BSU) in a 12:12 day / night cycle in rooms held at 22°C. Cardiac myocytes were isolated as previously described41. Isolated cardiac myocyte work-loop experiments were performed using adapted methods as described previously18’1942. In brief, myocytes were placed in a perfusion chamber and carefully attached to fine glass rods (high-speed length controller or highly sensitive cantilever force transducer respectively) (lonOptix, Milton, MA, USA). Once attached fresh buffer was cycled through the chamber to remove excess cells. Isometric and force-length protocols were implemented for separate sets of cells incubated in the presence of scrambled or disrupted peptide or DMSOvehicle control. Work-Loop involved electrically stimulating an isometric contraction; the length was held constant until the afterload value was achieved; this was followed by an isotonic phase during which the cell was shortened to maintain a constant level of force. The workloop protocol was initiated and the myocytes were paced at 1 Hz using a field stimulator (Myopacer; lonOptix, Milton, MA) and isometric contractions recorded for 5 minutes to obtain a baseline / control period. The work-loop protocol relies on the force length relationship and when initiated mimicks the cardiomyocyte length change cycle providing realistic evaluation of in-vivo ‘like’ myocardial contractile mechanics which involve force feedback work-loops with stepwise preload increases and ramped afterload increases overtime. Intervals between loop phases were filled by continuous isometric activations at 1 Hz. Is wer2hrs prior to the workploop experiment and the maximal isometric force (Fmax) and the relaxation velocity were recorded.
[0937] Fura-2 measurements
[0938] Isolated ARVMs were plated onto laminin (40 pg / ml)-coated coverslips and cultured overnight. Cells were loaded with 1 pM Fura-2 AM (Molecular Probes, OR, USA) in the dark at room temperature for 15 min and then washed three times. Coverslips were mounted in the perfusion chamber, continuously perfused with a Tyrode solution containing 1.4 mM Ca2+at 37 °C, and paced at 1 Hz using a field stimulator (Myopacer; lonOptix, Milton, MA). When at steady state, cells were perfused with ISO 0.3 nM or IBMX 100 pM for about 10 min. The background-subtracted Fura-2AM emission at 510 nm was recorded and expressed as a ratio of fluorescent light on excitation at 340 and 380 nm (R340 / 380). The recorded transients were analysed using the lonWizard software (lonOptix, Milton, MA).
[0939] Generation of ventricular cardiomyocytes from hiPSC
[0940] Monolayer differentiation of the PGP1 hiPSC cell line was performed via Wnt pathway modulation with small molecule inhibitors as previously published43. Cells were induced to the mesodermal layer with 5pM CHIR99021, 5ng / ml Activin A, 5ng / ml FGF2, 5ng / ml BMP4 and 100nM AGN in RPMI1640 supplemented with B27 minus insulin for 24 hours. This was day 0 of differentiation. At the end of 24 hours, media were replaced with 100nM AGN in RPMI1640 supplemented with B27 minus insulin. On day 2, cells were induced to ventricular cardiac lineage specification with 5pM IWP2, 100nM AGN and 65pg / ml L-ascorbic acid in RPMI1640 supplemented with B27 minus insulin for 48 hours. Cells were then cultured in 100nM AGN and 65pg / ml L-ascorbic acid in RPMI1640 supplemented with B27 minus insulin to day 8. On day 8, media were changed to 65pg / ml L-ascorbic acid in RPMI1640 supplemented with B27 plus insulin, minus Vitamin A for 48 hours. Spontaneous contraction was observed on day 8-10 of differentiation. Between days 10 and 14, cells were subjected to metabolic selection in the absence of glucose with 65pg / ml L-ascorbic acid and 4mM lactate in glucose-free RPMI1640 supplemented with Vitamin A-free B27 plus insulin. Thereafter, cardiomyocytes were cultured in 65pg / ml L-ascorbic acid in Vitamin A-free RPMI1640 supplemented with B27 plus insulin, minus Vitamin A.
[0941] On day 20, iPSC-CMs were dissociated with 10x TrypLE enzyme for 5 minutes. The dissociation reagent was quenched with plating media (20% fetal bovine serum, 10 pM Thioglycerol in RPMI 1640 supplemented with Vitamin A-free B27). Cells were collected in suspension, centrifuged at 200 ref for 3 minutes and resuspended in plating media. Cardiomyocytes were plated at a density of 8 x 104 on Matrigel-coated Ibidi 35mm imaging plates. Cells were subjected to metabolic selection in the absence of glucose with 65pg / ml L-ascorbic acid and 4mM lactate in glucose-free RPM11640 supplemented with Vitamin A-freebB27 plus insulin for 96 hours and subsequently cultured in 65pg / ml L-ascorbic acid in RPMI1640 supplemented with B27 plus insulin, minus Vitamin A.
[0942] On day 28 cardiomyocytes were transduced with Adenovirus-RGECO. On day 29, a second transduction was carried out with Adenovirus-a-Actinin-GFP to enable simultaneous calcium and contractility imaging.
[0943] Peptide treatment of iPSC-CMs
[0944] On day 30 cardiomyocytes were incubated for fifteen minutes with P33 and scrambled peptide (SC), and mixtures of both with the p-adrenergic stimulator Isoproterenol at 0.1 pM prior to imaging. Controls were provided by equivalent concentrations of dimethylsulfoxide (DMSO), 0.1 pM Isoproterenol, as well as plates incubated in the absence of any treatment. This was repeated in four biological replicates (separate differentiations). A minimum of 30 cells expressing both fluorescent reporters were recorded per plate. Time lapse videos acquired under 1 Hz electrical pacing at 20V and 5msec bipolar current.
[0945] Imaging was performed with a Nikon Ti-2 Eclipse inverted microscope (Nikon, Japan) at x100 / 1.45NA magnification with a Nikon Plan Apo A (Nikon, Japan). Excitations at 550nm (RGECO) and 470nm (a-Act-GFP) were provided with a CooLED pE4000 (CooLED, UK). Fluophores were imaged simultaneously using dual illumination through a Quod-Filter (LED-DAPI / FITC / TRITC / Cy5, Semrock, USA). Emissions were passed through a TwinCam dual camera splitter (Cairn Research, UK), split with a T565lpxr and filtered through an ET632 / 60 (RGECO) or ET520 / 40 (GFP) filter (Semrock I DEX, NY, USA). Emissions were collected overdual aligned Teledyne Photometries Kinetix sCMOS cameras (Teledyne Photometries, USA). Time lapses were acquired at 10ms exposure (100fps) at 37oC.
[0946] Time lapse videos were analysed for calcium using the published computational pipeline CalTrack44. Contractility videos were uploaded into the University of Oxford Advanced Research Computing (ARC) facility cluster and analysed using the automated motion-tracking pipeline SarcTrack45.
[0947] All in vivo experiments were approved by the Committee for Animal Care and Ethical Review at the University of Oxford and comply with the UK Animals (Scientific Procedures) Act 1986, as amended 2012. Mice were group housed in individually ventilated cages under specific pathogen-free conditions at 21 °C with controlled humidity of 55 % and a 13-11-h light-dark cycle.
[0948] TAC surgery was performed aseptically as described previously under isoflurane general anaesthesia (2% in medical oxygen with anaesthetic depth assessed by loss of pedal reflex)46. Buprenorphine analgesia was given subcutaneously immediately prior to surgery (0.8 mg / Kg) and again the morning after surgery (0.4 mg / Kg).
[0949]
[0950] and
[0951] Mice were maintained on isoflurane anaesthesia (1.0-1.5% in medical 02), placed on a homeothermic table and parasternal short-axis B-mode views obtained at the level of the papillary muscles using a Visualsonics Vevo 2100 ultrasound system with 22-55 MHz transducer (MS 550D). Data analysis was performed by a single operator blinded to genotype using Vevo Lab, Edition 3.1.1 (Visualsonics, Toronto, Canada). Retrograde LV cannulation was performed under isoflurane anaesthesia via the right carotid artery using a 1.4F solid- state pressure catheter (SPR-839, Millar Instruments, Texas, USA) as described previously47. The jugular vein was cannulated using flame-stretch polyethylene tubing (Portex 0.96 mm OD, 800 / 100 / 200, Smiths Medical, UK) for administration of dobutamine hydrochloride at 32 ng / g BWt / min. Mice were killed at the end of the experiment by overdose of pentobarbitone.
[0952] Example 3
[0953] This example models the interaction between human PDE4D9 and peptide P33.Protein Structure
[0954]
[0955] To study the interactions between PDE4D9, troponin I, and peptide P33, computational modelling was performed to generate reliable 3D structures. Since no experimentally solved structure of PDE4D9 exists, homology modelling was employed to construct its structure. The amino acid sequence of PDE4D9 was retrieved and aligned with available homologous structures in the Protein Data Bank (PDB). Swiss-Model was used to generate an initial model, with PDE4B (PDB ID: 4WZI) serving as the primary template, while PDE4D7 (PDB ID: 3G4G) was used for refinement. Given that the critical UCR1-UCR2 region (Upstream Conserved Regions) lacks structural coverage, MODELLER was also utilised to further refine the model.
[0956] For the peptide structure of P33, sequence-based predictions were conducted using homology modelling and de novo structure prediction. Structural folding simulations were performed, and the most optimal model was selected based on quality assessment scores. The structure of troponin I was obtained from PDB (PDB ID: 4Y99), with loop refinement conducted where necessary to improve structural accuracy.
[0957] PDE4D9-P33 and PDE4D9-TPNI Docking Simulations
[0958] To predict the interactions between PDE4D9 and peptide P33, as well as between PDE4D9 and troponin I, a two-step docking strategy was employed, integrating global and local docking approaches to refine binding predictions. Initially, a global docking search was performed using ZDOCK, a rigid-body docking algorithm that does not require predefined binding sites. This approach facilitated an unbiased exploration of potential interaction surfaces between PDE4D9 and peptide P33. The PDE4D9 structure obtained from Swiss-Model was docked against two peptide models: one derived from a calcium-free conformation (PDB ID: 7KO4) and another from a calcium-bound conformation (PDB ID: 1 J1E). A grid-based search with a resolution of 1.2 A was applied, generating the top ten binding conformations for each peptide structure.
[0959] Following the global docking step, a refined local docking was conducted using HADDOCK, which integrates experimental and computational data to enhance docking accuracy. Ambiguous interaction restraints (Al Rs) were applied to improve binding predictions, with active residues on PDE4D9 identified using CPORT (Consensus Prediction Of interface Residues in Transient complexes), while the entire peptide P33 sequence was treated as passive. Peptide P33 was modelled as flexible to account for potential structural adaptabilityupon binding. After docking, default clustering was performed to identify the most favourable conformations based on binding scores.
[0960] To further improve docking precision, a second round of HADDOCK docking was conducted, incorporating additional interaction constraints derived from experimental findings. Key lysine residues within the sequence of peptide P33 (GTRAKESLDLRAHLKQVKKEDIEKE. SEQ ID NO: 67) were designated as active residues, given their known role in binding. Additionally, PDE4D9 residues in the LR1 (linker region 1) region, situated between LICR1 and LICR2, were prioritised due to their potential involvement in interaction stabilization.
[0961] Interaction Analysis and Refinement
[0962] The docked complexes were further analysed using PDBe PISA to evaluate stability and binding interfaces. PDBe PISA was employed to calculate potential interaction surfaces, interface areas, and binding energy estimation. This analysis provided insights into hydrogen bonding, salt bridges, and hydrophobic interactions that contribute to complex formation. This facilitated the elimination of low-confidence docking results and ensured the prioritization of biologically relevant binding modes.
[0963] Additionally, solvent-accessible surface area (SASA) calculations were performed to assess the transient nature of the complexes. The final selection of docking models was based on a combination of HADDOCK clustering scores and PDBe PISA-derived interaction parameters, ensuring that the most stable and physiologically relevant conformations were retained for further investigation.
[0964] Results
[0965] The docking model between human PDE4D9 and peptide P33 is shown in Figure 21. The docking mo...
Claims
CLAIMS1. A peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein, wherein the peptide has a maximum length of 24 amino acids.
2. The peptide of claim 1, wherein the PDE4 protein is a PDE4D subfamily protein.
3. The peptide of claim 2, wherein the PDE4D subfamily protein is PDE4D9, preferably wherein PDE4D9 comprises a sequence according to SEQ ID NO: 1 or a sequence with at least 70% identity thereto.
4. The peptide of any preceding claim wherein the peptide is capable of binding to the PDE4 protein.
5. The peptide of any preceding claim, wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of the TPNI protein, preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of a troponin complex that comprises the TPNI protein, more preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of a myofilament that comprises the TPNI protein, more preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in the proximity of a myofibril that comprises the TPNI protein, most preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein leads to an increase in the concentration of cAMP in a cell that comprises the TPNI protein.
6. The peptide of any preceding claim, wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes the PKA-dependent phosphorylation of a troponin complex that comprises the TPNI protein.
7. The peptide of any preceding claim, wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes dissociation of Ca2+from a troponin complex that comprises the TPNI protein, preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes dissociation of Ca2+from a TPNC protein that is complexed with the TPNI protein as part of a troponin complex.
8. The peptide of any preceding claim, wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes relaxation of a sarcomere that comprises the TPNI protein, preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes relaxation of a myofibril that comprises the TPNI protein, most preferably wherein inhibiting a PDE4 protein from binding to a TPNI protein promotes relaxation of a muscle cell (i.e. , myocyte) that comprises the TPNI protein.
9. The peptide of claim 8, wherein the muscle cell is a heart muscle cell (i.e., cardiomyocyte), preferably a ventricular cardiomyocyte.
10. The peptide of any preceding claim, wherein the peptide comprises the motif DLRGKFK (SEQ ID NO: 9), the motif KKED(I / T)EK (SEQ ID NO: 10), the motif KKEDIEK (SEQ ID NO: 14), the motif KKEDTEK (SEQ ID NO: 15), the motif PAPAP (SEQ ID NO: 11), the motif ADAM MQAL (SEQ ID NO: 12), or the motif KKSKISASR (SEQ ID NO: 13), wherein up to four amino acids in the motif may be independently substituted.
11. The peptide of claim 10, wherein any one or more of the up to four amino acids are substituted for a positively charged amino acid, preferably wherein the positively charged amino acid may be selected from arginine, histidine, and lysine, more preferably wherein the positively charged amino acid is arginine.
12. The peptide of any preceding claim, wherein the peptide comprises a sequence selected from any of:KIFDLRRKFKR (SEQ ID NO: 52, P2-2);FDLRGKFKRP (SEQ ID NO: 49, P1);KIFDLRGKFK (SEQ ID NO: 50, P2);KIFDLRRKFK (SEQ ID NO: 51, P2-1);KIFDLRRKFKRR (SEQ ID NO: 53, P2-3);KIFDLRGKFKR (SEQ ID NO: 54, P2-4);KIFDLRGKFKRR (SEQ ID NO: 55, P2-5);PRPAPAPIRR (SEQ ID NO: 58, P6);KKEDIEKENR (SEQ ID NO: 63, P3);KQVKKEDIEKENRR (SEQ ID NO: 64, P3-1);RPAPAPIRRR (SEQ ID NO: 59, P7);IFDLRGKFKR (SEQ ID NO: 56, P8);EPRPAPAPIR (SEQ ID NO: 60, P9);REPRPAPAPI (SEQ ID NO: 61, P10);KKKSKISASR (SEQ ID NO: 69, P11);KKSKISASRK (SEQ ID NO: 70, P12);KQVKKEDIEK (SEQ ID NO: 65, P4);VKKEDIEKEN (SEQ ID NO: 66, P13);KKDENRIEEK (SEQ ID NO: 72, P5);KIFDLRGKFKRP (SEQ ID NO: 57, P14);REPRPAPAPIRRR (SEQ ID NO: 62, P15);KQVKKEDIEKENR (SEQ ID NO: 68, P16);KKKSKISASRK (SEQ ID NO: 71, P17);MADESSDAAGEPQPAPAPVR (SEQ ID NO: 112, Peptide Z1); SDAAGEPQPAPAPVRRRSSA (SEQ ID NO: 113, Peptide Z2); EPQPAPAPVRRRSSANYRAY (SEQ ID NO: 114, Peptide Z3); PAPVRRRSSANYRAYATEPH (SEQ ID NO: 115, Peptide Z4); RRSSANYRAYATEPHAKKKS (SEQ ID NO: 116, Peptide Z5); NYRAYATEPHAKKKSKISAS (SEQ ID NO: 117, Peptide Z6);ATEPHAKKKSKISASRKLQL (SEQ ID NO: 118, Peptide Z7);AKKKSKISASRKLQLKTLML (SEQ ID NO: 119, Peptide Z8);KISASRKLQLKTLMLQIAKQ (SEQ ID NO: 120, Peptide Z9);RKLQLKTLMLQIAKQEMERE (SEQ ID NO: 121, Peptide Z10); KTLMLQIAKQEMEREAEERR (SEQ ID NO: 122, Peptide Z11); QIAKQEMEREAEERRGEKGR (SEQ ID NO: 123, Peptide Z12); EMEREAEERRGEKGRVLSTR (SEQ ID NO: 124, Peptide Z13); AEERRGEKGRVLSTRCQPLV (SEQ ID NO: 125, Peptide Z14); GEKGRVLSTRCQPLVLDGLG (SEQ ID NO: 126, Peptide Z15); VLSTRCQPLVLDGLGFEELQ (SEQ ID NO: 127, Peptide Z16); CQPLVLDGLGFEELQDLCRQ (SEQ ID NO: 128, Peptide Z17); LDGLGFEELQDLCRQLHARV (SEQ ID NO: 129, Peptide Z18); FEELQDLCRQLHARVDKVDE (SEQ ID NO: 130, Peptide Z19); DLCRQLHARVDKVDEERYDV (SEQ ID NO: 131, Peptide Z20); LHARVDKVDEERYDVEAKVT (SEQ ID NO: 132, Peptide Z21); DKVDEERYDVEAKVTKNITE (SEQ ID NO: 133, Peptide Z22); ERYDVEAKVTKNITEIADLT (SEQ ID NO: 134, Peptide Z23);EAKVTKNITEIADLTQKIYD (SEQ ID NO: 135, Peptide Z24);KNITEIADLTQKIYDLRGKF (SEQ ID NO: 136, Peptide Z25);IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137, Peptide Z26);QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138, Peptide Z27);LRGKFKRPTLRRVRISADAM (SEQ ID NO: 139, Peptide Z28);KRPTLRRVRISADAMMQALL (SEQ ID NO: 140, Peptide Z29);RRVRISADAMMQALLGTRAK (SEQ ID NO: 141, Peptide Z30);SADAMMQALLGTRAKESLDL (SEQ ID NO: 142, Peptide Z31);MQALLGTRAKESLDLRAHLK (SEQ ID NO: 143, Peptide Z32);GTRAKESLDLRAHLKQVKKE (SEQ ID NO: 144, Peptide Z33);ESLDLRAHLKQVKKEDIEKE (SEQ ID NO: 145, Peptide Z34);RAH LKQVKKEDI EKEN REVG (SEQ ID NO: 146, Peptide Z35);QVKKEDIEKENREVGDWRKN (SEQ ID NO: 147, Peptide Z36); DIEKENREVGDWRKNIDALS (SEQ ID NO: 148, Peptide Z37);NREVGDWRKNIDALSGMEGR (SEQ ID NO: 149, Peptide Z38); DWRKNIDALSGMEGRKKKFE (SEQ ID NO: 150, Peptide Z39); and WRKNIDALSGMEGRKKKFEG (SEQ ID NO: 151, Peptide Z40); or a sequence having at least 70% identity thereto.
13. The peptide of any preceding claim, wherein the peptide comprises a sequence selected from any of:KIFDLRRKFKR (SEQ ID NO: 52, P2-2);FDLRGKFKRP (SEQ ID NO: 49, P1);KIFDLRGKFK (SEQ ID NO: 50, P2);KIFDLRRKFK (SEQ ID NO: 51, P2-1);KIFDLRRKFKRR (SEQ ID NO: 53, P2-3);KIFDLRGKFKR (SEQ ID NO: 54, P2-4);KIFDLRGKFKRR (SEQ ID NO: 55, P2-5);KKEDIEKENR (SEQ ID NO: 63, P3);KQVKKEDIEKENRR (SEQ ID NO: 64, P3-1);KQVKKEDIEK (SEQ ID NO: 65, P4);KKDENRIEEK (SEQ ID NO: 72, P5);SDAAGEPQPAPAPVRRRSSA (SEQ ID NO: 113, Peptide Z2);EPQPAPAPVRRRSSANYRAY (SEQ ID NO: 114, Peptide Z3);RRSSANYRAYATEPHAKKKS (SEQ ID NO: 116, Peptide Z5);NYRAYATEPHAKKKSKISAS (SEQ ID NO: 117, Peptide Z6);ATEPHAKKKSKISASRKLQL (SEQ ID NO: 118, Peptide Z7);AKKKSKISASRKLQLKTLML (SEQ ID NO: 119, Peptide Z8);KISASRKLQLKTLMLQIAKQ (SEQ ID NO: 120, Peptide Z9);QIAKQEMEREAEERRGEKGR (SEQ ID NO: 123, Peptide Z12); EMEREAEERRGEKGRVLSTR (SEQ ID NO: 124, Peptide Z13);KNITEIADLTQKIYDLRGKF (SEQ ID NO: 136, Peptide Z25); IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137, Peptide Z26);QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138, Peptide Z27);RRVRISADAMMQALLGTRAK (SEQ ID NO: 141, Peptide Z30);MQALLGTRAKESLDLRAHLK (SEQ ID NO: 143, Peptide Z32);GTRAKESLDLRAHLKQVKKE (SEQ ID NO: 144, Peptide Z33);QVKKEDIEKENREVGDWRKN (SEQ ID NO: 147, Peptide Z36);DWRKNIDALSGMEGRKKKFE (SEQ ID NO: 150, Peptide Z39); and WRKNIDALSGMEGRKKKFEG (SEQ ID NO: 151, Peptide Z40); or a sequence having at least 70% identity thereto.
14. The peptide of any preceding claim, wherein the peptide comprises the motif DLR(G / R)KFK (SEQ ID NO: 44), and wherein the peptide comprises a sequence selected from any of:KIFDLRRKFKR (SEQ ID NO: 52, P2-2);FDLRGKFKRP (SEQ ID NO: 49, P1);KIFDLRGKFK (SEQ ID NO: 50, P2);KIFDLRRKFK (SEQ ID NO: 51, P2-1);KIFDLRRKFKRR (SEQ ID NO: 53, P2-3);KIFDLRGKFKR (SEQ ID NO: 54, P2-4);KIFDLRGKFKRR (SEQ ID NO: 55, P2-5);IFDLRGKFKR (SEQ ID NO: 56, P8);KIFDLRGKFKRP (SEQ ID NO: 57, P14);IADLTQKIYDLRGKFKRPTL (SEQ ID NO: 137, Peptide Z26); and QKIYDLRGKFKRPTLRRVRI (SEQ ID NO: 138, Peptide Z27); or a sequence having at least 70% identity thereto.
15. The peptide of any preceding claim, wherein the peptide comprises the sequence KIFDLRRKFKR (SEQ ID NO: 52, P2-2), preferably wherein the peptide consists of the sequence KIFDLRRKFKR (SEQ ID NO: 52, P2-2).
16. A nucleic acid sequence encoding the peptide of any one of claims 1-15.
17. An expression construct comprising the nucleic acid sequence of claim 16.
18. A vector comprising the nucleic acid sequence of claim 16, or the expression construct of claim 17.
19. A conjugate comprising the peptide of any one of claims 1-15, nucleic acid sequence of claim 16, expression construct of claim 17, or the vector of claim 18, wherein the peptide, nucleic acid sequence, expression construct, or vector is covalently linked to a delivery group, preferably wherein the delivery group is a cell penetrating peptide.
20. A delivery particle comprising the peptide of any one of claims 1-15, nucleic acid sequence of claim 16, expression construct of claim 17, vector of claim 18, or the conjugate of claim 19, preferably wherein the delivery particle is selected from: a liposome, a lipid nanoparticle, and a virus particle.
21. A pharmaceutical composition comprising the peptide of any one of claims 1-15, nucleic acid sequence of claim 16, expression construct of claim 17, vector of claim 18, conjugate of claim 19, or the delivery particle of claim 20 and one or more pharmaceutically acceptable excipients.
22. A peptide capable of inhibiting a PDE4 protein from binding to a TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for use as a medicament.
23. Use of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for the manufacture of a medicament.
24. A method of treating a subject having a disease, or preventing a disease in a subject, wherein the method comprises administering to the subject an effective amount of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleicacid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle.
25. A peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for use in the treatment or prevention of: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 are upregulated, a disease or condition in which the expression of PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 with TPNI, a disease or condition involving an increased association of PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction, hypercontracture and / or hypertrophic cardiomyopathy, preferably wherein the heart failure involves diastolic dysfunction, more preferably wherein the heart failure is heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
26. Use of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, orvector, wherein the peptide, nucleic acid sequence, expression construct, or vector is covalently linked to a delivery group such as a cell penetrating peptide; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate, wherein the delivery particle may be for example a liposome, lipid nanoparticle, or virus particle; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, for the manufacture of a medicament for the treatment or prevention of: a disease or condition involving impaired heart muscle relaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 are upregulated, a disease or condition in which the expression of PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 with TPNI, a disease or condition involving an increased association of PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction, hypercontracture and / or hypertrophic cardiomyopathy, preferably wherein the heart failure involves diastolic dysfunction, more preferably wherein the heart failure is heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
27. A method of treating a subject having a disease, or preventing a disease in a subject, wherein the method comprises administering to the subject an effective amount of a peptide capable of inhibiting a PDE4 protein from binding to TPNI protein; a nucleic acid sequence encoding said peptide; an expression construct comprising said nucleic acid sequence; a vector comprising said nucleic acid sequence or expression construct; a conjugate comprising said peptide, nucleic acid sequence, expression construct, or vector, wherein the peptide, nucleic acid sequence, expression construct, or vector is covalently linked to a delivery group such as a cell penetrating peptide; a delivery particle comprising said peptide, nucleic acid sequence, expression construct, vector, or conjugate, wherein the delivery particle may be for example a liposome, lipid nanoparticle, or virus particle; or a pharmaceutical composition comprising said peptide, nucleic acid sequence, expression construct, vector, conjugate, or delivery particle, wherein the disease is: a disease or condition involving impaired heart musclerelaxation or a hypercontracted state of the heart muscle, a disease or condition involving reduced fractional shortening of the left ventricle, a disease or condition involving elevated end systolic pressure (ESP), a disease or condition involving elevated end diastolic pressure (EDP), a disease or condition in which the expression of any one or more subfamilies and / or isoforms of PDE4 are upregulated, a disease or condition in which the expression of PDE4D isoforms are upregulated, a disease or condition in which the expression of PDE4D9 is upregulated, a disease or condition involving an increased association of any one or more subfamilies and / or isoforms of PDE4 with TPNI, a disease or condition involving an increased association of PDE4D isoforms with TPNI, a disease or condition involving an increased association of PDE4D9 with TPNI, a disease or condition involving a lower level of TPNI phosphorylation, heart failure, diabetic cardiomyopathy, diastolic dysfunction, diastolic dysfunction associated with cardiac developmental defects, including paediatric and adult manifestations, hypercontracture and / or hypertrophic cardiomyopathy, preferably wherein the heart failure involves diastolic dysfunction, more preferably wherein the heart failure is heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
28. The peptide for use according to claim 22 or 25, use of the peptide according to claim 23 or 26, or the method of treating a subject or preventing a disease in a subject comprising administering the peptide according to claim 24 or 27, wherein the peptide is as defined in any of claims 1-15.
